[
  {
    "page": 1,
    "source": "text",
    "content": "Environmental, Social & Governance (ESG)Progress Report 2020/2021"
  },
  {
    "page": 2,
    "source": "text",
    "content": "Contents 2 Overview3 A letter from our CEO5 2020/2021 Highlights6 Our company7 Our ESG approach10 Access to health16 Employees19 Environmental sustainability23 Awards and recognition24 References25 GRI/SASB disclosures26 General disclosures50 Economic83 Environmental118 Social171 Indices171 Global Reporting Initiative (GRI)179 Sustainability AccountingStandards Board (SASB)182 UN Global Compact183 UN Sustainable DevelopmentGoals (SDGs)185 Culture of Health forBusiness (COH4B)187 World Economic Forum (WEF)Stakeholder Capitalism MetricsAbout this reportThis is the Environmental, Social & Governance (ESG) ProgressReport 2020/2021 of Merck & Co., Inc., Kenilworth, N.J., U.S.A.,which is known as MSD outside the United States (U.S.) andCanada. Information on documents filed with the Securities andExchange Commission (SEC), such as our Form 10-K and ProxyStatement, can be found on our corporate website, which isintended only for residents of the U.S. and Canada. All data iscurrent as of December 31, 2020, unless otherwise noted.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 2"
  },
  {
    "page": 3,
    "source": "text",
    "content": "Dear stakeholders,A letter fromFor 130 years, the people of Merck have brought hope to humanity through our discoveryof important medicines and vaccines, exemplary social responsibility and the positiveour CEO impact on health and health equity we have achieved. Our 2020/2021 Environmental,Social and Governance (ESG) Progress Report reflects our commitment to sustaining thislegacy. Through scientific breakthroughs, inclusive clinical development strategies, andenvironmentally responsible manufacturing, our products are increasingly accessible andaffordable to those in need around the world.As we face the second year of the COVID-19 pandemic, and its devastating impact onglobal health and economies, I am deeply grateful to the employees across our entirecompany. Because of their dedication and resilience, discovery research is flourishing in ourRobert M. Davis new research hubs, and patients and customers around the world can be confident in theChief Executive Officer and President continued quality and reliable supply of our products.In addition, our scientists are advancing an antiviral candidate, molnupiravir, in collaborationwith Ridgeback Biotherapeutics, for people with early COVID-19 infection outside ofhospital settings. We have already granted voluntary licenses to a number of establishedIndian generic manufacturers to accelerate the availability of molnupiravir in India and inother low- and middle-income countries, contingent upon authorization by local regulatoryagencies. We are also collaborating with Johnson & Johnson to scale up production of itspandemic vaccine to help expand global access.Our ESG efforts are grounded in the core values that have always guided our mission:responsibility to patients and animals who need our medicines and vaccines; respect,inclusion and accountability to our employees; sustaining the highest standards of ethicsand integrity; and innovation and scientific excellence.I am especially proud of our long-standing commitment to helping solve the world's mostvexing health challenges. In 2020, our products and pipeline targeted 88 percent of the top20 global burdens of disease. We also expanded patient access to these essential therapiesand are working to improve health equity for more people in low- and middle-incomecountries and in underserved people in the United States, through our social investments.For example, we are celebrating the 10th year anniversary of Merck for Mothers, our $500million investment in innovative programming that is helping to eliminate preventablecauses of maternal mortality.Visit our corporate websiteto learn more about ourCOVID-19related actionsMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 3"
  },
  {
    "page": 4,
    "source": "text",
    "content": "I'm committed to accelerating Merck's success in cultivating a diverse and inclusive workforce \" I am proud of what the people ofand a culture that inspires creativity and promotes health and wellbeing. Today, 46 percent of our Merck have achieved this year and Icompany's board of directors are women and 23 percent are from underrepresented groups. We haveam excited about the opportunity toalso come a long way with our workforce, and are confident that our momentum will allow usbuild on our innovation, science andto achieve our new Global Diversity & Inclusion goals-with a special focus on senior leadership roles.extraordinary talent to realize a betterWe've taken big steps to accelerate the impact of our environmental sustainability agenda as well. future for generations to come.\"By 2025, our goal is to achieve carbon neutrality across our operations-for our Scope 1 and 2emissions (the fossil fuels we burn on site and the electricity we purchase). We will also accelerateby 15 years our previous 2040 goal to source 100 percent renewable energy for purchased electricity.In addition, we are committed to reducing our Scope 3 value chain emissions 30 percent by 2030,by continuing to engage with suppliers to help reduce their emissions.These and other examples of our ESG progress are detailed in this report, which uses widelyrecognized reporting frameworks. Our goals are informed by our ESG materiality assessment,as well as input from stakeholders, and can be found on page 9 of the report. The report also reflectsour support for the 10 principles of the UN Global Compact and recognizes the importantrole we play in helping to meet the UN Sustainable Development Goals (SDGs).We have prioritized eight SDGs where we are positioned to have the most significant impact.Of these, our primary focus is SDG 3, Good Health and Well-being, which aligns with our corebusiness. This involves helping to ensure our science advances health care and our productsare accessible and affordable to those in need, and while doing so, minimizing our impact onthe environment, promoting inclusive economic growth, and establishing partnerships to achieveour goals.As I assume responsibility for ensuring our ongoing success as a socially responsible company,I am grateful for the extraordinary vision of Ken Frazier, our executive chairman and former CEO.His commitment to investing in discovery and translational research as the source of our long-termbusiness success, and the social value we contribute to our patients and customers, has neverwavered. His leadership and values are reflected in the ingenuity, resilience and perseverancethat our employees have shown throughout the COVID-19 pandemic, and permeate everyaspect of our company.I am proud of what the people of Merck have achieved this year and I am excited about theopportunity to build on our innovation, science and extraordinary talent to realize a betterfuture for generations to come.Sincerely,Robert M. DavisChief Executive Officer and PresidentMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 4"
  },
  {
    "page": 5,
    "source": "text",
    "content": "2020/2021 HighlightsTo view our ESG goals, please see page 9.88% 46% women 285 millionpeopleof the top 20 global burdens in Board roles4of disease targeted with ourproducts and pipeline1,2,3 reached through investment inpartnerships, programs and impactinvestment that support healthcare capacity-building and addressunderlying barriers to access to health523% members of Science-Based 14 assessment 31% womenunderrepresented Targets guides in senior management roles1,6ethnic groups certification received for our goals to developed to detect and addressreduce Scopes 1 & 2 GHG emissions human rights and environmentalin Board roles446%, and Scope 3 GHG emissions impact risks in our supply chain30%, by 2030417 million >99% of employees $2.3 billion 48% sitestreatments trained on our ethical expectations spend with diverse suppliers1 sent ZERO waste to landfill1and principles found in our Codeof MECTIZAN approved in 2020of Conductto eliminate river blindness andlymphatic filariasis (LF)26 languages 20% members of 38% purchased $3 billionavailability of our Business underrepresented electricity cash grants, in-kind donationsPartner Code of Conduct around and product donations1ethnic groups (U.S.) from renewable sources1,7the globein senior management roles1,6Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 55"
  },
  {
    "page": 6,
    "source": "text",
    "content": "Our companyWe invent for life.For more than 130 years, Merck has been inventing for life, bringingforward medicines and vaccines for many of the world's mostchallenging diseases in pursuit of our mission to save and improve lives.We aspire to be the premier research-intensive biopharmaceuticalcompany in the world and demonstrate our commitment to patientsand population health by increasing access to health care throughour policies, programs and partnerships. Today, we continue to be atthe forefront of research to prevent and treat diseases that threatenpeople and animals-including cancer, infectious diseases such as HIVand Ebola, and emerging animal diseases.Research and products74,000employees1We bring creative minds together to transform world-class scienceinto life-changing medicines and vaccines to address the world's mostdifficult health concerns. Our scientists are revolutionizing how wediscover and develop medicines and vaccines to address pressinghealth needs in the areas of oncology, vaccines, infectious diseases 78% of countriesand cardio-metabolic disorders.around the world reached withMore information about our products, pipeline and patient support our products8programs is available on our corporate website as well as our MerckAnimal Health website.$13.6 billioninvested in R&DMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 6"
  },
  {
    "page": 7,
    "source": "text",
    "content": "Our ESG approachWe are committed to a high level of environment, social and governance (ESG) performance, which helps us drive sustainable value for ourbusiness and society. Our ESG strategy ensures that we apply our global resources and investments to ESG priority areas that matter most:expanding access to health, developing and rewarding a diverse, inclusive and healthy workforce, protecting the environment and operatingwith the highest standards of ethics and values. Through these four focus areas, we continue to challenge ourselves to innovate, make ambitiouscommitments and form collaborative partnerships to solve major global issues. We hold ourselves accountable to those we serve through ourgovernance and reporting practices.Guided by stakeholder input, our ESG actions are integrated into our business strategy. We recently established the ESG Strategy ManagementTeam, a group of senior-level functional experts within the company, to strategically assess and activate long-term business actions related to ourESG focus areas.Operating with ethics, integrity and respect for human rights is critical to our success. Our Ethics & Values focus area is foundational to our work inthe other three areas.Access to health Employees Environmental Ethics & valuesIn collaboration with key We recognize that our ability to sustainability Through our unwaveringstakeholders, we have a role excel depends on the integrity, commitment to transparency,to play in helping to ensure our knowledge, imagination, skill, A healthy planet is essential we earn the trust andscience advances health care, diversity and wellbeing of to human health and the confidence of our stakeholders.and our products are accessible our employees. sustainability of our business.and affordable to those in need.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 7"
  },
  {
    "page": 8,
    "source": "text",
    "content": "ESG materiality Our priority topicsFrom our 2021 ESG materiality assessment update, we identified the following top priorities for our stakeholders from amongUnderstanding and prioritizing thethe 32 most significant ESG topics for our sector. To learn more about this process, see page 48.ESG issues that matter most to ourbusiness and stakeholders enables usto focus and report on them effectivelyand transparently. Our ESG materiality• Access to medicine • E mployee healthassessment process provides us withand safetyan opportunity to listen and engage our• P roduct qualitymany stakeholders, helps us improve Accessand safety Employees • Employee engagementas an organization through focused to health a nd diversityactions, and yields insight into future • Public health riskstrends and potential business risks andopportunities that influence our abilityto create value.• C limate change • B usiness ethicsEnvironmental Ethics • Ethics in R&Dsustainability & values• D ata securityFor more information about ourand privacyESG materiality assessment, please seeGRI 102-46 on page 47. • G overnance structuresand mechanismsSustainable Development Goals Well-being) is at the core of our business and is aligned with ourmission to save and improve lives. While we realize that all of the SDGsare essential to fostering sustainable development, we have prioritizedThe SDGs represent the international community's plan of action foreight global goals where we are positioned to have the biggest impact.\"people, planet and prosperity.\" The 2030 Agenda for SustainableDevelopment, adopted by all United Nations Member States in 2015,provides a shared blueprint for peace and prosperity for people and theplanet, now and into the future. At its heart are the 17 SDGs, which arean urgent call for action by all countries in a global partnership.At Merck, we believe we have an important role and responsibility tohelp reduce the burden of disease and improve access to medicinesand vaccines around the world. That is why SDG 3 (Good Health and A full SDG index can be found on page 183.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 8"
  },
  {
    "page": 9,
    "source": "text",
    "content": "Our ESG goalsWe expanded our ESG goals to reflect our ongoing commitment to the long-term health of our patients, communities, planet, employees, shareholders and society.In addition, an expanded set of environmental goals can be found on on pages 19-22, 93, 100, 101 and 107, and additional access to health goals on page 57.Access Employees Environmental Ethicsto health sustainability & valuesFurther advance health Increase representation in Achieve carbon neutrality across Foster a \"Speak Up\" cultureequity by reaching 30 million senior management roles,12 our operations by 2025 (Scopes 1 by maintaining or exceedingpeople in low- and middle- by 2024: & 2 emissions).15 our current percentageincome countries and in U.S. of employees respondingunderserved populations • Women globally to 40%, favorably to the \"Speakwith our social investments, up from 31% in 2020. Reduce our operational Freely\" question in the Pulseby 2025.9 greenhouse gas (GHG) emissions survey as an annual average.16(i.e., Scopes 1 & 2) 46% by 2030,• Black/African Americans in thefrom a 2019 baseline.U.S. to 10%, up from 3% in 2020.Reach at least 75% of Maintain 100% compliancecountries around the world to regulatory requirements• Hispanics/Latinos in the U.S.annually with our products.10 Source 100% of our purchased for active incident monitoring,to 10%, up from 5% in 2020.electricity from renewables risk/harm analysis andby 2025.7 on-time notification ofdata breaches.17Enable 100 million moreMaintain or exceed our currentpeople to access ourinclusion index score, by 2025.13innovative portfolio globally, Work with our suppliers tothrough access strategies, achieve a 30% reduction insolutions and partnerships, Scope 3 GHG emissions by 2030,by 2025.11 Maintain or exceed our current from a 2019 baseline.employee engagement indexscore, by 2025.14Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 9"
  },
  {
    "page": 10,
    "source": "text",
    "content": "Access to healthEnabling greater access to health around the worldWith strategic input and guidance from our Public Policy andResponsibility Council (PPRC), our global approach to access is guidedby our Access to Health Guiding Principles, which span the areas ofdiscovery and invention, availability, affordability, and strengtheningsystems and addressing inequity. Strategies and actions to enableaccess are embedded across Merck.As a research-intensive biopharmaceutical company, our role isfirst and foremost to discover and develop, in a responsible andeconomically sustainable manner, innovative medicines and vaccinesthat address unmet medical needs and tackle some of the world'sgreatest health threats.Our research and development (R&D) priorities focus on addressingvital global health needs where we can have the greatest impact, nowand in the future. We invest in R&D to address infectious diseasesthat have a significant global public health burden, including in low-and middle-income countries (LMICs), and where emerging sciencesuggests opportunities to substantially reduce this burden throughmedicines or vaccines. Our R&D priorities also address the increasingneed for new therapies or vaccines targeted at diseases such as cancer,cardiovascular diseases, diabetes and other metabolic diseases,neurosciences and respiratory diseases. In 2020, our products andpipeline targeted 88 percent of the top 20 global burdens of disease.1,2,3We also recognize that, in collaboration with key stakeholders, we havea role to play in helping to ensure our science advances health care,and our products are accessible and affordable. We are committed toensuring a reliable, safe global supply of quality medicines and vaccines,and to developing, testing and implementing innovative solutionsthat address barriers to access and affordability of our medicines andvaccines. Our approach enables us to serve the greatest number ofpatients today, while meeting the needs of patients in the future.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 10"
  },
  {
    "page": 11,
    "source": "text",
    "content": "Planning for productOngoing commitment to addressaccess strategiesthe global HIV epidemicWe evaluate our R&D candidates to identify the potential to addressBuilding upon our proud legacy of innovation in HIVsignificant public health challenges and unmet medical needs ofprevention, we are collaborating with the Bill & Melindapatients, including in resource-constrained settings. Our approachGates Foundation on a pivotal Phase 3 study to evaluate theinvolves assessing the level of disease burden that exists, theefficacy and safety of islatravir as a once-monthly oral PrEPavailability of alternative medications and the appropriateness(Pre-exposure prophylaxis) option in women and adolescentof our products to improve public health. Additionally, understandinggirls at high risk for HIV infection in sub-Saharan Africa. Morewhere health system infrastructure and funding mechanisms are inthan half of new HIV infections globally occur in sub-Saharanplace is an important component of enabling safe and effective usage,Africa, with women accounting for nearly 60 percent of newwhich ultimately facilitates meaningful patient access. This processinfections in this region. This collaboration with the Bill &informs our product access solutions with the goal of making ourMelinda Gates Foundation exemplifies how we design tailoredmedicines and vaccines available to as many people as possible.solutions, often in partnership with key stakeholders, toreach the patients and populations who can benefit from ourHealth care access innovations. For more information, visit our investigationalHIV prevention option news story.and affordabilityOur approach to expanding access and patient reach is predicatedon the belief that broadening access requires sustained effort andis best achieved through solving the underlying challenges in the In many markets around the world, including LMICs, one of the recurringhealth care system. We expand access to our products through access challenges patients face is the potentially high out-of-pocketdedicated, market-based affordability solutions. We consider public costs for critical illness treatments, such as the treatment for cancer.health needs, economic conditions and health care infrastructure Recognizing this, we collaborate with reinsurers and insurance companieswhen designing these solutions, providing flexibility to reach at-need in several countries to enable them to develop accessible health insurancepopulations and patients. products that cover innovative cancer therapies. This provides options forthe population and drives greater health care inclusion.As this model further expands, it offers the potential to solve onemajor access hurdle and widen access to innovative cancer therapies268 millionfor patients in a commercially sustainable way. The approach reinforcesour commitment to being part of a wider ecosystem, collaborating withestimated people reachedothers with complementary capability to tackle affordability challenges.globally through productdonation and patient assistance When market-based solutions are inadequate or unavailable, weprograms and partnerships pursue programs to provide direct access to our medicines andvaccines, including product donations and patient assistance programs.In low-income countries, we continue our long-standing policy of notfiling for product patents.40 countrieswhere dedicated affordabilitysolutions have been initiatedMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 11"
  },
  {
    "page": 12,
    "source": "text",
    "content": "Eliminating river blindnessand lymphatic filariasis (LF)MECTIZAN® Donation Program:Our 30+ year commitment to eliminatingneglected tropical diseasesThe MECTIZAN Donation Program (MDP) is the longest-running drugdonation program and partnership of its kind. The program works withpartners to achieve a future free of onchocerciasis (river blindness)- Countries where MECTIZAN has been donated18one of the leading causes of preventable blindness worldwide-andlymphatic filariasis (LF or elephantiasis), both of which are on theCountries where elimination of LF as a publicWorld Health Organization (WHO)'s list of prioritized neglectedhealth problem has been validated by the WHOtropical diseases (NTDs).Widely regarded as one of the most successful public-private healthCountries where the elimination of rivercollaborations in the world, the MDP has influenced the developmentblindness has been verified by the WHOof a number of other drug donation programs and highlights ourcommitment to donate MECTIZAN® (ivermectin)for the treatmentof onchocerciasis to all who need it, for as long as needed.We have donated 4.4 billion MECTIZAN treatments since the$2.74 millionprogram launched in 1987, and there are now more than 15 millionpeople globally who no longer need treatment for river blindness direct financial investmentthanks to community-level efforts. In addition, several countries in the program in 202019, 20are making significant progress towards eliminating both diseases.In Latin America, four countries-Colombia, Ecuador, Mexico andGuatemala-have received WHO verification of river blindnesselimination. LF has now been eliminated as a public health problemin Togo, Yemen and Malawi. For more information, visit theMECTIZAN Donation Program website.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 12"
  },
  {
    "page": 13,
    "source": "text",
    "content": "Health equity Diversity in clinical trialsOne of the ways we address health disparities is by ensuring our clinicalAligned with our mission to save and improve lives, we take a focusedtrials are diverse and inclusive. Clinical trials function as the gatekeeperapproach to addressing health equity. This approach helps us betterto bringing effective new medicines and vaccines safely to patients andmeet the diverse needs of the populations and communities we serve,communities. Therefore, it is vital that we have diverse representationin recognition that everyone should have a fair and just opportunity toin our research efforts. We are pursuing new ways-includingbe as healthy as possible.partnerships with organizations like Black Health Matters, the NationalUrban League and the Lazarex Cancer Foundation-to recruit andWe have a long history of promoting health equity. Since 1957, weengage clinical trial participants who are racially, socioeconomically andhave contributed nearly $1 billion to support programs that addressdemographically representative of the communities we aim to serve.important global health and societal needs. Through July 2021, ourcompany contributed or committed more than $49 million (cash andin-kind) in support of global, national and local COVID-19 response Establishing the world's first Ebola vaccineefforts, part of which includes helping to address the needs ofstockpilevulnerable patient populations and communities most impacted bythe pandemic.In early 2021, we announced an agreement with UNICEF to establishthe world's first global Ebola vaccine stockpile with ERVEBO®(Ebola Zaire Vaccine, Live). This agreement represents anotherlandmark milestone in the fight against Ebola and is the result ofbreakthrough innovation and collaboration across Africa and the world.The global stockpile will offer a critical, rapid-response tool to helpcombat future outbreaks of this highly contagious, hemorrhagic illnessthat is endemic in parts of Central and West Africa. The stockpileinventory will be built over time and maintained by Merck and governedby the International Coordinating Group (ICG) on Vaccine Provision.For more information, visit the UNICEF collaboration news story.$49 millionannual investment in partnerships,programs and impact investmentsthat support health care capacity-building and address underlyingbarriers to access to health5Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 13"
  },
  {
    "page": 14,
    "source": "text",
    "content": "13 millionwomenreached with healthierpregnancies and saferdeliveries in more thanMerck for Mothers50 countries since 2012Merck for Mothers is our company's $500 million global initiative toend maternal mortality and improve the quality of maternity care.Since 2011, we've focused on strengthening health systems to sustainMore thanthe delivery of high-quality maternity care services that benefit womenand their communities. 78 millionpeopleIn 2021, we announced the creation of the Kenneth C. FrazierAward for Maternal Health Equity, a new grant award of up toreached through$250,000 that will be given annually to an organization in recognitionimproved accessof its commitment to addressing racial inequities in maternalto quality facilitieshealth outcomes.since launchFor more information about Merck for Mothers, visit the Merck forMothers website or see GRI 203 on pages 53-72 of this report.\" It is our vision that all women experience a healthy and safe pregnancy and childbirth. With strong localleadership and coordinated action among our growing group of collaborators, Merck for Mothers willcontinue on our path forward to make this a reality.\"- Julie L. Gerberding, M.D., M.P.H., Chief Patient Officer and Executive Vice President, Population Health & SustainabilityMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 14"
  },
  {
    "page": 15,
    "source": "text",
    "content": "Animal Health Supporting veterinary wellbeingWe support the health and wellbeing of the veterinary professionOur global Animal Health business is dedicated to preserving andthrough education and resources to help them build sustainable,improving the health, wellbeing and performance of animals throughresilient careers. In 2020, we released our second comprehensivescience. We provide innovative products, application systems andstudy of wellbeing and mental health among U.S.-based veterinarians.services to our customers that reduce environmental impact, improveConducted in collaboration with the American Veterinary Medicalanimal welfare and optimize animal productivity. Healthier animalsAssociation (AVMA), the study examined job satisfaction,mean more sustainable food supplies, protection against zoonoticcompensation, burnout, substance use disorder, cyberbullying anddiseases, a reduction in the burden of certain food-borne diseasessuicide among veterinarians, while evaluating potential solutions.and longer companionship for pet owners and happier pets.Due to the impacts of COVID-19, we increased our support for mentalhealth resources for veterinary professionals.As one of the only biopharmaceutical companies focused on bothhuman and animal health, we recognize the interconnection betweenAll of these efforts are in service of providing a safer and healthier futurethe health of people, animals, plants and their shared environment.for humans, the environment and the species upon which we depend.Our company is actively collaborating with stakeholders to tacklemajor population health challenges including antimicrobial resistance, For more information, visit our Animal Health website.zoonotic diseases, vector-borne diseases and ensuring a safe andsustainable food supply.Supporting a sustainable food supplySustainable agriculture supports communities and helps to addressfood insecurity. It also requires continuous innovation. For this reason,our Animal Health business is a strong supporter of researchersseeking to further the field of animal science. Our programs suchas CattleCare365, DairyCare365 and AquaCare365 are focusedon promoting animal welfare and increasing the environmentalsustainability of our sector. We are highly involved in associations suchas the Consumer Goods Forum, The Global Roundtable for SustainableBeef and the U.S. Roundtable for Sustainable Poultry and Eggs.Promoting animal welfare eventsWe understand the complexity of animal health care, which iswhy we provide our customers with more than vaccines andpharmaceuticals. Our highly attended educational offerings provideindustry-leading expertise to share best practices across fields andhelp customers maintain the health of their animals and positivelyimpact their business.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 15"
  },
  {
    "page": 16,
    "source": "text",
    "content": "EmployeesA culture that fosters diversity, inclusion, belonging andwellbeing drives a healthy and high-performing workforceThroughout our history, we have fostered a diverse and inclusive culturethat embraces different perspectives and values the contributions of eachindividual. Our long-standing commitment makes us a more innovativeand agile company-one better attuned to the needs of patients,customers and the health care providers. To harness the knowledgeand insights of our global diverse workforce, we take a thoughtful andstrategic approach to workplace inclusion, and investments in employeedevelopment and wellbeing.Global diversity and inclusion (GD&I)We are accelerating diversity, equity and inclusion in the health careecosystem, and in the communities and societies in which we operate.Cultivating a diverse and inclusive workforce, and fostering an environmentthat empowers wellbeing, helps us attract and retain top talent. Westrive to develop a culture of belonging and to ensure the diversity of ouremployees mirrors the external world. This helps us better understandthe unique needs of the customers, health care providers and patients weserve, including those with different abilities.We continue to grow our current diversity and inclusion efforts in fourkey areas:• Internal work environment• Health equity Black innovators and our legacy• Workforce development efforts of invention• Economic inclusionA diverse workforce is not only fundamental to ourWe have recently announced new representation goals to increase seniorfuture success, but it's also a part of our rich history.management roles for women, and Black/African American and Hispanic/Latino leaders by 2024. We are also adding new actions to create change For more information, visit our news story aboutwithin our company and deliver meaningful impact in the fight against Black innovators and moments that shape our legacy.systemic racism.See newESG Goals for Employees.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 16"
  },
  {
    "page": 17,
    "source": "text",
    "content": "GD&I Ambassador teams and EmployeeBusiness Resource GroupsOur GD&I Ambassador teams and Employee Business ResourceGroups (EBRGs) help foster our inclusion strategy.We have five diversity ambassador teams that work with thecompany's GD&I Center of Excellence to increase diverse patientrepresentation in clinical trials, grow supplier diversity, leverage diverseperspectives of employees and create strategic alliance partnerships todrive corporate reputation and trust.With more than 19,000 members across 10 groups, the EBRGs playa critical role in driving an inclusive culture and supporting the careergrowth of employees. They represent a diverse set of interests andaffinities, including:• Alianza• Asia Pacific Association In 2020, our employeebusiness resource group,• capAbility NetworkLeague of Employees of• Interfaith Organization African Descent, celebrated• League of Employees of African Descent (LEAD) 50 years of impact• Native American & Global Indigenous People• Next Gen Network• Rainbow Alliance• Veterans Leadership Network• Women's NetworkSupplier diversity and inclusionExternal engagementDiversity is critical for innovation and scientificWe engage with partners to advance the efforts of our global diversityexcellence as well as for better decision-making andand inclusion commitments and to support underserved communitiescultural agility. We exceeded our corporate goal ofall over the world. Some of our engagements include:spending at least $2 billion with minority-owned,• OneTen (Founding Member)women-owned, veteran-owned, LGBT-owned and• Year Up (Corporate Partner) disability-owned business enterprises. This is our 35thyear pursuing goods and services from diverse suppliers• CEO Action for Diversity & Inclusion (Signatory)through our Supplier Diversity & Inclusion program.• Paradigm for Parity (Signatory)• The Valuable 500 (Member)• International Labour Organization's (ILO) Global Business DisabilityNetwork (Member)Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 17"
  },
  {
    "page": 18,
    "source": "text",
    "content": "Culture of wellbeingA global pandemic turned our world upside down in 2020 and changedthe way we live and work. As a company that aspires to improveaccess to health and save and improve lives, we knew that to be trulysuccessful, we had to begin with the health, wellbeing and safety of ouremployees. In 2020, we placed a special emphasis on mental health tohelp employees cope with the effects of the COVID-19 pandemic, andwe're incredibly proud of their resilience and their ongoing efforts tohelp others in need.For more information, visit our Wellbeing Report on ourcorporate website.Nurturing wellbeing in a remote worldIn response to the pandemic, we expanded our health and wellbeingprograms to help employees adapt to this new normal. We also madesignificant investments in programs to support their unique needsincluding expanded backup child and elder care, subsidized remotetutoring services, a caregiving concierge and other tools to supportworking from home for parents and those caring for elderly parents.Other initiatives include: Employee engagement and volunteeringCOVID-19 global town hall series We created a Medical Volunteer Program to enable colleagueswith medical skills to volunteer throughout the pandemic with noOur chief patient officer and executive vice president of populationinterruption in pay, allowing them to help our community. While wehealth & sustainability, Julie L. Gerberding, hosted 12 town halls topaused our flagship skills-based volunteer program, Fellowship forprovide critical information about COVID-19 safety and wellbeing,Global Health, we continued to provide grant funding to our NGOresilience, ways of working during challenging times and COVID-19partners to support program needs. We've recently relaunched thetesting and vaccines.program in a virtual format for 2021. Through our Pro Bono LegalGrants program, we continued to support nonprofits with grantMental health resourcesfunding and pro bono legal support.To address the effects of the pandemic, including stress and anxiety,we offered programs and workshops on mindfulness, resilience and For more detailed information on our employee diversity, wellbeing,sleep to support our employees' emotional and mental wellbeing. equity and inclusion efforts, please see pages 118-154.The future of workThe kind of agility we've learned over the last year will remain centralto the way we all work together. We've recently introduced a flexible,hybrid work model - a combination of in-person collaboration andremote work - to help us be even more agile and productive as wedeliver for patients. For more information, visit our hybrid work modelnews story.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 18"
  },
  {
    "page": 19,
    "source": "text",
    "content": "Environmental Our climate action goalssustainability By 2025, we commit to achieve carbon neutrality across ouroperations by increasing our energy efficiency, applying sustainablebuilding standards and continuing to transition away from the useA healthy planet is essential to human health of fossil fuels.and the sustainability of our businessBy 2030, we commit to reduce our value chain emissions by30 percent, by continuing to engage with suppliers to reduce theiremissions, promoting opportunities for suppliers to source renewableenergy and using existing procurement and supply chain processes todrive additional strategies to decrease emissions (Scope 3).Our company has a long history of environmental stewardship and We are accelerating our previous goal of sourcing 100 percentcompliance, and we realize that our strategy and efforts need to renewable energy for purchased electricity by 15 years, to 2025. Wecontinuously improve for us to excel in an increasingly resource- are also pursuing renewable energy projects to reduce our emissions,constrained world. Our environmental sustainability strategy has and have recently signed on to three new virtual power purchasethree areas of focus: agreements (VPPAs) that will address approximately 35 percent ofthe emissions from our electricity use.• Driving efficiency in our operations• Designing new products to minimize environmental impact• Reducing any impacts in our upstream and downstream value chain.100% renewableWe have recently adopted a set of new climate goals to address therising expectations of our customers, investors, external stakeholderssources for our purchased electricity by 2025and employees regarding the environmental impact of our operationsand supply chain.\"O ur new climate action goals reflect our Carbon neutralityongoing commitment to operating responsiblyacross our operations by 2025and will help us drive long-term sustainability (Scopes 1 & 2 GHG emissions)for our business, society and for the patientsand communities we serve.\"- Robert M. Davis, Chief Executive Officer and President 30% reductionin value chain (Scope 3) emissions by 2030See our complete ESG Goals.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 19"
  },
  {
    "page": 20,
    "source": "text",
    "content": "Our 2020 performanceThis past year, we achieved all of our 2020 environmental goals andcontinued to make progress on longer-term targets to decrease energydemand, increase the amount of renewable energy we purchase andengage suppliers in efforts to reduce the environmental footprintoutside of our operations.52% high-impactsuppliershave GHG emission reduction targetsGlobal water use and stewardship1.1 million 14%Our global water strategy aims to achieve sustainable watercubic meters reductionmanagement within our operations and our supply chain, as well asaddress water-related risk. Access to clean water is critical for humanof water recovered, in water use in 2020health, and water is a key input to our manufacturing operations.reused or recycled at from 2015 levelsOur sites employ a variety of technologies and techniques, such as our facilities in 2020 (3.4 million m3 belowclosed-loop cooling systems and reused reverse osmosis \"reject water,\"2015 levels)to reduce our water footprint and improve operational performance.In addition to reducing our water use by 14 percent from our 2015baseline, we achieved our goal of developing water conservation plansfor sites in \"high water risk\" locations by 2020. Lastly, we are on trackwith our 2025 supplier goal, as 45 percent of high-impact suppliershave water use reduction targets. Our goal is at least 90 percent ofthese suppliers will have water use reduction targets by 2025.57% 80%Waste management and diversionof hazardous waste of non-hazardous wastebeneficially reused beneficially reused inWe continuously strive to reduce the amount of operational waste in 2020 2020we generate and to maximize the use of environmentally beneficialdisposal methods such as recycling, composting and waste-to-energy.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 20"
  },
  {
    "page": 21,
    "source": "text",
    "content": "Product stewardship and green Green chemistry leadershipand sustainable science We aspire to be the leader in the industry for thedevelopment of innovative, efficient, green andsustainable commercial syntheses of small-molecule,Our product stewardship program focuses on identifying andactive pharmaceutical ingredients (APIs). Sinceeither preventing or minimizing potential safety and environmental1996, we've been recognized seven times by the U.S.hazards throughout a product's life cycle. We are also committed toEnvironmental Protection Agency and the Americanunderstanding, managing and reducing the environmental impactsChemical Society's (ACS) Green Chemistry Challengeof our products and the materials associated with discovering andAwards, the most in the industry, including awards inproducing them. Our green and sustainable science program uses a2020 and 2021.\"green-by-design\" approach. By using more efficient and innovativeprocessing methods and technologies, we are reducing the amount ofenergy, water and raw materials we use to make our products, therebyminimizing the amount of waste we generate and loweringour production costs.For more information on our product stewardship approach, see ourGlobal Antimicrobial Action Plan, policy on the Responsible Disposalof Medicines and our approach to Pharmaceuticals in the Environmenton our corporate website.90%of new human health APIprocesses met internal 100%sustainability targets at 2021 Peter J. Dunn Awardof our new humanlaunch by 2020 for Green Chemistry andhealth products launchedEngineering Impact in thein 2020 reviewed forPharmaceutical Industryenvironmental impactand improvement in Recognized by ACS's GreenChemistry Institute for developingtheir packaginga novel photo-flow process thatcreates a more efficient andenvironmentally safe reaction inthe manufacturing process.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 21"
  },
  {
    "page": 22,
    "source": "text",
    "content": "Simplifying animal Animal conservationhealth packagingWe are a leading worldwide supplier of individual identification,real-time data access and advanced analytics for the conservationIn 2020, we launched an initiative to standardize the packaging options community. This enables us to produce actionable insights that informfor our medicines and vaccines, including identifying efficiencies in our recovery actions on a global scale, for species ranging from wild fish tosupply chain, to help reduce the environmental impact of our products. penguins. Our product lines include the most advanced aquacultureWe are working closely with colleagues in human health to share automation and species-recognition products on the market. Together,learnings and gain additional efficiencies across the company. these technologies ensure the future of natural resources by reducingthe inadvertent loss of endangered species in commercial harvest, andsupport the global need for reliable and safe sources of protein.For more information on our environmental impact and progress,please see pages 83-117.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 22"
  },
  {
    "page": 23,
    "source": "text",
    "content": "Select awards and recognitionNewsweek Fortune Disability:IN®America's Most World's Most 2021 Best PlacesResponsible Admired Companies to Work forCompanies 2020 2020 and 2021 Disability Inclusionand 2021Ranked #2 most 7th year in a rowadmired company in theRanked #2 in the Health CarePharmaceutical category forand Life Sciences sector forboth yearsboth yearsThe Human Rights Forbes Fast CompanyCampaign FoundationAmerica's Best Top 50 Most InnovativeBest Place to Work for Employers for New Companies 2020LGBTQ Equality 2020 Graduates 2021Ranked #1 in BiotechBarron's Energy Star Just Capital100 Most Sustainable 2021 Partner of the 2021 Just 100 ListCompanies in the Year-SustainedRanked #1 in BiopharmaUnited States 2021 Excellence Award and #30 overall14th year in a rowAdditional employee-related awards and recognition included in GRI 405 on page 145.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 23"
  },
  {
    "page": 24,
    "source": "text",
    "content": "References 1 As of December 31, 2020.2 As defined by the Institute for Health Metrics and Evaluation (IHME) using GBD 2017 data; excludingroad injury, self-harm, interpersonal violence and neonatal disorders.3 This number was slightly higher in 2019 than in years past due to our expanded collaboration withMSD-Wellcome Trust Hilleman Laboratories and our acquisitions of Immune Design and Peloton, TilosTherapeutics and Calporta in 2019.4 Data for Board members as of August 20, 2021.5 Represents investments by our Office of Social Business Innovation.6 Our company has publicly disclosed EEO-1 information since 1999. Our 2020 data is available on ourESG resource page on Merck.com. Senior management roles reflect Band 700 at Merck.7 We have defined \"purchased electricity\" as electricity sourced from external suppliers as well asrenewable electricity that was generated and utilized onsite where we retained the renewable attributesor where we have obtained renewable attributes through contract.8 As defined by the World Bank Country and Lending Groups.9 Social investments include Merck's philanthropic partnerships, programs and impact investments.Underserved populations are defined as those that face health disparities due to disadvantages relatedto insurance status, social determinants of health, race, ethnicity, gender identity/sexual orientation,age and/or language preference.10 Includes reach for all products. Countries are as defined by the World Bank Country and Lending Groups.11 Access strategies, solutions and partnerships includes patient assistance programs, voluntary licenseagreements, and partnerships. Enable more people is defined as implemented and launched in marketand is in comparison to the baseline in 2020. Access is defined as products registered, launched andavailable in the market. Portfolio of products include Oncology, Vaccines, HIV treatments, and COVID-19treatments if approved.12 Senior management roles reflect Band 700.13 The Inclusion Index is the average favorability score for employees' responses to three items in theemployee pulse survey (manager supports inclusion, sense of belonging, leaders value perspective).14 The Employee Engagement Index is the average favorability score for employees' responses to items inthe employee pulse survey (employees recommend Merck).15 Scope 1 emissions are direct greenhouse (GHG) emissions that occur from sources that are controlled orowned by an organization (e.g., emissions associated with fuel combustion in boilers, furnaces, vehicles).Scope 2 emissions are indirect GHG emissions associated with the purchase of electricity, steam, heator cooling. Scope 3 emissions are the result of activities from assets not owned or controlled by thereporting organization, but that the organization indirectly impacts in its value chain.16 Favorable response indicates the percentage of respondents who gave the top two favorable responseoptions on a five-point agreement scale.17 Regulatory requirements differ by region.18 As of July 2021.19 Following our company's commitment in 2017 to expand the donation of Mectizan to support theimplementation of triple-therapy for the elimination of LF in certain settings, the Mectizan DonationProgram expanded in 2018 to include donations for LF elimination in countries not endemic forriver blindness.20 Direct investment includes operational support and grants.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 24"
  },
  {
    "page": 25,
    "source": "text",
    "content": "GRI/SASBdisclosuresMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 25"
  },
  {
    "page": 26,
    "source": "text",
    "content": "GeneraldisclosuresSee our GRI Index on page 171.Organizational profile We are a global health care company that delivers innovative healthsolutions through our prescription medicines, vaccines, biologictherapies and animal health products. In the U.S. and Canada, we areknown as Merck & Co., Inc., Kenilworth, NJ, U.S.A. Elsewhere we areknown as MSD.GRI 102-1 Organization name (Core)Our operations are principally managed on a products basis and includeGRI 102-2 Primary brands, products, and services (Core)two operating segments:GRI 102-3 Headquarters location (Core)• PharmaceuticalGRI 102-4 Location of operations (Core)• Animal HealthGRI 102-5 Ownership and legal form (Core)GRI 102-6 Markets served (Core) Operating segmentsNumber of drugs (1) in portfolio and (2) in researchSASB 000.B Our Pharmaceutical segment includes human health pharmaceuticaland development (Phases 1-3)and vaccine products. Human health pharmaceutical products consistof therapeutic and preventive agents, generally sold by prescription,for the treatment of human disorders. We sell these human healthpharmaceutical products primarily to drug wholesalers and retailers,hospitals, government agencies and managed health care providersMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 26"
  },
  {
    "page": 27,
    "source": "text",
    "content": "such as health maintenance organizations (HMOs), pharmacy benefitmanagers (PBMs) and other institutions. Human health vaccineproducts consist of preventive pediatric, adolescent and adult vaccines,primarily administered at physician offices. We sell these human healthvaccines primarily to physicians, wholesalers, physician distributors andgovernment entities.The Animal Health segment discovers, develops, manufacturesand markets a wide range of veterinary pharmaceutical and vaccineproducts, as well as health management solutions and services, for theprevention, treatment and control of disease in all major livestock andcompanion animal species. We also offer an extensive suite of digitallyconnected identification, traceability and monitoring products. Theprimary customers for our animal health products are veterinarians,distributors and animal producers.A list of our pharmaceutical products can be found on pages 2-6$13.6 billionof our 2020 Form 10-K.in R&D expendituresLocationsOur corporate headquarters are located in Kenilworth, New Jersey,U.S.A. We previously announced that we intend to consolidate our 74,000New Jersey campuses into a single corporate headquarters location inemployeesRahway, New Jersey, by the end of 2023. We also maintain operationalor divisional headquarters in Madison, New Jersey and UpperGwynedd, Pennsylvania.Our principal U.S. research facilities are located in Rahway andOur operations outside the U.S. are conducted primarily throughKenilworth, New Jersey; West Point, Pennsylvania; Boston,subsidiaries. Sales worldwide by subsidiaries outside the U.S. as aMassachusetts; South San Francisco, California; and Elkhorn,percentage of total company sales were 56 percent in both 2020Nebraska (Animal Health). Principal research facilities outside theand 2019 and were 57 percent in 2018.U.S. are located in the United Kingdom, Switzerland and China. Ourmanufacturing operations are headquartered in Whitehouse Station, The principal market for trading of our common stock is the New YorkNew Jersey. Stock Exchange (NYSE) under the symbol MRK. As of January 31,2021, there were approximately 104,900 shareholders of record ofThe production facilities for our human health products include ninethe company's common stock.locations in the U.S. and Puerto Rico. Outside the U.S., throughsubsidiaries, we own or have an interest in manufacturing plants You can find a full list of our products, as well as our pipeline, on ouror other properties in Japan, Singapore, South Africa, and other corporate website.countries in Western Europe, Central and South America, and Asia.A number of properties transferred to Organon in the spinoff. For more information, also see our 2020 Form 10-K.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 27"
  },
  {
    "page": 28,
    "source": "text",
    "content": "As of December 31, 2020, the company had approximately 74,000employees worldwide, with approximately 27,000 employed in theGRI 102-7 Scale of the organization (Core) U.S., including Puerto Rico, and approximately 26,000 third-partycontractors globally. Approximately 73,000 of the company'sGRI 102-8 Information on employees and other workers (Core)employees are full-time employees. Women and individuals withethnically diverse backgrounds comprised approximately 50 percentand 31 percent of the workforce in the U.S., respectively. As ofAugust 20, 2021, women comprised 46 percent of the membersof the Board of Directors.For more information on our diversity, equity and inclusion figures,please see GRI 405 on page 145.Employeesby regionCanada Europe (Western) JapanNumber of Worldwide668 | 0.9% 20,995 | 28.1% 3,266 | 4.4%employees percentageU.S.26,826 | 36% China7,273 | 9.8%Asia-PacificLatin America 6,730 | 9.0%5,469 | 7.3%Eastern Europe,Middle East and Africa3,357 | 4.5%Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 28"
  },
  {
    "page": 29,
    "source": "text",
    "content": "• A cross-functional team that oversees program development,processes and guidelines to encourage best practices, preventGRI 102-9 Supply chain (Core) violations of supply chain standards and limit risk• Established sustainability requirements that are communicatedOur company is committed to the highest ethical standards to help to our suppliers and included in supplier selectionmaximize the long-term sustainability of our business and of the• Review, tracking and communication of supplier sustainabilitycommunities in which we operate. We strive to conduct business withprogramsthird parties which share our commitment to high ethical standardsand who operate in a responsible and ethical manner. The term \"third • Collaboration as we educate and learn from our supply chain,party\" is broadly interpreted to include any individual or entity that peer companies and best-in-class organizationsprovides any type of goods or services in support of our sourcinginitiatives. We expect all third parties with whom we engage to comply Third-Party Risk Management teamwith all applicable regulations, as well as share in our commitment tothe principles outlined in our Business Partner Code of Conduct. To help manage and address potential areas of risk associated withthird party business relationships, our company has an establishedWe manufacture, package and distribute products to more thanThird-Party Risk Management program and committee chaired by the140 markets around the world. We have established businesssenior vice president for Global Procurement. The team establishes,relationships with over 40,000 suppliers. Our network comprisesimplements and monitors environmentally, socially responsible andapproximately 1,700 direct suppliers (including external manufacturingethical sourcing practices to ensure that performance is aligned withproviders), 1,800 capital expenditure suppliers, 32,000 indirectour mission. The cross-functional team includes leaders from oursuppliers and 4,700 research providers. Our direct suppliers providebusiness areas as well as functional areas that monitor risk, including:us with goods such as packaging, components and ingredients. CapitalCompliance, Global Safety and the Environment, Informationexpenditure suppliers provide goods and services such as engineeringTechnology Risk Management & Security, Business Development,and construction. Our indirect suppliers include those that provideand ESG Strategy & Engagement. Representatives from eachservices such as logistics, travel and meetings, facility managementfunction meet regularly to discuss, assess and manage issues onand marketing. Our research providers include lab supplies and othera risk-driven basis.research related services.Supplier selection and setting expectationsOur approach to sustainable sourcingWe select suppliers that share our commitment to our values andWe have a sourcing management process in which environmentalprinciples. We expect appropriate standards of conduct and respectsustainability, social responsibility and economic inclusion and supplierfor human rights from our suppliers, contractors, vendors and externaldiversity (EI&SD) principles are integrated in each stage. Throughoutpartners to be consistent with our own. We use our Business Partnerthe supplier life cycle, our company establishes expectations, assessesCode of Conduct to communicate our expectations for Human Rights,risk, supports supplier development and manages performance.Labor & Employment, Health, Safety & Environment and EthicalBusiness Practices. Our Business Partner Code of Conduct, along withOur Global Supplier Management Group (GSMG) is responsibleour company's Supplier Performance Expectations, are communicatedfor driving our Sustainable Sourcing program and maintaining theto existing and potential third parties. They are included in requestsassociated standards and processes by which suppliers are identified,for information, proposals and quotes, as well as in our purchase orderqualified and managed. Our Sustainable Sourcing program has theterms and conditions. We make it available in 26 languages.following key elements:• Integration into our Global Sourcing & Procurement Strategyand processesMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 29"
  },
  {
    "page": 30,
    "source": "text",
    "content": "Our Code Of Conduct adheres to and references the Pharmaceutical Additionally, we initiated and participated in a collaborative researchSupply Chain Initiative (PSCI) Principles for Responsible Supply project with PSCI to identify risks associated with our suppliersChain Management (the Principles). PSCI is a group of almost 50 including prioritizing materials that are considered sensitive. PSCI haspharmaceutical and health care companies which promotes sustainable identified materials commonly used within our industry that warrantsourcing and better business conditions across the industry, and the further examination.Principles set the standard for human rights, ethics, labor, healthThese include:and safety, environment and related management systems. In 2020,the Principles were updated to include a specific reference to human• Rubber • Glass • Soyrights, the UN Guiding Principles on Business and Human Rights, anenhanced ethics section and new clauses on resource efficiency and • Corn • Sugar • Cellulosesustainable sourcing. • Palm oil • Talc • Ethanol• Aluminum • Fish oil • Carnaúba waxSupplier certification and material review• Shellac • Castor seed/oilIn 2020, GSMG initiated a program to certify our suppliers' social andenvironmental sustainability program capabilities. We request select We recognize that potential risks may also exist beyond our Tier 2suppliers provide sustainability certifications and assurance, which are suppliers and plan to participate in efforts (in collaboration with PSCI)evaluated to determine if the supplier can be certified as a member of to ensure that the materials we use are sourced responsibly.our GREEN Supplier Program. Travel and Meetings (including Fleet),We are incorporating findings from the PSCI joint project into ourIntegrated Logistics and Paper-based Packaging Categories areinternal risk assessment and mitigation approaches. We have also beencurrently included in this program which:mapping our supply chain to identify which of our suppliers operate• Encourages supplier engagement in countries that are known to present significant risks. We use thisinformation to help us decide the appropriate level of due diligence for• Shares best practices and improves sustainability practicesour ingredients.• Tracks supplier sustainability goalsWe also initiated the collection of supplier packaging data. Based on• Generates a list of GREEN Suppliers and proposed2020 data received (as of March 2021), our packaging ranges fromsustainability projectshaving no post-consumer recycled content or certifications to 100• Monitors progress utilizing a key performance indicator (KPI) percent. We plan to continue to enhance our packaging data collectionon the GSMG Scorecard for future reporting.Supplier due diligence assessmentsWe have a defined risk-management process, and our supply base ismeasured against the process criteria. Using a risk-based approach,supplier assessments and audits are conducted based on multiplefactors (e.g., risk profile, engagement and activity type, geography). Theassessments and audits evaluate a supplier's ability to meet both industryand our own standards for quality, safety and ethical business practices.Results are reviewed with senior management across the company.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 30"
  },
  {
    "page": 31,
    "source": "text",
    "content": "Examples of our due diligence include: Protecting the privacy of personal information• Anti-bribery and corruption • Information securitySome of our suppliers, such as contract research organizations, marketand cybersecurity• Conflict minerals research agencies, information technology systems developers and• Intellectual property other suppliers, process personal information in connection with their• Denied-party screeningperformance of services for our company. We require these suppliers• Labor and human rights• Ethics and compliance to provide appropriate privacy protection for personal information• Financial solvency • Privacy (data protection) that they handle in accordance with our privacy policies and applicable• Supply-chain security privacy laws, regulations and guidelines.Where assessments and audits identify deficiencies or opportunities Protecting against cyberattacks and assuringfor improvement, we monitor suppliers to ensure that our concernsbusiness continuityare addressed in a responsible and compliant manner. As part of ouroversight and monitoring, we have established mechanisms to report,We recognize that cybersecurity events at suppliers pose an increasedtrack and monitor supplier plans to address nonconformance and helprisk to our business continuity. In 2020, our company continueddrive continued improvement. Additional review(s) are performed forour supplier cyber resiliency risk management program to conductexternal manufacturing suppliers and suppliers that manage personalassessments and review risks and remediation actions with keyand private information.suppliers. We also expanded the program by introducing joint cyber-resiliency tabletop exercises and rolling out cybersecurity contractExternal manufacturers of our products language with selected key suppliers. The program fosters mutuallybeneficial working relationships with our top suppliers. We continueProspective external manufacturers of active pharmaceutical to enhance the program to improve operational excellence andingredients and finished products are screened for environmental, continuous monitoring capabilities.health and safety (EHS) compliance in addition to quality, supply andtechnical competence requirements. The EHS screening includes aCollaboration is keysurvey covering such topics as regulatory compliance, fatalities andmajor incidents.We are an active member of PSCI. The member companies sharea vision of better social, health, safety and environmental outcomesBased on the screening results and activities undertaken by thein the communities where we buy. Collectively, PSCI memberssupplier, certain external manufacturers are subject to a more detailedshare knowledge and expertise across our industry to drive complex,onsite assessment conducted by a multidisciplinary team, which mayglobal change more effectively with our suppliers than any oneinclude our company's Quality, Global Safety and the Environment,organization alone.Global Technical Operations and GSMG representatives.Our company currently holds a position on the Board, co-leadsThe external manufacturers we contract with are periodicallythe Environment Team and is the board liaison for the Capabilityreassessed using a risk-based approach; higher-risk externalCommittee. We are also an active member of the Human Rights andmanufacturers are subject to more frequent onsite assessments.Labor team. In 2020, PSCI focused on updating the Principles andWe expect that observations made during the audit process will bedeveloping supplier training, tools and maturity models.remediated by our external manufacturers, and we monitor and trackcorrective actions through completion.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 31"
  },
  {
    "page": 32,
    "source": "text",
    "content": "TrainingWe understand the importance of training and, in 2020, developed andprovided numerous training events assigned to employees, industrypeers and suppliers. Most of our internal classes are assigned throughour centralized learning system. In addition to providing trainingthrough our internal systems, we also work with PSCI to develop andprovide training to our suppliers and peers.Some examples of our training and associated tools include:• Procurement Onboarding• Third-Party Risk Management• Business Partner Code of Conduct Training (Edition 2)• Mitigating Modern Slavery Risks in Our Supply Chain• 10 Environmental Sustainability Guides• 14 Responsible Sourcing Guides for Key Materials• Responsible Sourcing of Raw Materials Training• Sustainable Packaging• Revised PSCI PrinciplesCommunication to our stakeholdersWe have an internal webpage maintained by GSMG that providesinformation on our Sustainable Sourcing programs to stakeholders.Examples of materials provided include: our program summary,supplier data, benchmarking, supplier programs, training materialsand newsletters. We also have quarterly newsletters in addition tomonthly updates that are provided via email.Additional details regarding our supplier-focused ESG programs canbe found in GRI 204 on page73, GRI 308 on page116, and GRI 414 onpage 157.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 32"
  },
  {
    "page": 33,
    "source": "text",
    "content": "Assessing the effectiveness of our programDuring 2020, we reviewed the following key performance indicators (KPIs) to help us assess the effectiveness of our efforts in our business andsupply chain. We use these measures to monitor our performance and identify opportunities to help improve our programs.Supply chain KPIs 2017 2018 2019 2020Employees trained on mitigating modern slavery risks in our supply chain1,2 N/A 451 4 8Employees trained on updated Business Partner Code of Conduct (Edition II)1 195 148 190 183Employees trained on Third-Party Risk Management1,3 N/A N/A N/A 185Supplier Self-Assessment Questionnaires performed4 466 595 706 547Supplier LHR audits conducted5 32 104 39 47Supplier LHR audit observations addressed/remediated6 100% 100% 99% 95%Supplier personnel trained in ESG7 N/A N/A N/A 1,492GREEN supplier spend8,9 N/A N/A N/A $247M1 Primary target: Procurement and business development staff with responsibility for supplier management2 Training on our modern slavery risks in our supply chain began in 2018 with applicable employees, and is provided to all new relevant hires going forward.3 Formal training was created and rolled out in late 2020; prior to 2020, informal training was provided on an as needed basis4 Undertaken as part of initial and ongoing supplier due diligence, managed and overseen by GSMG; Scope includes labor and human rights, environment and safety, and ethical business practices5 Announced on-site audits, independently performed by third-party audit firms; primary focus on direct material (Tier 1) supplier facilities located in China, India, Mexico and Indonesia6 Monitoring closure of past audit observations revealed by supplier LHR audits; not all CAPAs are due within the same year7 Formal Training created in 2020 and conducted as joint effort with PSCI; includes Sustainable Packaging, PSCI Principles, Forced Labor and Modern Slavery8 2020 metric represents 2019 spend data for the 2020 list of GREEN Suppliers9 Our GREEN supplier program officially launched in 2020.We also had a Healthcare Services segment that provided services andsolutions focused on engagement, health analytics and clinical servicesOrganizational changes duringGRI 102-10 to improve the value of care delivered to patients. We divested thethe reporting period (Core)remaining businesses in this segment in the first quarter of 2020.For more information on the spinoff, please visit our 2020 FormIn February 2020, we announced our intention to spinoff products10-K, pages 1, 28, 40-42, 47-48, 57-60, 83 and 97, as well as relatedfrom our women's health, biosimilars and established brandsinformation on our corporate website.businesses into a new, independent, publicly traded company namedOrganon & Co. (Organon) through a distribution of Organon's publicly For more information on the divestiture of our Healthcare Servicestraded stock to our shareholders. We completed the spinoff on June 2, segment, please visit our 2020 Form 10-K, pages 1, 47, 61, 83, 107, 127,2021. The financial and other information contained in this report 132 and 133.relating to the year ended December 31, 2020, and earlier periods,includes the information related to the Organon businesses that werespun-off in 2021.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 33"
  },
  {
    "page": 34,
    "source": "text",
    "content": "local communities and other interested parties to address globalwater challenges. We are working to identify partnerships thatGRI 102-11 Precautionary principle (Core) will help us advance our water stewardship priorities in the areas inwhich we operate. These projects also support the goals of SDG 15,which strives to \"protect, restore and promote sustainable use ofWe take a precautionary approach when evaluating potential humanterrestrial ecosystems.\"exposures and environmental impacts resulting from ourmanufacturing processes. Conservative assumptions are made whendata is limited, and safety factors are added to address uncertainty and Human rightsvariability in our assessments.Our company believes in the dignity of every human being andThis type of approach is particularly relevant to our work in toxicology,recognizes the international human rights principles embodied inindustrial hygiene, biosafety and environmental protection.the United Nations Global Compact and as defined in the UnitedNations Universal Declaration of Human Rights and its subsequentFor more information on our approach to the precautionary principle,changes, the International Covenant on Economic, Social and Culturalplease refer to the following sections:Rights, the International Covenant on Civil and Political Rights, theGRI 301 - Materials (page 83) Organization for Economic Cooperation and Development Guidelinesfor Multinational Enterprises and the core labor standards set out byGRI 302 - Energy (page 88)the International Labor Organization.GRI 303 - Water (page 93)GRI 305 - Emissions (page 100) Supply chainGRI 306 - Effluents and Waste (page 106)Our human rights practices are informed and guided by the PSCI'sGRI 307 - Environmental Compliance (page 110)Pharmaceutical Industry Principles for Responsible Supply ChainGRI 403 - Occupational Safety (page 128) Management which set the standard for ethics, labor, health, safetyand the environment for our industry.DiversityGRI 102-12 External initiatives (Core)In 2009, we signed onto the United Nations Women's EmpowermentPrinciples. These principles reflect seven areas of focus designed toThough not an exhaustive list, below are examples of third-partypromote gender equality in business.principles and initiatives we have endorsed. Additionally, there aremulti-party collaborations mentioned throughout this report, thatKenneth C. Frazier, our Executive Chairman and former CEO, is noware mentioned in relation to specific disclosures.the chair of the OneTen Initiative, a coalition of leading executiveswho are coming together to upskill, hire and advance one million BlackWater individuals in America over the next 10 years into family-sustaining jobswith opportunities for advancement. You can learn more about thisWe have endorsed the UN CEO Water Mandate, a public commitment initiative in GRI 405 on page 152.to adopt and implement a comprehensive approach to watermanagement, and we have aligned our water program with itsClinical researchprinciples. CEO Water Mandate endorsers have a responsibilityto make water-resource management a priority and to work withIn accordance with our public policy position statement, allgovernments, UN agencies, nongovernmental organizations (NGOs),investigational studies in human subjects are conducted in a mannerMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 34"
  },
  {
    "page": 35,
    "source": "text",
    "content": "• American Chemistry Council's (ACC) Green Chemistry Initiative• AMR Alliance Common Antibiotic Manufacturing Framework• Billion Dollar Roundtable (BDR)• Compliance Program Guidance for Pharmaceutical Manufacturers• International Federation of Pharmaceutical Manufacturers & Associations(IFPMA) Code of Practice• Paradigm for Parity• PhRMA Code on Interactions with Health Care Professionals• Science-Based Targets Initiative (SBTi)GRI 102-13 Membership associations (Core)Our company is a member of numerous industry and trade groups.We work with these groups because they represent the pharmaceuticalindustry and business community in debates led by governments andother stakeholders, and because they help the industry reach consensuson policy issues.Our top three trade associations in 2020:• Pharmaceutical Research and Manufacturers of America (PhRMA)consistent with laws, regulations and guidelines for the protection of• U.S. Chamber of Commercehuman subjects, including those issued by the International Council for• Biotechnology Industry Organization (BIO)Harmonisation Good Clinical Practice (ICH GCP).When our trade associations actively lobby on our core business issues, weAnimal health seek to align their positions with our own. There are times, however, whenwe may not share the views of our peers or associations - both on issuesWe encourage proactive vaccination of animals to prevent disease and that are central to our business and on those that, while important, aresupport the responsible use of antibiotics to treat and improve the not directly material to our mission. With representatives on the boardshealth of animals. As a global animal health company, we support the and committees of industry groups and trade associations, we can voiceAntibiotic Commitment established by the animal health industry. questions or concerns we may have about policy or related activities. Wemay even recuse ourselves from related trade association or industry groupactivities when appropriate.Other initiativesThe Corporate Secretary sends an annual report to our company'sIn addition to the ESG reporting frameworks we report againstBoard of Directors on trade association dues greater than $25,000 that(see pages 171-192), we also support the following external initiativeswere spent in the previous year on lobbying and political activity in theand commitments (among others), the details of which can be foundU.S. The Governance Committee of the Board of Directors has ongoingthroughout this report:oversight of the company's membership in trade associations andgrassroots lobbying activities.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 35"
  },
  {
    "page": 36,
    "source": "text",
    "content": "Below is a list of industry and trade groups of which we are a member, and our trade association dues (those greater than $25,000) that are used forlobbying purposes:Trade Association Dues Used for Lobbying 2016 2017 2018 2019 2020Animal Health Institute $32,726 $39,271 $70,687 $70,687 $56,550Bio New Jersey* $1,980 $4,860 $5,100 $10,140 $8,490Biotechnology Industry Organization $238,208 $231,679 $237,468 $274,964 $320,471California Life Sciences Association $13,680 $11,300 $49,980 $49,980 $47,760Council of the Americas* $1,250 $1,250 $1,250 $1,250 $1,500Chemistry Council of New Jersey $6,000 $8,775 $8,951 - -Healthcare Institute of New Jersey $126,004 $122,100 $114,404 $113,645 $116,983Healthcare Leadership Council $90,000 $90,000 $90,000 $90,000 $90,000Life Sciences Pennsylvania* $3,960 $4,500 $4,520 $6,360 $4,858Massachusetts Biotechnology Council $9,669 $9,884 $10,164 $10,461 $11,055National Association for Biomedical Research $20,000 $20,000 $20,000 $20,000 $20,000National Association of Manufacturers $70,845 $61,792 $56,443 $59,083 $62,132New Jersey Chamber of Commerce $4,001 $4,142 $4,245 $4,374 $3,003New Jersey Civil Justice Institute $30,000 $30,000 $30,000 $30,000 $30,000Pharmaceutical Research and Manufacturers of America $6,418,500 $11,630,454 $12,548,663 $11,743,028 $18,730,134Texas Healthcare & Bioscience Institute* $3,500 $5,500 $5,500 $5,500 $5,500U.S. Chamber of Commerce $345,000 $206,250 $237,500 $297,000 $130,000U.S. Council for International Business - - $3,445 $3,728 $7,456*Includes associations where dues are > $25,000. Because the U.S. tax law that requires this reporting does not apply outside the U.S., trade associations that are not subject to this do not providebreakouts of lobbying expenditures from membership dues.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 36"
  },
  {
    "page": 37,
    "source": "text",
    "content": "Through our top three trade associations (listed above), we engaged on • Legislative and regulatory restrictions for access to animalthe following policy issues in 2020. health products» EU-UK trade and cooperation agreementIn the U.S., the top issues at the federal level for which our companylobbied were: » New Veterinary Regulation (NVR) implementation• Medicare Part B » Pharmaceuticals in the Environment• Medicare Part D » Antimicrobial Resistance (AMR)• International Reference Pricing » One Health strategy• Medicaid Average Manufacturer Price (AMP) cap » New technological developmentsIn the U.S., our company lobbied at the state level to address thesekey issues:• Drug price transparency and price controls• Market-based solutions for access to innovative pharmaceutical,vaccine and biologic products• Maintaining a strong business environment for U.S. operations• Support for a strong immunization infrastructure• Removal of legislative and regulatory restrictions for access to animalhealth products• Support the regulatory/legislative environment for veterinarymedicine and technological developmentIn Europe, the top issues for which the company advocacy focused on:• Addressing the European Commission's review of incentives forbiopharmaceutical products• Fostering frameworks for sound pricing and procurement regimesin and across diverse European Union (EU) member state economies• Supporting government vaccination, hepatitis anddiabetes programs• Advancing the dialogue for sustainable models to fund futurecancer care• Improving standards for health technology assessment andhealth literacy• Ensuring science-based policies for biological medicinesMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 37"
  },
  {
    "page": 38,
    "source": "text",
    "content": "Strategy The Office of Ethics also serves as a channel for the receipt, triagingand redress of ethics and compliance-related concerns. Depending onthe concern type, the concerns will be investigated by the Office ofEthics, the Office of Global Investigations, Legal or Human Resources.GRI 102-14 CEO Letter (Core)Employees are encouraged to raise their concerns to theirmanagement, Human Resources, Compliance, Legal or the Officeof Ethics. The Office of Ethics maintains a global ethics program,Please see the letter from our President and CEO on page 3.Speak Up, and the MSDethics.com reporting tool. The reportingtool is operated by an independent third party and is available 24/7.Ethics & Integrity MSDethics.com allows employees and suppliers to raise concerns orask questions confidentially and anonymously (where permitted bylaw) in their preferred language via phone or internet.In alignment with our priority to protect and enhance our company'sValues, principles, standards, and normsGRI 102-16 reputation through safe, ethical and compliant behaviors, and to fosterof behavior (Core)a strong culture of compliance and ethics touchpoints in marketsGRI 102-17 Mechanisms for advice and concerns about ethicsoutside of the U.S., the three Regional Ethics Officers continue toCode of ethics governing interactions with health manage a network of site-based volunteer Ethics Ambassadors outsideSASB 510a.2care professionals of the U.S. The Ethics Ambassadors are trained to answer employeequestions about the company's reporting and investigation processand actively support the Speak Up Program.Our company's Office of Ethics is responsible for ensuring thatemployees are aware of and trained on the Code of Conduct andEthics and integrity are the bedrock of all that we do. And, theCorporate Policies addressing ethics and compliance.company strives to maintain a transparent work environment.Our Code of Conduct, Our Values and Standards, is available in Accordingly, all employees are required to report concerns that are23 languages and applies to all employees worldwide. Our Values potentially inconsistent with the company's Code of Conduct andand Standards set clear ethical expectations and principles that policies. Our company maintains multiple reporting channels (i.e.,allow us to be a company worthy of trust. The Code of Conduct management, Human Resources, Compliance, Legal, Speak Up tool atrepresents the very core of our character as a company and helps us MSDethics.com) and communicates regularly to employees to ensureto protect the reputation we have earned. In addition to publishing a they understand how they can report potential misconduct. EmployeesPDF version of our Code of Conduct's external website, our company are encouraged, prepared and empowered to raise concerns.offers a Code of Conduct (internal) website that allows employeesWe maintain a fulsome process for escalation and investigation ofto download a PDF of the Code of Conduct, search for a policy, ask apotential compliance-related concerns. The process is designed toquestion or raise a concern through MSDethics.com. It also offers toolsensure that we promptly investigate all reports of behavior thatand resources to help employees put our values into practice with everycould violate our company's policies, values or standards and takedecision and every action.appropriate remedial action in response to such concerns as needed.Corporate policies are reviewed every three years by business contentIf we substantiate allegations of ethical misconduct, we takeowners and updated as needed.appropriate disciplinary actions to ensure that those who wereWe abide by strict ethical standards in our own operations, and we responsible are held accountable.insist on equivalent standards from our suppliers. Our BusinessDisciplinary actions can include, but are not limited to, dismissal fromPartner Code of Conduct is based on our company's Code of Conduct,the company, issuance of final written warning letters or financialas well as on the PSCI Pharmaceutical Industry Principles and theTen Principles of the UN Global Compact.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 38"
  },
  {
    "page": 39,
    "source": "text",
    "content": "penalties. In addition, we take appropriate steps to address any needed Code of ethics governing interactionsimprovements in organizational and process controls.with health care professionalsRetaliation against employees who report such concerns is a violationof corporate policy and is not tolerated.Continuing Medical Education (CME) and ContinuingEducation (CE) programsWe also maintain a policy that will give our company the discretion torecoup incentive payments made to employees in certain instances. Our CME/CE Grant Program supports independent educationalThis policy will apply when a senior leader engages in misconduct or programs whose purpose is to maintain, develop or enhance thefails to reasonably supervise an employee who engages in misconduct knowledge, skills and/or professional performance that health carethat results in a material policy violation relating to the research, professionals rely on to provide services for patients, the publicdevelopment, manufacturing, sales or marketing of company products or the profession. We are committed to ensuring that our CME/where the policy violation causes significant financial or reputational CE programs are educational and not promotional. Through theseharm to the company. programs, we seek to increase physicians' knowledge about the latestscientific data and health care topics, thereby improving patient care.The Office of Ethics and the Office of Global Investigations areresponsible for oversight of the global processes for managing The environment in which we sponsor or support educationalinvestigations into potential ethics and compliance concerns to programs worldwide is complex, governed by a multitude of laws,ensure consistent and timely resolution of potential concerns and regulations and medical or industry association guidelines. We areimplementation of remediation actions. committed to honoring all applicable programs required for CME/CEin the countries in which we operate.CME programs that we support or sponsor are governed by aninternal policy that is aligned with the appropriate standards andregulations to which the programs are held including, among otherthings, independence and financial disclosure.U.S. Medical ForumsWe deliver balanced medical and scientific information to health careprofessionals within the U.S. through our company's Medical Forums,which are conducted by external speakers. Speakers are selectedon the basis of their expertise in the relevant subject matter. Byattending one of our Medical Forums, health care professionals learnabout therapeutic and health care industry topics. The goal of theseinteractions is to help attendees achieve improved medical results fortheir patients.With our strict standards for conducting these Medical Forums,we comply with the PhRMA Code on Interactions with Health CareProfessionals as well as with U.S. Food and Drug Administration(FDA) regulations, which ensure that any product presentation isappropriately balanced with information regarding both the product'spotential benefits and its risks, and is consistent with approvedproduct labeling.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 39"
  },
  {
    "page": 40,
    "source": "text",
    "content": "Governance BoardThe Board, as a whole and through its committees, has responsibilityfor overseeing the company's ESG matters. For example, the full Boardhas oversight for human capital management, and the CompensationGRI 102-18 Governance structure of the organization (Core) & Management Development Committee assists the Board in thatregard. This includes overseeing the company's programs, policiesGRI 102-19 Delegation of responsibilityand practices related to its management of human capital resources,GRI 102-20 High-level accountability for sustainability topics including talent management, culture, diversity and inclusion. TheGovernance Committee oversees public policy matters, environmental,GRI 102-21 Access to the boardhealth and safety practices, and also reviews social, political andGRI 102-22 Composition of the board and its committees economic trends affecting our business. Additional information on thecommittees' responsibilities can be found in our company's 2021 ProxyGRI 102-23 Chair of the highest governance bodyStatement (pages 18-20) or in their committee charters available onour corporate website.The primary mission of our Board is to represent and protect theinterests of our company's shareholders. The Board generally meets atleast six times per year to provide strategic direction and to review ourprogress on a wide variety of measures.In overseeing the affairs of the company, including our governance,the Board has established four committees, each of which is composedsolely of independent directors:• Audit• Compensation & Management Development Committee• Governance• ResearchAll of our standing committees are governed by Board-approvedcharters, which are available on our corporate website. Information onour company's board committees can be found in our company's 2021Proxy Statement (pages 18-20).Robert M. Davis, our company's chief executive officer and president,currently serves on our Board. Our former chief executive officer,Kenneth C. Frazier, is currently the executive chairman of the Board.ESG management structureWe are committed to governance policies and practices that servethe interests of the company and its shareholders. Our reporting andgovernance structure is an integral part of this commitment.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 40"
  },
  {
    "page": 41,
    "source": "text",
    "content": "Public Policy and Responsibility Council (PPRC) Overall, the PPRC promotes further integration of ESG and policyconsiderations into our business activities.The PPRC is a high-level forum for strategic input and guidance on oursocial business investments, ESG approach and public policy issuesand positions. The diverse, cross-functional membership of the PPRC ESG Strategy Management Teamprovides vision, leadership and cross-divisional input and alignment on This team, comprising functional experts throughout our company,policy and responsibility strategy, issues and initiatives. helps drive our long-term ESG strategy. This includes identifyingrisks and opportunities and advising on long-term goals andSpecifically, the company's PPRC enables policy and ESG issuemetrics. Members of this team include senior leaders from each ofidentification and debate; makes recommendations to our CEO'sour four focus areas (Access to Health, Employees, EnvironmentalExecutive Team, as necessary; informs policy and ESG strategy;Sustainability, and Ethics & Values), as well as leaders in our Officeand reviews performance and reporting against defined objectives.of the Secretary, Investor Relations, and Corporate Strategy,among others.Corporate Governance 2016 2017 2018 2019 2020Independent directors on the Board 12 12 11 12 12Percent of Board members who are independent 92% 92% 92% 92% 92%Separate chairman of the Board and CEO No No No No NoLead independent director Yes Yes Yes Yes YesIndependent audit committee Yes Yes Yes Yes YesIndependent compensation and benefits committee Yes Yes Yes Yes YesIndependent governance committee Yes Yes Yes Yes YesWomen on the Board 23% 23% 33% 46% 46%Members of underrepresented ethnic groups 23% 15% 17% 23% 31%on the BoardNumber of Board meetings scheduled or held1 8 8 6 6 7Shareholder support of the advisory vote on 95% 95% 93% 92% 91%executive compensation2Note: Except as otherwise noted, all figures above are derived from our proxy statement filed the following year.1 Per internal records. Meetings were held in person and/or via telephone.2 Percentages derived from Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission after the applicable annual meeting of shareholders.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 41"
  },
  {
    "page": 42,
    "source": "text",
    "content": "ESG Strategy & EngagementOur ESG Strategy & Engagement team (formerly the Office ofCorporate Responsibility) is responsible for raising the visibility GRI 102-24 Board nomination and selection processesof ESG issues and activities across the company. This includesGRI 102-25 Board conflicts of interestfostering connections across business units and functional areas tointegrate our approach to ESG into business policies, strategies and GRI 102-26 Board and executive rolespractices, including the enterprise risk management (ERM) process.Its aim is to bring the views of external stakeholders into ourFor more information on our Board of Directors, please see ourdecision-making processes.2021 Proxy Statement. For an overview of our Board nomination process,see pages 24-25.The ESG team also coordinates the development, implementationand communication of our global approach and, with strategicInformation on our Board conflict of interest policy can be found inguidance from the ESG Strategy Management Team, Public Policyour Policies of the Board, in Section 13 (pages 8-9).and Responsibility Council (PPRC), Executive Team and the Board'sGovernance Committee, and is responsible for publishing our annual For information on our Board's and senior executives' roles in theESG Progress Report. development, approval, and updating of the organization's purpose, valueor mission statements, strategies and policies, see pages 12-14 of ourESG Report Working Group 2021 Proxy Statement.The members of the ESG Report Working Group, a diverse selection ofemployees from all divisions of the company, serve as subject matterexperts in their respective areas and work closely with the ESG Strategy& Engagement team to help set goals and develop metrics that GRI 102-27 Board ESG knowledgesupport and measure our overall ESG strategy and objectives. Individual Board identification of ESG impacts, risks,GRI 102-29members have been chosen to be active advocates for ESG within their and opportunitiesrespective departments, and coordinate the content writing for thisGRI 102-30 Board review of ESG risk management processesreport with subject-matter experts in their functional areas.GRI 102-31 Frequency of board reviewContacting the Board Highest committee or position that formally reviewsGRI 102-32and approves the organization's ESG reportThe Board welcomes input from shareholders and other interestedparties and has established a process to receive these communications. Our entire Board has responsibility for overseeing the company's ESGShareholders and interested parties may communicate directly with matters, and does so as a whole and through its individual Committees,the Board, the independent lead director, the non-management or depending on the topic. The full Board has oversight for human capitalindependent directors as a group, or other members of the Board by management, for example, and the Compensation & Managementwriting to the following address: Development Committee assists the Board in that regard. This includesoverseeing the company's programs, policies and practices related toBoard of Directors its management of human capital resources, including talentmanagement, culture, diversity and inclusion.Merck & Co., Inc.2000 Galloping Hill Road, K1-4157 Chaired by our company's independent lead director, the GovernanceKenilworth, NJ 07033 U.S.A. Committee is responsible for advising the Board and management onpolicies and practices that pertain to our responsibilities as a globalFor more information on our approach to governance, please visitcorporate citizen, our special obligations as a health care companyGRI 102-29 to 102-32 on pages42-43.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 42"
  },
  {
    "page": 43,
    "source": "text",
    "content": "whose products and services affect health and quality of life aroundthe world, and our commitment to the highest standards of ethics andProcess for communicating critical concernsintegrity in all of our dealings. GRI 102-33to the boardThe Governance Committee's role includes monitoring and evaluatingsome of the company's ESG programs and activities, including public The Board welcomes input from shareholders and other interestedpolicy matters, environmental, health, and safety practices and supply parties and has established a process to receive these communications.chain manufacturing strategy and governance and third-party Shareholders and interested parties may communicate directly withsourcing programs. the Board, the independent Lead Director, the non-management orindependent Directors as a group or other members of the Board byIn addition, the Governance Committee is responsible for considering writing to the following address:and making recommendations to the full Board regarding the Board'spolicies and practices. The company monitors and evaluates trends in Board of Directorscorporate governance and regularly asks for and receives input fromMerck & Co., Inc.shareholders and other stakeholders. The Governance Committee2000 Galloping Hill Road, K1-4157reviews these trends against our current practices and structures andKenilworth, NJ 07033 U.S.A.considers input received from shareholders and other stakeholders aspart of this review.For information on communicating to the Board, please visit our2021 Proxy Statement (page 29).Information on the Governance Committee's responsibilities can befound on page 19 of our company's 2021 Proxy Statement, and in itscommittee charter, available on our corporate website.Remuneration policies for the boardIn addition to the Governance Committee and the Compensation & GRI 102-35and senior executivesManagement Development Committee, two other Board committeesGRI 102-36 Process for determining remunerationoversee certain ESG matters as well. For example, the ResearchCommittee monitors compliance with the highest standards of GRI 102-37 Remuneration shareholder resolutionsscientific integrity in the conduct of the company's research anddevelopment, and the Audit Committee monitors compliance with theA full discussion of our approach to remuneration for Namedcompany's policies on ethical business practices.Executive Officers (NEOs) can be found on pages 43-58 of our2021 Proxy Statement.To learn more about the non-binding advisoryFor information on our board structure, please see GRI 102-19 andvote to approve the compensation of our named executive officers,GRI 102-20 on pages 40-42.please see our Form 8-K from May 27, 2021. This proposal receivedInformation on the Board's role in assessing risk can be found on 91.21 percent approval vote at our annual meeting on May 25, 2021.page 14 of our 2021 Proxy Statement.For information on compensation for the Board, please visit pages40-41 of our 2021 Proxy Statement.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 43"
  },
  {
    "page": 44,
    "source": "text",
    "content": "Many of these engagements with partners can be found throughoutthis report. The groups of stakeholders with which we regularlyGRI 102-38 CEO/employee pay ratioengage include:Patients and caregiversThe total annual compensation of our median employee in 2020 was$109,482. This figure was comprised of base salary, annual incentive, We embrace the opportunity to engage with individual patients,savings plan company match and change in pension value. The total patient advocacy organizations and caregivers to better understandannual compensation for our CEO was $22,088,429. their health care journeys, expected outcomes and decision-makingconsiderations.A reasonable estimation of the ratio of our CEO's compensation to ourmedian employee's compensation was 202 to 1. For more information on our work with patient groups, please seeour Patient & Caregiver Resources page on our corporate website.Under the SEC rules, companies may identify the median total annualcompensation using a wide variety of methods, including reasonableHealth care professionalsassumptions and estimations. It is therefore difficult to compare thisWe are committed to providing appropriate and balanced informationratio to those of other companies.to physicians and other health care providers about our medicines,For more information on our methodology for determining this ratio, vaccines and ongoing research.please see page 62 of our 2021 Proxy Statement.For more information on our work with health care professionals,please see GRI 206 on page 78.Stakeholder engagementFor our disclosures on payments to health care professionals, visitthe Transparency Disclosures page on our corporate website.PayersA list of stakeholder groups engaged by theGRI 102-40organization (Core) We work with payers worldwide to inform their understanding of therelationship between the prices of our products and the true value theyGRI 102-41 Union representation (Core)deliver to patients and health care systems.Basis for identifying and selecting stakeholdersGRI 102-42with whom to engage (Core) For more information on our work with payers, please visit our2020 Form 10-K, pages 7-12, as well as our Pricing and AccessGRI 102-43 Approach to stakeholder engagement (Core)Position Statement.We engage with a diverse group of stakeholders to more fullyGovernments, multilateral organizations and regulatorsunderstand their needs and expectations, and to gain insights that canWe work with policy makers, legislators, multilateral organizationsinform our efforts to improve access to health care and foster progressand governments worldwide to ensure that policy and regulatorytoward solutions that benefit society and support our business.environments globally, nationally and locally foster patient access tomedicines and vaccines, and that they are conducive to ethical businesspractices, science and innovation.There is more information on these engagements throughout thisreport, as well as in our 2020 Form 10-K, pages 7-12.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 44"
  },
  {
    "page": 45,
    "source": "text",
    "content": "Shareholders As part of our mission to maintain a satisfying and productive workenvironment, we routinely survey all employees to learn about theirWe strive to create shareholder value by identifying opportunities toperspectives on the business and on how we are responding to themeet customer needs and by managing our business responsibly toneeds of our global workforce. The Voice Survey, our company'sachieve superior financial results over the long term. Throughout theall-employee opinion survey, is our flagship employee feedbackyear, we regularly engage with our investors on both financial andmechanism, and is conducted on a biannual basis, although it wasESG performance.not sent out in 2020. We will be conducting the Voice Survey in 2021,and will include the results in our next ESG report.Local communitiesWe work toward developing culturally appropriate mechanisms to Suppliers and business partnersengage and build relationships with our local community stakeholdersWe strive to engage a diverse supplier base and to encourageand NGOs. We conduct this engagement predominantly through ourresponsible approaches on the part of suppliers regarding labor,philanthropic efforts, which can be found on the Philanthropy page onemployment, human rights, health and safety, ethics, diversityour corporate website.and protection of the environment.Environmental stakeholders To learn more, please see GRI 102-9 on page 29, GRI 308on page 116, GRI 412 on page 154, and GRI 414 on page 157.We work to reduce the environmental effects of our operations andproducts and to promote sustainable environmental practices withinthe company, among our partners and throughout our supply chain. Trade and industry associationsWe engage with stakeholders through membership in numerousTo learn more, please see GRI 301 to 308 on pages 83-117 inorganizations. Within these groups, we aim to inform relevant debatesthis report.in ways that are constructive and that ultimately foster improvedpatient access to medicines and vaccines globally.EmployeesTo learn more, please see GRI 102-13 on page 35.We strive to foster a positive and inclusive working environment for ouremployees by providing resources to improve their health and that oftheir families, opportunities to further their professional developmentand ways to get more involved in the communities where they live.To learn more, please see GRI 401 to 405 on pages 118-154of this report, as well as our Wellbeing Report available on ourcorporate website.Union membership 2016 2017 2018 2019 2020Employees represented by an independent trade union or covered 29% 29% 30% 30% 30%by a collective bargaining agreement (approximate)Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 45"
  },
  {
    "page": 46,
    "source": "text",
    "content": "Reporting practice There have been no significant changes from previous reportingperiods in the scope, boundary or measurement methodsapplied in this report. Data regarding employees who are part ofunderrepresented ethnic groups are provided for the U.S. only.GRI 102-45 Entities included in financial statements (Core) As mentioned in GRI 102-10 on page 33, in February 2020, weannounced our intention to spinoff products from our women'sAll of our company's global operations, including those of subsidiaries, health, biosimilars and established brands businesses into a new,are in scope for this report unless stated otherwise. This report independent, publicly traded company named Organon & Co. Thisincludes activities at all facilities, owned and leased, over which we have spinoff was completed on June 2, 2021, but does not affect ouroperational control, unless otherwise noted. reporting on 2020 initiatives and performance data. The financialand other data contained in this report for 2020 does not reflectThe basis for reporting on other matters specific to the operations ofthe spinoff of Organon.our business can be found in our 2020 Form 10-K, which is filed withthe SEC. For more information on this transaction, please see our pressrelease on Merck.com.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 46"
  },
  {
    "page": 47,
    "source": "text",
    "content": "GRI 102-46 Defining report content and topic boundaries (Core)GRI 102-47 Material aspects included (Core)An ESG materiality assessment helps us focus on those issues thatmatter most to our stakeholders, our company and the world. Ourassessment provides insight into future trends and potential businessrisks and opportunities.Our priority ESG topicsIn our recently updated assessment, the following topics emerged as the most critical for our company to address:• Access to medicine • Employee health and safetyPages 53-72 Pages 128-139Access• Product quality and safety • Employee engagementEmployeesPages 29-32, 53-72, 76-77, to health a nd diversity161-168, Clinical trials page Pages 28, 44-45, 145-154• Public health risksPages 38, 128-139• C limate change • B usiness ethicsPages 52, 88-92, 100-106 Pages 38-39, 76-81, 167-168,Code of Conduct & ComplianceEnvironmental Ethics • Ethics in R&Dsustainability & values Pages 38-39, 53-72, 161-167,Clinical trials page• Data security and privacyPages 168-170• G overnance structuresand mechanismsPages 38, 40-45, 129-132,153-154, 170Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 47"
  },
  {
    "page": 48,
    "source": "text",
    "content": "Our approachTo conduct the assessment, we partnered with Datamaran, a materiality and ESG risk-management software company that uses a comprehensiveand data-driven process for evaluating the relevance of ESG issues and trends to our business and our stakeholders. We leveraged Datamaran'sbusiness intelligence platform, which applies SASB Accounting Metrics and is GRI-certified software, to evaluate the external landscape. Thefollowing 32 topics, specific to the pharmaceutical sector, were found to be of the highest importance to our external stakeholders.• Access to health care and medicine • Employee engagement and diversity • Product design and lifecycle• Air quality • Employee health and safety • Product quality and safety• Business ethics • Energy management • Public health risks• Business model resilience • Ethics in R&D • Responsible and smart transportation• Climate change risks • GHG emissions • Selling practices and product labeling• Community relations • Governance • Supply chain management• Competitive behavior • Human rights • Transparency• Critical incident risk management • Inclusion and affordability • Waste and hazardous materials management• Customer welfare • Innovation and technology • Water and wastewater management• Data security and customer privacy • Labor practices • Workforce management• Ecological impacts • RegulationThe external sources drawn from included:• Corporate reports (financial, sustainability/ESG and integrated annual reports)• Global regulations and initiatives (mandatory laws and soft norms)• Social media (Twitter)• Online news sourcesTo supplement the data-driven analysis, we also engaged with internal stakeholders through an online survey, and interviews with externalstakeholders, to validate and prioritize the issues that have the greatest impact to our business and our stakeholders.ESG materiality assessment processSectorExternallandscapescorereviewAnalysis ESG materialandtopicsexternalvalidation identifiedInternalInternalstakeholderscoresurveyMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 48"
  },
  {
    "page": 49,
    "source": "text",
    "content": "We have included the management approach disclosures for our top We welcome your feedback on this ESG Progress Report, as well as any10 priority topics in this report, as well as these disclosures for many of other comments or questions you may have. You may contact us at thethe 32 material topics above that are specific to our industry. address below or email us at corporate_responsibility@merck.com.We have already used this assessment to identify a new set of ESG ESG Strategy & Engagementgoals (found on page 9), and its findings will help to set the direction of 2000 Galloping Hill Road, K1-3181our work in the years ahead. Kenilworth, N.J. 07033 USA908-740-4000GRI 102-48 Restatements (Core)Claims of reporting in accordance with the GRIGRI 102-49 Reporting changes (Core) GRI 102-54 Standards (Core)GRI 102-55 GRI content index (Core)Any restatements of information are included in the footnotes beneaththe specific performance data tables. Claims of reporting in accordance with the GRIGRI 102-54Standards (Core)The spinoff of Organon & Co. was completed on June 2, 2021, andGRI 102-55 GRI content index (Core)does not impact the content of this report. All entities that were partof Merck & Co., Inc. on December 31, 2020, and are included in ourfinancial statements, are represented in this report. This report has been prepared in accordance with the GRI Standards atthe Core option. An index for all of our GRI disclosures, as well as thosefor the other frameworks we report on, can be found on pages 171-189.GRI 102-50 Reporting period (Core)GRI 102-51 Date of most recent report (Core)GRI 102-56 External assurance (Core)GRI 102-52 Reporting cycle (Core)GRI 102-53 Report contact (Core) ERM conducted an independent third-party review of our 2020greenhouse gas and water inventories, and provided limited assuranceExcept as otherwise noted, we report on our ESG initiatives and for the data that we submit to CDP and for inclusion in this report.progress annually. These disclosures cover the prior calendar year, fromJanuary 1 to December 31, 2020. To ensure that readers have the most To view ERM's limited assurance letter for our environmental data,up-to-date information, some of the narrative in the report is about please visit the ESG Resources page on our corporate website.decisions and initiatives that took place in the first half of 2021. Our lastWe did not obtain external verification for this ESG Progress Report inreport was published in October 2020.its entirety.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 49"
  },
  {
    "page": 50,
    "source": "text",
    "content": "EconomicSee our GRI index on page 171.Economic performance Impact investingImpact investing is one of our innovative approaches to advancingsustainable global health solutions in line with our company's overallobjectives. Through impact investing, we are able to deploy financialGRI 201-1 Direct economic value generated and distributed resources in ways that may generate not only improved access tohealth care for underserved populations, but also financial returnsWe believe that addressing the environmental, social and governance and commercial opportunities - all while growing a sustainable globalaspects of our business is critical to our company's success, and can health ecosystem and attracting additional capital and partners.provide us with new opportunities to create shared value and todemonstrate our purpose to stakeholders. At the most basic level, Impact investing is led by our Office of Social Business Innovation withour principal economic contribution to society is made through guidance from the Impact Investing Committee. Established in 2019,the discovery, development, manufacturing and marketing of our the Impact Investing Committee is a cross-functional team of seniorproducts, which directly improve and maintain the health of individuals company leaders that reviews and approves new investments in lineand communities around the world, helping them to lead more with established policies and guidelines and monitors the financialproductive lives. and social returns of the impact portfolio. We are also members ofthe Global Impact Investing Network (GIIN), through which we cancontribute to and benefit from the growing body of expertise in theFor more information on our overall tax strategy, please seeimpact investing ecosystem.GRI 207 on page 81.For more information, please visit our Impact Investing pageFor additional information about our business and economicon Merck.com.performance, please see our 2020 Form 10-K for the year endedDecember 31, 2020, on our corporate website.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 50"
  },
  {
    "page": 51,
    "source": "text",
    "content": "Financial information 2016 2017 2018 2019 2020Sales $39.8B $40.1B $42.3B $46.8B $48.0BResearch and development expenses1 $10.3B $10.3B $9.8B $9.9B $13.6BNumber of employees (approximate) 68,000 69,000 69,000 71,000 74,000Number of stockholders of record2 128,600 121,125 115,320 109,500 104,900Annual cash dividend declared per share $1.85 $1.89 $1.99 $2.26 $2.48Global tax expense as reported on income statement $0.72B $4.1B $2.5B $1.7B $1.7BNote: Financial information is in accordance with Generally Accepted Accounting Principles in the U.S. (GAAP).1 Includes restructuring costs, acquisition-related charges and upfront payments related to collaborations and licensing arrangements.2 Approximate number as of January 31 of the year immediately following the reported year.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 51"
  },
  {
    "page": 52,
    "source": "text",
    "content": "In 2020, the company's Energy Capital fund became the SustainabilityCapital Fund, expanding the scope of the funds to water and wasteFinancial implications and other risks andGRI 201-2 projects. It is used exclusively for sustainability projects at companyopportunities due to climate changesites around the world that bring long-term value to the company andfocus on carbon footprint, water use and solid waste reduction. TheWe believe that climate change could present risks to our business.fund allocates up to $12 million per year which allows us to adopt lowSome of the potential impacts of climate change to our business includecarbon technology, better position the company to respond to climateincreased operating costs due to additional regulatory requirements,change and supports a more circular economy.1physical risks to the company's facilities, water limitations anddisruptions to our supply chain. These potential risks are integrated Since 2015, our sites have completed more than 95 projects throughinto the company's business planning, including investment in reducing the Sustainability Capital Fund. This has saved over $9 million per year,energy, water use and greenhouse gas emissions. averaging a payback of about three and a half years and avoiding theproduction of 50,000 metric tons of carbon per year.We have made it a priority to reduce our demand for energy and haveestablished internal policies and practices focused on reducing energy For more information, please see GRI 305 on page 100anduse at our sites and minimizing greenhouse gas (GHG) generation the ESG Resources page on our corporate website for a link to ourthroughout the company. By taking these steps, we are not only response to the CDP Climate Change questionnaire.minimizing GHG emissions but also reducing operating costs andmitigating the business impacts expected to be associated with future 1 As defined by the Ellen MacArthur Foundation, \"a circular economy is based on theclimate change requirements. principles of designing out waste and pollution, keeping products and materials in use,and regenerating natural systems\".Sustainability Capital Fund projects:95 projects $9 millionsaved annuallyMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 52"
  },
  {
    "page": 53,
    "source": "text",
    "content": "Indirect economic impactsGRI 201-3 Benefit plan coverageOur compensation and benefits programs are rooted in maintaining GRI 203 Management approachour competitive position in the market by providing a comprehensiveAccess to health care for priority diseasesand valuable package of rewards to attract and retain a talented and SASB 240a.1and in priority countriesdiverse workforce while building a robust and supportive culture.Products on WHO's List of PrequalifiedSASB 240a.2Medicinal ProductsOur compensation programs, which include competitive base pay,short-term incentives and long-term incentives, target different Percentage change in: (1) average list price andaspects of individual and company performance and are monitored SASB 240b.2 (2) average net price across U.S. product portfolioto ensure that they are competitive with those of other companies- compared to previous yearand appropriate for the markets in which we compete for talent. Percentage change in: (1) list price and (2) net priceSASB 240b.3 of product with largest increase compared toOur health and wellbeing, retirement and insurance programs draw previous yearfrom best practices to ensure quality, competitive value, protectionfrom significant financial hardship and access to tools and resources For more than a century, we have been inventing medicines andto support employees and their family members in all life stages. vaccines for many of the world's most challenging diseases.In the U.S., the percentage of pay contributed by employees into We are committed to addressing unmet medical needs throughour U.S. Savings Plan is approximately 8.6 percent. Approximately innovative research and development (R&D). R&D expenses in97 percent of U.S.-based employees participate in this retirement 2020 reflected higher clinical development spending and increasedplan, and 100 percent of U.S.-based employees participate in the investment in discovery research and early drug development.pension plan.Our success is largely dependent on our continued ability to attractFor more information, please see GRI 401-2 on pages 123-127. and retain highly qualified scientific, technical and managementpersonnel, as well as personnel with expertise in clinical research anddevelopment, governmental regulation and commercialization.We have strategically located discovery centers in regions with activebiomedical research communities in California and Massachusetts,as well as principal sites outside of the U.S., including the UnitedKingdom, Switzerland and China. These centers allow us to recruittalented local scientists and facilitate collaboration with local academicinstitutions and companies. These discovery sites complement andconnect with our strong research and development capabilities andexpertise based at our New Jersey and Pennsylvania sites.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 53"
  },
  {
    "page": 54,
    "source": "text",
    "content": "While the primary responsibility for managing a health system and embedding access across our organization. Our Access toproviding its citizens with access to health resides with government, Health Guiding Principles span the areas of discovery andpharmaceutical companies have a substantial role to play in working invention, availability, affordability and strengthening systemswith governments to enable access to health. and addressing inequity.As we pursue our core mission of inventing, developing and deliveringSystematic evaluation to inform productmedicines and vaccines, we work to support governments in theirefforts to protect the right to health. access strategiesWe do this in several ways, including:Embedded within our research and development process, we• Monitoring and reporting on the safety of our products systematically evaluate our candidates to identify the potential toaddress significant public health burden and unmet medical needs• Providing health care workers and consumers with importantin under-resourced health care settings. This evaluation processinformation on the benefits and side effects of our productsinforms our product access strategies with the goal of making our• Safeguarding the health, safety and privacy of patients involved in medicines and vaccines available to as many people as possible throughour clinical trials sustainable solutions.In addition, we are also working to improve access to new medicines To facilitate access to our products in under-resourced health careand vaccines, address deep-rooted and multifaceted barriers to access settings, we undertake a systematic evaluation at the onset ofand advocate for health care capacity strengthening in ways that are Phase 2 clinical studies to determine a candidate's potential toaligned with our business mission and core capabilities. We often meet unmet medical needs for patients in low- and middle-incomepursue this work through partnerships. countries (LMICs). Our approach involves evaluating the level ofdisease burden that exists, the availability of alternative medicationsOur enterprise-wide approach to access is guided by our Accessand the appropriateness of our candidates to improve public health.to Health Guiding Principles, and is responsive to internationallyAdditionally, understanding where health system infrastructurerecognized standards and priorities. This reflects our approach toand funding mechanisms are in place is an important componentMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 54"
  },
  {
    "page": 55,
    "source": "text",
    "content": "of enabling safe and effective usage, which ultimately facilitates Sometimes the evaluation of a candidate reveals barriers to accessmeaningful patient access. Our R&D governance committee is in an under-resourced setting. In these situations, the evaluationaccountable for the process, and all recommendations are reviewed by process can inform our approach to strengthening health systemsour Public Policy and Responsibility Council (PPRC), an internal cross- and improving health equity.divisional forum of senior leaders.We recognize that addressing the complex and multi-facetedWhen a drug or vaccine candidate with the potential to address challenges to accessing health care in LMICs requires the collaborationsignificant public health burden in under-resourced health care of multiple stakeholders. We actively seek partnerships to achievesettings is identified, the access planning process includes engaging solutions that enable access.all parts of our enterprise as well as external stakeholders to identifythe most optimal solution. All candidates undergo this systematic Examples of access strategies our company has initiated includeevaluation at Phase 2. For candidates with significant potential in the granting of voluntary licenses that can contribute to timely andunder-resourced settings, access planning may start in the pre-clinical affordable access, our agreement with the Bill & Melinda Gatesphase. Once a product is approved, we commit to registering the Foundation to advance HIV research in sub-Saharan Africa throughproduct and making it available in all countries where clinical trials have clinical trials and partnering with external stakeholders to supportbeen conducted, including LMICs. Products continue to be evaluated health system strengthening.for their potential throughout their lifecycle to account for changes inthe external environment.Research and development 2016 2017 2018 2019 2020Research and development expenses (in billions)1 $10.3 $10.3 $9.8 $9.9 $13.6Employees involved in research activities 12,300 12,700 14,500 15,600 16,750New products approved2 3 4 2 2 1Products in the pipeline and under regulatory review 39 26 24 36 39Top 20 global burdens of diseases addressed by our products 88% 88% 88% 100% 88%and pipeline3,4Established significant external licenses and collaborations 57 55 64 78 123Filed U.S. patent applications 195 190 127 103 1141 R&D expenses include a 2020 $2.7B charge related to the acquisition of VelosBio and a 2017 $2.4B charge related to the formation of a collaboration with AstraZeneca.2 C andidates in our company's research pipeline or under regulatory review as reported in the company's Form 10-K, filed on February 25, 2021. Approval of new products only.This does not include approvals for supplemental indications. When candidates attain regulatory approval, they are removed from this pipeline view.3 As defined by the Institute for Health Metrics and Evaluation (IHME) using GBD 2019 data; excluding road injuries, age-related hearing loss and neonatal disorders.4 This number is slightly lower in 2020 than in 2019 (but in line with numbers for previous years) due to changes in the top 20 GBD list.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 55"
  },
  {
    "page": 56,
    "source": "text",
    "content": "Global burden of disease of human subjects, including those issued by the International Councilfor Harmonisation Good Clinical Practice (ICH GCP). However,As defined by the GBD Visualization tools developed by the Institute individual country regulations and guidelines should remain thefor Health Metrics and Evaluation (IHME), the diseases that we address primary determinant of specific requirements for the conduct ofrank high on the list of worldwide causes of death. Our research into medical research.vaccines and infectious diseases addresses major burdens of diseaseWe have a commitment, where appropriate, to the study of diversethat are prevalent in all countries, and our preventive treatments couldpatient populations, including underrepresented groups, women andhave the greatest impact in the developing world, where health carechildren, in our clinical trials in all regions of the world. As a result,infrastructure is weak or nonexistent.we strive to obtain information from diverse populations, ensuringConsidering our pipeline, the list of products we currently market and a thorough evaluation of the safety and efficacy of our medicinesexternal collaborations, we estimate that our company is seeking to and vaccines. These efforts allow us to seek regulatory approvalsaddress 88 percent of the top 20 global burdens of disease as defined throughout the world and thereby offer our medicines globally toby the IHME, excluding road injuries, age-related hearing loss and patients who need them.neonatal disorders.Consistent with ICH-GCP requirements, as part of the informedconsent process, clinical trial patients are made aware of theCompliancecompensation and/or treatment available to them in the event of atrial-related injury. They are also informed of the person(s) to contactEnsuring compliance with applicable laws and requirements inin the event of a trial-related injury. Our company maintains policiesall business areas is critical. As such, the stated objective of theand procedures that address the costs of treatment of trial subjectsCompliance Committee Charter within our research laboratories isin the event of trial-related injuries in accordance with applicableto ensure ongoing compliance through appropriate managementregulatory requirement(s).structure, processes and training.In order to manage compliance, the Compliance Committee is Genetic researchcomposed of members of the Research Leadership Team. As a result,compliance efforts encompass the entire division and go beyond simply The rapid development of new technologies that interrogate variabilityaddressing the conduct of clinical trials. in human DNA and RNA, combined with powerful computing hardwareand software, has made it practical to investigate genetic and genomicThe Compliance Committee also promotes ethical science and determinants for risk of human disease or predictors of humanprovides guidance to our employees within the research organization response to drugs.on our company's standards and corporate policies, as well asnecessary education related to specific requirements applicable to Our company conducts genetic and genomic research within our ownthe research community. clinical trials and in collaboration with external organizations that havecollected human genetic and genomic samples and health data.Clinical researchWe collect genetic and genomic samples in our clinical trials, primarilyto understand how genetic and genomic variation impacts patientClinical trials can offer hope for many people and may help researchersresponse to medicines. This enables us to communicate information tofind better treatments for others in the future. Our Global Clinicalregulatory authorities and prescribers that will improve the use of ourDevelopment department is responsible for conducting clinical trialsmedicines, and understand how genetics contribute to the underlyingworldwide to evaluate the safety and efficacy of our products.disease, which has the potential to identify new drug targets.In accordance with our public policy position statement, allWe obtain subject consent for use of genetic and genomic samplesinvestigational studies in human subjects are conducted in a mannerin accordance with ethical principles of human-subjects research,consistent with laws, regulations and guidelines for the protectionwhich include respect for persons/autonomy, beneficence and justice,Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 56"
  },
  {
    "page": 57,
    "source": "text",
    "content": "Access to healthGoal: Goal: Goal:100% of logistics partners with a security 75% of countries1 around the world reached 95% of orders shipped on time and in fullrisk assessment completed annually annually with our productsProgress: Progress: Progress:Achieved Exceeded target (78%) Exceeded target (98.3%)1 As defined by the World Bank Country and Lending Groups.consistent with the Declaration of Helsinki, U.S. FDA requirements, Our company's Regenerative Medicine Oversight Committee, whichICH E6 Good Clinical Practices guidelines and the 1997 UNESCO comprises both internal and external experts, oversees company-Declaration on the Human Genome and Human Rights. When sponsored research involving stem cells, including highly targetedcollaborating with external organizations, we ensure that consent has research using human embryonic stem cells and induced pluripotentbeen obtained by individuals who have contributed DNA or RNA and/or stem cells. The committee is responsible for ensuring that all projectshealth-related data to the organization via these same standards. involving stem cells adhere to our policies.For more information on our company's R&D, please visit theRegenerative medicineResearch & Products page on our corporate website.Together with the scientific community, we believe that research usingstem cells has the potential to help identify medicines, therapies and Maintaining a global supply networkvaccines to treat, cure or prevent diseases.Through our manufacturing and supply division, we strive to maintainMany of the most advanced scientific technologies in regenerative an uninterrupted, unconstrained, highest-quality global supplymedicine involve animal or human embryonic stem cells. network. Our supply chain is designed to ensure we operate a leanand efficient network that produces our medicines and vaccines to theFor more than a decade, we have been applying advances made inhighest quality, safety and environmental standards, in full compliancestem-cell technologies to support our research and development.with regulations and Good Manufacturing Practices (cGMPs) basedThe capacity of stem cells to differentiate into specific cell typeson U.S. and international requirements and industry best practices.underscores their versatility and utility, from early target validation andThrough digitally enabled \"end-to-end supply planning,\" we areidentification, to screening and testing of potential new therapeutics,digitizing our shop floors and conducting efficient and balanceddisease-modeling and pre-clinical proof of concept.planning decisions to maximize business results and deliver medicinesand vaccines to customers, which include hospitals, retail outlets andWe conduct research using stem cells in full accordance with allpatients, when and where they need them.applicable laws and regulations, and our own internal research policies.Our research policy involving stem cells adheres to the U.S. NationalWith both an environmental and socially conscious mindset, ourAcademy of Sciences guidelines as well as those of the Internationalfacilities, along with our external contractors, suppliers and partners,Society for Stem Cell Research.make up an integrated, interdependent global manufacturing network.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 57"
  },
  {
    "page": 58,
    "source": "text",
    "content": "Solving affordability challenges through We have focused on making this approach systematic. We haveestablished a framework which is available to all our markets fordedicated sustainable access solutionsassessing, designing and delivering practical solutions that solveaccess and affordability challenges. We have established a dedicatedWe aspire to enable solutions and shape the ecosystem that deliversinternal unit to systematically accelerate innovation and capturesustainable access to innovative medicines for patients. We collaboratelearnings across emerging markets. Through this approach we havewith different stakeholders, including private, governmental, multi-been able to accelerate the development of innovative access solutionslateral and non-profit organizations, in the ecosystem to design andacross the globe.deliver solutions that address the access challenges at the payer,provider and patient levels. We also recognize that the policy environment is critical to solvingaccess and affordability challenges. Therefore, we collaborate withOur approach is predicated on the belief that broadening accessgovernments, industry associations, trade and economic forums, thinkrequires sustained effort and is best achieved through solving thetanks and academia to advocate for evidence-based policy solutions.underlying challenges in the health care system that constrain accessFor example, we are actively involved in the APEC Health Coalition thatfrom care delivery to capacity and financing. We also believe that weshares best practices and brings industry, governments and academiaexist within a wider eco-system, comprising of multiple stakeholders,together to diagnose and solve pressing affordability challenges.each playing a unique and varied role. Therefore, key to our approach isSimilarly, we are increasing our engagement in value-based healtha focus on solutions and collaboration.care discussions to solve access challenges more holistically acrossthe health care system. This engagement includes representation onthe Global Innovation Hub Expert Review Committee of the WorldEconomic Forum's Global Coalition on Value in Healthcare.Our current portfolio of projects focused on dedicated sustainableaccess solutions spans across 40 countries. These projects are inWe expand access to ourvarious stages of development, from diagnosing the access challengesproducts through dedicated, to delivering solutions in the market.market-based sustainableOur market teams based in LMICs address affordability throughaccess solutions that expand the multiple initiatives, in pursuit of innovative solutions that enablebroadening of access to medicines in these countries. For example,reach to at-need populationsin LMICs, one of the recurring access challenges is the potentiallyand patients-including high out-of-pocket costs for critical illness treatments. Recognizingthis issue, we collaborated with reinsurers and insurance companiesthose in LMICs-taking intoin South Africa and Indonesia to enable them to develop affordableconsideration public health health insurance products for the population, including coveringinnovative cancer therapies. This provides much needed optionality forneed, economic conditions andthe population and drives greater health care inclusion. As the reachhealth care infrastructure. of this insurance product further expands, we expect to solve onemajor access hurdle and widen access to innovative cancer therapiesfor patients in a commercially sustainable way. The approach reinforcesour commitment to being part of a wider ecosystem, collaborating withothers with complementary capability to tackle these challenges.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 58"
  },
  {
    "page": 59,
    "source": "text",
    "content": "Addressing barriers to health in the Democratic Republic of Congo. As of April 2021, the vaccine hasbeen approved in nine African countries. These approvals mark a historicThrough partnerships, investment and innovation, we apply our moment for global public health and represent an unprecedented effortexpertise and invest our human and financial resources to address by a diverse set of partners from around the world.systemic barriers to access to health where we believe our companyOn January 13, 2021, our company confirmed an agreement withcan make the strongest contributions to health systems, communitiesUNICEF to establish the world's first global Ebola vaccine stockpileand our patients around the world. We provide this support inwith ERVEBO® (Ebola Zaire Vaccine, Live). This agreement representsseveral ways, including through philanthropic social investments,another landmark milestone in the fight against Ebola and is the resultkey initiatives and impact investing. To be most effective, whereof breakthrough innovation and collaboration across Africa and theappropriate, we align our investments with country-led priorities andworld. The global stockpile will offer a critical, rapid-response tool topartner with governmental, multi-lateral and non-profit organizations.help combat future outbreaks of this highly contagious, hemorrhagicOur investments are guided and approved by internal and external illness that is endemic in parts of Central and West Africa. Theexpert advisory bodies, including an internal advisory board for our stockpile inventory will be built over time and maintained by Merck.company's Foundation, an internal Impact Investing Council, andWhile licensed supply is starting to be manufactured and built,external expert advisory committees for the MECTIZAN Donationthe investigational vaccine continues to be leveraged to supportProgram and Merck for Mothers.international outbreak response efforts, in close collaboration withWe are committed to measuring the impact of our efforts on improving the WHO. In the past three years, we have donated more thanaccess and therefore provide support to evaluate the impact of many of 300,000 doses of the investigational V920 to response efforts.our investments. In 2020, 10 percent of our investment in partnershipsand programs to strengthen health care capacity and address barriersAccess pricingto access supported by our company's Foundation was allocated toOur company works with governments, international health andimpact evaluation.development organizations, donor groups, NGOs and others tosupport countries' population health aims and help improve sustainableVaccines vaccination programs.We use tiered pricing for vaccines as an equitable way to achieveKey accomplishments and milestonesdual objectives: to expand access for people who can benefit fromThe total number of doses of our vaccines that have been distributed vaccination; and to ensure sufficient return on investment overhas increased significantly since 2010 and our global reach has also time to support the complex and costly research, development andincreased dramatically: in 2020 approximately 74 percent of our manufacturing capacity necessary to create and supply new vaccinesvaccines were distributed outside the U.S., up from 28 percent in 2010. and address post-licensure regulatory requirements.More than 70 million doses of two of our vaccines-GARDASIL® We consider a variety of factors in arriving at a price in a given country,[Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) including the local burden of disease, the health economic value of theVaccine, Recombinant] and ROTATEQ® (Rotavirus Vaccine, Live, vaccine, the country's ability to support vaccine delivery and achieveOral, Pentavalent)-have been distributed in Gavi-eligible countries population health coverage, its level of economic development, itsthrough 2019. This represents important progress toward ensuring fiscal capacity for investments in health and actual health spending, asthat these vaccines reach people in low-income settings with a high well as its mechanism and policies for procuring vaccines. In addition,burden of disease. we work with governments to address affordability challengesand increase system efficiencies to support the sustainability ofWe made progress in our efforts to help address Ebola virus disease. Inimmunization programs.December 2019, ERVEBO® (Ebola Zaire Vaccine, Live), our vaccine to helpprevent this disease, was approved by the U.S. FDA and also approvedMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 59"
  },
  {
    "page": 60,
    "source": "text",
    "content": "We also consider inequities in access within a country. Where Maintaining product quality is paramount. To provide high-quality vaccinesregulations and infrastructure allow, reduced pricing has been offered to people who need them, we manage our supply chain through policiesto support government- or donor-funded coverage of lower-economic- and procedures designed to keep the distribution system secure.tier segments.We continue to explore potential strategic partnerships with otherOur commitment to helping protect global health by improving the manufacturers to increase supply and promote greater access inaffordability, availability, accessibility and use of our vaccines around local markets.the world is fundamental to our business and overall mission. We offerGARDASIL, which helps to protect against HPV-related diseases, at anCOVID-19 manufacturing agreementsaccess price that is significantly less than the value-based price in otherIn response to the COVID-19 pandemic, we have entered into multiplecountries. The access price is exclusive to the public sectors of theagreements to support efforts to expand the manufacturing capacitycountries eligible for support from Gavi, the Vaccine Alliance.and supply of COVID-19 medicines and vaccines. Under our agreementIn 2015, we extended our current Gavi prices for GARDASIL through with the Biomedical Advanced Research and Development Authority2025 to Gavi-graduated countries with a per-capita gross national (BARDA), a division of the Office of the Assistant Secretary forincome (GNI) not exceeding $3,200. This action greatly assists Preparedness and Response (ASPR) within the U.S. Department ofGavi-transitioned countries by facilitating access to these vaccines in Health and Human Services (HHS), we will receive funding to adaptthose countries, while also making sure they remain affordable and and make available a number of existing manufacturing facilities for thesustainable in the long term. In the short period of time since we made production of COVID-19 vaccines and medicines.our price commitment to countries transitioning out of Gavi support,Under separate agreements with Janssen Pharmaceuticals, Inc.,numerous countries have taken advantage of the offer to introduce orone of the Janssen Pharmaceutical Companies of Johnson & Johnson,continue existing national HPV vaccination programs.we will support the manufacturing and supply of Johnson & Johnson'sWe also remain actively engaged with Gavi on policy efforts to improve COVID-19 vaccine, using our facilities in the U.S. to produce drugaccess to vaccines in Gavi-transitioned countries. We believe that our substance, formulate and fill vials.pricing approach contributes to broader access to our vaccines whiletaking into account our need to continue investing in vaccine research, Registration and prequalificationdevelopment and production.We seek to ensure global access to our vaccines by obtaining andmaintaining up-to-date product registrations around the globe.Manufacturing and supplyAdditionally, we seek to obtain WHO prequalification so that ourIn the last few years, countries around the world have enacted vaccines may be easily obtained and distributed to underservednew or expanded vaccination programs. This has contributed to an populations across some of the world's poorest countries. Onunprecedented increase in global demand for vaccines. November 12, 2019, we obtained WHO Prequalification for our vaccineERVEBO to help prevent disease caused by Ebola Zaire virus in adults.We are committed to increasing our capacity and supply capability. Ourcommitment to invest in capital projects over five years has increased The table below summarizes the registration and WHO prequalificationto $20 billion, with a significant portion dedicated to vaccines. In fact, status of a select list of our vaccines.in 2019, we supplied our highest ever quantity of vaccines globally.In addition to having our medicines and vaccines approved by stringentWe continue to invest in manufacturing and end-to-end supply regulatory authorities, when relevant to enhancing access in low- andimprovements in both capability and capacity to help ensure a sustainable, middle-income countries, we also work to have certain medicines andreliable supply of quality and affordable vaccines to serve global needs. vaccines prequalified through the WHO prequalification process.Our manufacturing division continuously works to improve manufacturing WHO prequalification can facilitate product procurement byprocesses and reduce operating costs by increasing efficiency, minimizing international procurement agencies. WHO's prequalification programprocurement spending and improving supply performance. covers medicines for HIV, tuberculosis (TB), malaria, neglectedMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 60"
  },
  {
    "page": 61,
    "source": "text",
    "content": "tropical diseases, influenza, reproductive health and diarrhea, in U.S. product pricingaddition to vaccines. In the absence of reliable national medicineauthorities that can certify health care products meet required quality, We have a long history of making our medicines and vaccinessafety and efficacy standards, stringent regulatory authority and accessible and affordable through responsible pricing practices andWHO prequalification can serve as a basis for quality assurance for industry‐leading patient access programs. In 2017, we began disclosingprocurement by international agencies and national programs in information about the price of our medicines in the U.S.lower-income countries.We are working to bring our medicines and vaccines to more peopleWe have made efforts to address the unique needs of low-income around the world in ways that are as accessible and affordable ascountries where the infrastructure and personnel to deliver possible for the patients who need them.immunization services can be severely limited. A specific emphasishas been on making improvements to products in a way that make While each individual situation varies based on factual circumstancesthem compatible to the Programmatic Suitability Criteria for vaccines and market dynamics, generally we consider:candidates for WHO Prequalification (PSPQ). These features include• Value provided to patientsvaccine vial monitors (VVMs), the acceptability of a two-dose regimen• Value provided to health care systemsfor HPV vaccines and use in controlled-temperature-chain conditions.• Unmet needIn order to make our products available to the people who need them• Accessthroughout the world, we registered 79 products and devices in 2020.The majority of these products were registered in low- and middle- • R&D sustainabilityincome countries in the Asia-Pacific, Central and Eastern Europe,• CompetitionMiddle East and Africa, and Americas regions.For more information on our Access to Health Guiding Principles,and related key performance indicators, please visit the ESG Resourcespage on our corporate website.GARDASIL® GARDASIL® ROTATEQ® M-M-R®II VARIVAX® ERVEBO®[Human 9 (Human (Rotavirus (Measles, (Varicella Virus (Ebola ZairePapillomavirus Papillomavirus Vaccine, Mumps & Vaccine Live) Vaccine, Live)Quadrivalent 9-valent Live, Oral, Rubella Virus(Types 6, 11, 16 Vaccine, Pentavalent) Vaccine Live)and 18) Vaccine, Recombinant)Recombinant]Product is WHO prequalified Yes Yes Yes Yes Yes YesDate of prequalification May 20, February 9, October 7, January 6, February 9, November 12,2009 2018 2008 2009 2018 2019Approximate number of countries 132 85 126 81 85 40where product is registered(as of April 2021)Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 61"
  },
  {
    "page": 62,
    "source": "text",
    "content": "In our fifth consecutive report, our 2020 U.S. Pricing Transparency Medicine Assistance ToolReport shows an average annual net price decrease of our productsof 0.9 percent in 2020. As a demonstration of our commitment to helping low-income,uninsured patients gain access to our medicines and adult vaccines,The report also shows that our annual average list price increaseswe also participate in Pharmaceutical Research and Manufacturersacross our portfolio have gone down each year for the past six years.of America's Medicine Assistance Tool (MAT). MAT is a search engineFor example, in 2020, the average annual list price across our portfoliodesigned to help patients, caregivers and health care providersincreased by 3.1 percent as compared with a 4.3 percent increase inlearn more about access resources available through the various2019. In 2020, our gross U.S. sales were reduced by 45.5 percent as abiopharmaceutical industry programs.result of rebates, discounts and returns.MAT helps eligible patients get free or nearly free brand namemedicines through a single website that provides information forand access to public and private patient assistance programs,including programs offered by biopharmaceutical companies. To date,this tool has helped millions of Americans get free or reduced-costprescription medicines.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 62"
  },
  {
    "page": 63,
    "source": "text",
    "content": "U.S. product portfolio pricing1,2 2016 2017 2018 2019 2020List price change (wholesale acquisition cost) vs prior year3 9.6% 6.6% 5.5% 4.3% 3.1%Net price change vs prior year4 5.5% (1.9%) 2.99% 1.8% (0.9%)Average discount5 40.9% 45.1% 44.3% 43.7% 45.5%Note: The amount of rebates, discounts and returns is estimated by the company and methodologies used may differ from methodologies used by other companies. This data is not auditedand should be read in conjunction with the company's filings with the U.S. Securities and Exchange Commission.1 U.S. Product Portfolio includes human health pharmaceutical and vaccine products marketed by the company, excluding partnered products. The product sales utilized in the analysisrepresent ~97 percent of the total U.S. Product Portfolio in 2010 and approached 99.5 percent of coverage in 2020.2 Annual percent change vs. prior year was calculated at a product level and weighted across the company's U.S. Product Portfolio.3 Represents the year‐over‐year change in the average list price or wholesale acquisition cost (WAC).4 Represents the year‐over‐year change in average net price, which is WAC less rebates, discounts and returns.5 Weighted average annual discount is calculated by dividing annual rebates, discounts and returns by annual gross sales.For more information, you may also see our Pricing and Access Position Statement on our corporate website.Patient assistance programs summary 2016 2017 2018 2019 2020Patients utilizing our U.S. Patient Assistance Programs1 306,000 244,000 233,000 239,000 189,50030-day prescriptions filled (in millions) 1.7 2.1 2.1 2.2 1.61 Totals represent 2016-2020 volumes of our U.S. Patient Assistance Program. Volumes vary across years based on changes in covered product offerings and changes across the health carelandscape. Volumes in 2020 reflect a decline as a result of the COVID-19 pandemic with fewer patients visiting their health care providers for care and prescriptions.Affordability 2019 2020Number of countries where dedicated affordability solutions have been initiated* 40 40People reached globally through product donation and patient assistance programs and partnerships1,2 404 268(estimate in millions)*Number of patents filed in low-income countries, as defined by The World Bank in its country and lending groups 0 0classifications (annual)** New key performance indicators (KPI) reported in 2019 to support refreshed Access to Health Guiding Principles.1 Estimate includes product donations through our company's Office of Social Business Innovation and patient assistance program.2 The significant decrease in people reached in 2019 vs 2020 is due to postponed mass drug administration programs as well as shipping delays as a result of the pandemic in 2020.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 63"
  },
  {
    "page": 64,
    "source": "text",
    "content": "GRI 203-1 Infrastructure investments and services supportedGRI 203-2 Indirect economic impactsProduct registration 2016 2017 2018 2019 2020New product and device registrations (annual)1,2 143 143 124 97 79Products submitted that have achieved WHO prequalification 11 13 13 13 13(cumulative)3Number of patent applications filed in low-income countries4 NR NR NR 0 0NR: Not reported1 Data include new products and new indications.2 Data for all years have been updated based on a tracking system upgrade that corrected miscounts in prior years.3 CRIXIVAN® (indinavir sulfate) was removed from our product list in 2019 and is no longer included in the total number of products that have achieved WHO prequalification.4 Countries classified as low-income countries in the 2019 World Bank Country and Lending Group classifications.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 64"
  },
  {
    "page": 65,
    "source": "text",
    "content": "Below is a list of products that have been prequalified by WHO as of April 1, 2021.Products International Nonproprietary Name (INN) Date of prequalificationprequalifiedby WHOFamily planning1,2MARVELON 28® Ethinylestradiol + Desogestrel September 2010EXLUTON® Lynestrenol June 2010IMPLANON NXT® Etonogestrel May 2013VaccinesMMR-II® Measles, Mumps, Rubella Virus Vaccine Live January 2009ROTATEQ® Rotavirus Vaccine, Live, Oral, Pentavalent October 2008GARDASIL® Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant (including a VVM) May 2009GARDASIL® Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant October 2014(two-dose regimen to support its programmatic feasibility in developing countries)GARDASIL® Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant May 2016(compatibility for use in a controlled temperature chain to facilitate its administration inhigh-temperature, low-cold-chain infrastructure areas of developing countries)GARDASIL®9 Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant February 2018(including a two-dose-regimen variation) 3VARIVAX® Varicella Virus Vaccine Live (first varicella vaccine to receive WHO prequalification) February 2018ERVEBO® Ebola Zaire Vaccine, Live November 2019HIV/AIDS treatmentsSTOCRIN® Efavirenz (600mg tablet, Oral Solution 30mg) May 2006Efavirenz (50mg tablet, 200mg tablet) May 20081 Source: Medicines/Finished Pharmaceutical Products | WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control)2 As of June 2, 2021, our family planning products have been spun off to Organon.3 Not currently available through UNICEF procurement; awaiting Vaccine Vial Monitor (VVM).Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 65"
  },
  {
    "page": 66,
    "source": "text",
    "content": "Access initiatives The MECTIZAN® Donation ProgramThe MECTIZAN® Donation Program (MDP) is the longest-runningWe have made substantial contributions to strengthening healthdisease-specific drug donation program and partnership of its kind andsystems and access to health through long-standing key initiatives.is widely regarded as one of the most successful public-private healthThese initiatives include Merck for Mothers, the MECTIZAN® Donationcollaborations in the world. MDP operationalizes the commitmentProgram and our company's Medical Outreach Program (MMOP).our company made in 1987 to donate MECTIZAN for the treatment ofonchocerciasis (also known as river blindness) to all who need it, forMerck for Mothers as long as needed. Since then, the program has expanded to includeadditional commitments to donate MECTIZAN for the treatment ofMerck for Mothers is our company's $500 million global initiative tolymphatic filariasis. Since the program's inception, our company hashelp create a world where no woman has to die while giving life. Fordonated more than 4 billion MECTIZAN treatments. In addition tonearly a decade through Merck for Mothers, we have brought Merck'sproviding direct access for communities in need of treatment, thescientific and business expertise to help improve maternal healthprogram has made significant impacts on health systems in some ofoutcomes. Our efforts are focused on generating fresh thinking andthe hardest-to-reach communities.infusing new approaches to help end the longstanding challenge ofmaternal mortality. We focus on strengthening health systems toFor more information on our efforts, please see the MECTIZAN storysustain the delivery of high-quality maternity care services that benefiton Merck.com.women and their communities. With our grantees and collaborators,we are improving health systems for women today and for the longterm by advancing quality standards, catalyzing solutions that respondto community needs and harnessing innovations for maternal health.For more information, please visit the Merck for Mothers website.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 66"
  },
  {
    "page": 67,
    "source": "text",
    "content": "MECTIZAN Donation Program 2016 2017 2018 2019 2020Direct financial investment in the program (in millions)1, 2 $3.74 $3.10 $2.20 $3.10 $2.74Total treatments approved (in millions) 283 300 346 403 417Treatments approved for river blindness (in millions) 64 97 111 131 139Treatments approved for lymphatic filariasis (LF) in river blindness 141 89 140 141 141endemic countries (in millions)Treatments approved for joint river blindness and LF programs (in millions) 78 114 83 70.7 75Treatments approved for lymphatic filariasis (LF) in countries not endemic N/A N/A 12 60 62for river blindness2River blindness endemic countries where elimination of LF has been 0 1 1 2 3validated by the World Health Organization (target: 30)Latin American countries where the elimination of river blindness has been 3 4 4 4 4verified by the World Health Organization (target: 6)1 Direct investment includes operational support and grants.2 F ollowing our company's commitment in 2017 to expand the donation of Mectizan to support the implementation of triple-therapy for the elimination of LF in certain settings, the MectizanDonation Program expanded in 2018 to include donations for LF elimination in countries not endemic for river blindness.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 67"
  },
  {
    "page": 68,
    "source": "text",
    "content": "Medical Outreach ProgramOur company's Medical Outreach Program (MMOP) is the primarymeans through which we donate pharmaceuticals and vaccines forhumanitarian assistance in the developing world and in supportof disaster relief worldwide. The MMOP helps expand access toour products, particularly in developing countries, by donatingpharmaceuticals and vaccines to a limited number of qualified,U.S.-based NGO partners. The scope and reach of the MMOP variesfrom year to year and is influenced by changing medical needs indeveloping countries, the quantity of our medicines available fordonation and the unpredictable nature of emergencies or disasters.For more information, please visit the MMOPpage on ourcorporate website.Merck Medical Outreach Program (MMOP) 2016 2017 2018 2019 2020Countries and territories reached by the MMOP 55 62 72 56 46Estimated number of people reached1, 2, 3 109,400 376,300 349,570 457,520 283,100Disaster relief (product) contributions (in millions)4 $13.41 $19.91 $12.76 $15.38 $11.21 E stimated figures, which assume all product reached patients, are based on converting volume of medicines and vaccines donated. Conversion factors for this estimate were developed usinga combination of QuintilesIMS SMART Data and U.S. product information found on our company's product website.2 Inhalation brands were analyzed differently after 2016. Prescriber Information dosing information was used to calculate total doses for one year for chronic asthma patient and assumessplitting inhalers.3 Decline in patients reached in 2020 primarily due to a decrease in topical corticosteroid medicine donations.4 We set the value of our product donations based on the U.S. wholesale acquisition cost.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 68"
  },
  {
    "page": 69,
    "source": "text",
    "content": "Disaster reliefOur company is committed to supporting communities around the world that are affected by natural disasters. We look to local authorities andhumanitarian relief agencies to first assess need and then respond in a timely, coordinated manner. We provide aid through financial and productdonations to meet the immediate needs of affected communities.Disaster relief 2016 2017 2018 2019 2020Total giving value of disaster relief contributions $13.4 $23.9 $10.2 $16.7 $20.3(cash and products, in millions)1, 21 Funding provided through the Office of Social Business Innovation.2 We set the value of our product donations based on the U.S. wholesale acquisition cost.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 69"
  },
  {
    "page": 70,
    "source": "text",
    "content": "Addressing barriers to health 2016 2017 2018 2019 2020Health care workers trained through major programs and 32,000 74,000 67,000 68,000 78,000partnerships (estimate)1Annual investment in partnerships, programs and impact $28 $40 $37 $63 $49investments that support health care capacity-building andaddress underlying barriers to access to health (in millions)1People reached through investment in partnerships, programs 293 311 357 422 285and impact investment that support health care capacity-building and address underlying barriers to access to health1,2(estimate in millions)Percentage of investment in partnerships and programs to NR NR NR 10% 10%strengthen health care capacity and address barriers to access,that is allocated to impact evaluation3Investment in patient-and-provider education programs $80 $90 $115 $102 $96(in millions)NR: Not reported1 Represents investments made by our Office of Social Business Innovation.2 The significant decrease in people reached in 2019 vs 2020 is due to postponed mass drug administration programs as well as shipping delays as a result of the pandemic in 2020.3 Percentage calculated based on total investments in partnerships and programs to strengthen health care capacity and address barriers to access supported through our company's Foundation.Philanthropic social investments our philanthropic priorities. Our company and Foundation supportinnovative programs and partnerships to improve the health andOur philanthropic social investments address underlying barriers to wellbeing of people around the world. Through these programs, weaccess to health and help advance health equity around the world. believe that by working closely with others-governments, donors,Our approach to these investments is guided by several key principles: patient groups, health care professionals, NGOs, academic institutions,addressing critical global health needs where we can have a meaningful multilateral agencies and the private sector-we can help strengthenimpact; promoting health equity by addressing health disparities in health systems and improve population health outcomes.vulnerable, underserved communities; collaborating with diversepartners to build healthier, stronger communities; and leveraging our For more information on our philanthropy programs, please visitrange of resources (financial, product, and expertise) to achieve greater the Philanthropy page on our corporate website. For information onimpact on population health outcomes. philanthropic programs specific to our Animal Health business please visitour Merck Animal Health website.Established in 1957, our company's Foundation is funded entirelyWe recognize that our company's success depends in large part onby the company and is our chief source of financial support forour relationships and interactions with local communities, includingqualified, eligible nonprofit organizations whose programs align withMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 70"
  },
  {
    "page": 71,
    "source": "text",
    "content": "community leaders, nonprofit organizations, local businesses, schools, Our Neighbor of Choice (NOC) grants program supports the work ofelected officials and local media. The communities where we operate local nonprofit organizations dedicated to promoting the wellbeingare home to our workforce as well as many of our suppliers. It is critical of community residents in areas where we have a major presence.to understand the concerns and needs of our communities and address Additionally, our company's Partnership for Giving (P4G) matchinglocal challenges so that we can help build stronger communities and gift program doubles the donations made by employees in the U.S.support the sustainability of our business. and Puerto Rico to causes that are important to them. Through adollar-for-dollar match of employee contributions, our company'sWe contribute to the economy of local communities directly and Foundation supports nonprofits that promote a healthier society,indirectly through employment, training, support of local suppliers, advance education, foster the arts, address the welfare of animalslocal R&D and paying taxes. We also strive to have a positive impact and preserve the environment.on communities by protecting the environment, maintaining safeoperations and respecting human rights. Our community engagementprograms aim to strengthen communities where our employees liveand work by helping address critical health and social needs.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 71"
  },
  {
    "page": 72,
    "source": "text",
    "content": "Grants and contributionsGrants and contributions 2016 2017 2018 2019 2020Grants and contributions (total cash, in-kind and product) $2,238 $2,722 $2,793 $3,096 $2,890(in millions)1Cash grants and contributions (in millions) $117 $94 $84 $82 $104Product donations through U.S. Patient Assistance Program $798 $1,112 $1,242 $1,460 $1,600(in millions)Product donations for ex-U.S. programs and U.S. disaster relief $1,320 $1,513 $1,464 $1,550 $1,280(in millions)2Valuation of employee volunteer time (in-kind, in millions)3,4 $2.6 $3.2 $3.1 $4.1 $1.01 Due to shipping delays in 2020, some product donations approved in 2020 were shipped in 2021.2 I ncludes our Medical Outreach Program (including U.S. disaster relief), the African Comprehensive HIV/AIDS Partnerships (2016 only), the MECTIZAN® Donation Program and MSD divisionand subsidiary donations.3 I ncludes valuation of volunteer time for only those employees who participated in the MSD Fellowship for Global Health program and our company's Pro Bono Legal and other skills-basedvolunteer programs.4 2 020 decrease in employee volunteering valuation is due to the temporary suspension of the MSD Fellowship for Global Health Program and decreased in-person volunteering as a resultof COVID-19.Partnership for Giving (P4G) 2016 2017 2018 2019 2020Total contribution (in millions)1, 2 $26 $25 $22 $15.1 $19.3Number of organizations that benefited3 6,200 8,770 7,350 5,645 6,468Number of employee participants4 8,200 8,302 6,503 5,083 5,3961 T otal contribution includes Foundation matching funds for Dollars for Doers and P4G matching gift programs, and 2020 active-employee participant funds donated through the P4G DirectGiving program.2 2020 increase is largely due to increase in employee giving and matching gifts to support COVID-19 response efforts.3 Includes organizations receiving funds through the P4G matching gift and Dollars for Doers programs.4 Includes active employee participants in the P4G matching gift program.For more information on access and pricing, see GRI 203 Management approach on page 53.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 72"
  },
  {
    "page": 73,
    "source": "text",
    "content": "Procurement practicesGRI 204 Management approachGlobal Economic Inclusion & Supplier DiversityGlobal Economic Inclusion & Supplier Diversity (EI&SD) is integratedinto our overall Global Diversity & Inclusion (GD&I) strategy andsupports our corporate vision. The EI&SD Center of Excellence (CoE) isa member of the GD&I Business Consortium, where EI&SD is one offour target areas focusing on:Celebrating 35 years of impact and inclusion• Increasing business performance through diversity and inclusion• Creating a competitive business advantage Diversity is mission critical for innovation and scientific excellence,• Attracting and retaining top talent as well as for better decision-making and cultural agility. This is our35th year of pursuing goods and services from diverse suppliers.• Driving shareholder valueWe see that as a huge milestone. It's an opportunity for us to increaseEconomic Inclusion & Supplier Diversity is the epicenter of our our program awareness and to look more deeply at our pipeline andcompany's diverse and inclusive procurement practices. We create the suppliers we work with to see where we can expand opportunitieseconomic opportunities for underrepresented communities by for the communities that we serve.procuring products and services from minority-, women-, veteran-,lesbian-, gay-, bisexual and transgender (LGBT)-, and disability-2020 Virtual Engagement Centerowned enterprises.The challenges posed by the COVID-19 pandemic haven't changedOur goals go beyond the amount of dollars we spend with small-our commitment to Economic Inclusion and Supplier Diversity.and diversity-owned businesses, as we focus on the growth andInstead, they've inspired innovation. In 2020, we launched the Virtualdevelopment of our suppliers to drive economic impact and valueEngagement Center with the purpose of modernizing educationaldelivery to our company. We are committed to supporting theofferings by curating our company's online educational content andbusinesses that are the economic engine of growth around thedeveloping webinars specific to diverse business needs. Topics includedworld by making a difference in global economic inclusion.the following:• Certification to Success • Think Globally, Act Locally• Get to Know Your Target Client • Differentiate Yourself• Show up and Follow up • Winning the Business• Increase Visibility in the Network• Create and Communicate a Supplier Diversity ProgramMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 73"
  },
  {
    "page": 74,
    "source": "text",
    "content": "In addition, this platform allowed us to establish meaningful businessconnections via the Virtual Business Opportunity Fair, a remote-hostedexhibition/tradeshow for diverse suppliers. Two events were held-onein June and another in November.Attendees of the virtual events included nearly 2,000 diversesuppliers, partners and advocacy representatives from the U.S.,Puerto Rico, Canada, Brazil, Mexico, Colombia, the United Kingdom,Germany, India, China, Vietnam and South Africa. The events includedwebinars, speaker sessions, panel discussions and virtual tradeshows.Throughout the course of the day, attendees engaged in over2,700 private chats connecting suppliers, our procurement specialistsand advocacy groups.PerformanceIn 2020, diverse spend represented 12 percent of our totalprocurement spend, exceeding our corporate goal to achieve$2 billion in spend with minority-owned, women-owned, veteran-owned, LGBT-owned and disability-owned business enterprises.$2.3 billionspending withdiverse suppliersSupplier diversity 2016 2017 2018 2019 2020Diverse-supplier spend (in millions) $1,500 $1,962 $2,111 $2,433 $2,270Small-business spend (in millions) $753 $802 $973 $979 $775Note: The acquisition of small suppliers may have impacted their small business status and therefore affected the small business spend reflected above.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 74"
  },
  {
    "page": 75,
    "source": "text",
    "content": "Billion Dollar Roundtable In addition to the Billion Dollar Roundtable, we work in partnershipwith others, including:Our ongoing economic inclusion and supplier diversity efforts will• Disability:INenable us to continue our membership in the Billion Dollar Roundtable(BDR), an exclusive industry organization that recognizes and • LGBT-owned Business Certification in Canada (CGLCC)celebrates corporations that achieve spending of at least $1 billion with• Minority Supplier Development Council UK (MSDUK)minority-, women-, veteran-, LGBT and disability-owned enterprises• Minority-owned Business Certification in Canada (CAMSC)headquartered in the U.S. and globally. Our membership in the BDRallows us to share and access best practices in supply chain diversity • National LGBT Chamber of Commerce (NGLCC)excellence with other organizations that have also achieved this status.• National Minority Supplier Development Council (NMSDC)As part of our 35 years of inclusion and impact, we are proud to be • National Veterans Business Development Council (NVBDC)hosting the next Billion Dollar Roundtable Summit in 2022. The• United States Hispanic Chamber of Commerce (USHCC)Summit will provide another opportunity to chart a course for the boldand transformative steps which are urgently needed to ensure we are • United States Pan Asian American Chamber of Commerceoptimizing positive economic impact to some of our most distressed (USPAACC)areas, share best practices and encourage global partners to continue• SASDC-South Africa Supplier Diversity Council (South Africa)to deliver on our mission.• SupplyNation• WeConnect International• Women Business Enterprise National Council (WBENC)Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 75"
  },
  {
    "page": 76,
    "source": "text",
    "content": "AnticorruptionGRI 205 Management approachOur company is built on the reputation forged with our customers,partners and stakeholders. Bribery and corruption tarnishes reputationand undermines public trust. Offering or paying bribes or kickbacks isagainst the laws of the markets where we do business. Our company iscommitted to observing the laws and regulations that govern ouroperations and activities wherever we do business. To that end, wemaintain policies and procedures that require compliance with the lawsand regulations that govern the way we market and sell our medicines,vaccines and other products.We have a well-established global ethics and compliance programthat is consistent with the International Federation of PharmaceuticalManufacturers & Associations (IFPMA) Code of Practice requirements,as well as with other applicable regional or country industry codes ofconduct, including those issued by the Pharmaceutical Research andManufacturers of America (PhRMA) and the European Federation ofPharmaceutical Industries and Associations (EFPIA).Our company's Board of Directors and senior management, includingthe chief ethics and compliance officer, provide the foundationalelements of leadership, accountability and structure to oversee thecompany's global ethics and compliance program.Our policy prohibits the offer, promise or giving of any paymentThe chief ethics and compliance officer reports directly to ouror benefit at any time to an individual or entity for the purposecompany's CEO and provides regular updates to senior leaders, andof improperly influencing decisions or actions with respect to ourthe Audit Committee of the Board of Directors, on key indicators ofbusiness. Our policy also prohibits any act that gives the appearance ofethical culture. This reporting structure supports open communicationsoffering anything of value for a business advantage. This policy appliesregarding important developments that relate to ethics and compliance.to direct engagements (i.e., those conducted by our company) as wellOur company's robust anti-bribery/anticorruption program and as to indirect engagements (i.e., those managed through a third-partycorporate prevention of bribery and corruption policy give our intermediary or partner).employees the awareness and knowledge to comply with applicablelaws and regulations, and to understand that the company will nottolerate any act, or even the appearance of, impropriety.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 76"
  },
  {
    "page": 77,
    "source": "text",
    "content": "Ethics and compliance training is an important part of creating astrong culture. To ensure that all employees understand our ethicalGRI 205-2 Communications and training on anticorruption expectations and principles, we have a Code of Conduct annualtraining series that has been completed by nearly 100 percent of ourAnnual ethics and policy certification employees. The 2020 topics included four specific modules: code ofconduct, anti-bribery and anti-corruption, accurate books and records,An important component of our corporate ethics and compliance and conflicts of interest.program is our annual ethics and policy certification. The annual reviewprocess requires selected company employees to certify adherence to Supplemental training on anti-bribery and anti-corruption is alsothe Code of Conduct and corporate policies on preventing bribery and provided for employees who engage with non-U.S. governmentcorruption, antitrust-law compliance and conflict of interest and insider officials. Additionally, our program ensures that there are cross-trading. In addition, U.S.-based (including Puerto Rico) employees functional discussions in the regions and markets where we do businessmust certify compliance with our corporate policy on the effects of to ensure that our bribery and corruption policies, requirements andexclusions, debarments, suspensions and health care-related criminal processes are implemented and applied appropriately.convictions, reporting and screening.Employees in the Human Health Division in the U.S. are also requiredThese employees are also expected to regulate their outside activities to understand, among other things, their responsibilities under theto avoid any conflicts of interest and to certify, in writing, whether Anti-Kickback Statute, the U.S. Prescription Drug Marketing Act andactual or potential conflicts of interest exist. Where potential conflicts all applicable FDA promotional regulations.are identified, the Office of Ethics will work with management to takeEthics and integrity are key leadership competencies that are assessedactions to mitigate the potential conflict.as part of annual performance reviews and play an integral role in ourdecisions about employee advancement within the company.>99%employees trained onthe Code of Conducttraining series100%employees respondedto the disclosurestatement onthe Conflicts ofInterest formsMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 77"
  },
  {
    "page": 78,
    "source": "text",
    "content": "Anti-competitive behavior Fostering ethical practicesWe believe that our marketing, sales and advertising activities makean important contribution to medicine by informing our customers oftreatment options based on the most recent scientific information andGRI 206 Management approachfindings from rigorous clinical studies.Our sales and marketing practices are governed by external lawsWe adhere to strict ethical sales and marketing practices in all ourand regulations and industry codes of conduct, and by our own globalbusinesses, whether pharmaceuticals, vaccines or animal health.Code of Conduct, our corporate policies and procedures, and our ethicsOne of the ways we provide product information is by maintaining and compliance program.informative and ethical professional relationships with healthOur ethics and compliance program seeks to address and preventcare providers.inappropriate practices, and we evaluate our policies and practices asOur interactions with providers, other customers and consumers are appropriate. Our practices are monitored, and compliance is enforcedgoverned by laws and regulations, and by our long-standing global to ensure that our interactions with customers and consumers helpCode of Conduct, Our Values & Standards. We enforce these external inform their decisions accurately and in a balanced manner. We believeand internal standards through our ethics and compliance program. that compliance with all policies governing scientific, business andpromotion-related activities, in letter and spirit, is a corporate andWe recognize that both our reputation for integrity and the trust that individual responsibility of the highest order. Through our ethicalour stakeholders place in us are dependent on our ethical practices. behavior, we strive to ensure that scientific information predominatesConsequently, we want to make certain that the ways in which in prescribing decisions.we market and sell our products to our customers - health careprofessionals, health insurers and governments - include accurate,balanced and useful information so that prescribers can make the bestdecisions for their patients.Our high ethical sales and marketing standards require that scientificinformation is the predominant factor in prescribing decisions,reinforcing our reputation for providing high-quality products and forcontributing to improvements in public health.Our professional sales representatives and other employees informour customers about our medicines and vaccines and their appropriateuse. To respond to increasing requests for on-demand information, incertain countries we offer resources and product information to healthcare providers on company websites and other digital platforms.In some countries, where permitted by law, we may directly informpatients and other consumers about diseases and available treatmentsthat they may wish to discuss with their doctors. We believe direct-to-consumer advertising contributes to greater awareness aboutconditions and diseases, which can benefit public health by increasingthe number of patients appropriately diagnosed and treated.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 78"
  },
  {
    "page": 79,
    "source": "text",
    "content": "GRI 206-1 Anti-competitive behaviorAs a condition of employment, all of our sales and marketingemployees are required to be certified periodically on sales andmarketing practices.In the U.S., for example, employees who do not satisfactorily meetthese training requirements may not conduct specific activities on theirown and must repeat the training until they meet the requirements.All new employees receive training and testing and must be certified onrelevant policies and our company's ethical operating standards. AndOur guiding principles for ethical business although many of our employees who market and sell our medicines andvaccines have advanced scientific or medical degrees and backgrounds,practices involving the medical and scientificall of our sales representatives must complete general sales and productcommunity include the following: training. Training is specific to the country where an employee is basedand covers the scope of the employee's responsibilities in ensuringWe provide current, accurate and balanced information about our products; compliance with applicable laws and regulations.we share sound scientific and educational information; and we supportSales representatives are trained on anti-bribery and anticorruptionmedical research and education.laws such as the U.S. Foreign Corrupt Practices Act and the UK BriberyOur employees are prohibited from offering health care professionals items Act. Sales representatives in the U.S. are also required to understand,of personal benefit, such as tickets to sporting events, support for office among other things, their responsibilities under the Anti-Kickbacksocial events or gift certificates for stores or golf outings. Where permitted, Statute, the U.S. Prescription Drug Marketing Act and all applicablewe may occasionally provide health care professionals with approved FDA promotional regulations.educational items that are not of substantial monetary value and that areAfter this initial training, we require periodic training aimed atintended primarily for educational purposes. Such materials may includerecertifying employees on relevant policies and practices in accordancemedical textbooks, medical journals and anatomical models.with local and functional requirements.Our employees and others speaking on behalf of the company may giveWe stress that if our employees are unsure about the appropriatenesspresentations specifically designed to provide the type of information thatof the conduct that they ask for help. There are several placespracticing health care professionals have indicated is needed and most usefulemployees can turn for assistance. The first option is to talk with theirin the treatment of their patients, in accordance with U.S. Food and Drugmanager. If they do not feel comfortable with that course of action,Administration (FDA) regulations and the regulations of other countries inthe other resources they may contact are:which the presentations or discussions are taking place.• Divisional Compliance DepartmentsA company representative may offer occasional modest meals tohealth care professionals in connection with an informational • Office of Ethicspresentation; however, such meals must be in accordance with • Privacy Officelocal codes and regulations.• Office of General CounselFor more information, please see GRI 102-16 on page 38. • Human Resources Department• MSDethics.comMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 79"
  },
  {
    "page": 80,
    "source": "text",
    "content": "In addition to mandatory training on our Code of Conduct, employees Direct-to-consumer (DTC) advertisingreceive training on other levels of business practice and compliance,according to their roles and responsibilities. We evaluate and update We believe that DTC advertising can be an important and helpfulthe content for all marketing and sales training periodically to ensure way to inform patients about diseases that may be relevant tothat it remains relevant and current. them and about therapeutic options they may want to discusswith their physicians.Industry codes of conductOur company has a long-standing policy of voluntarily submitting newU.S.-based DTC advertising campaigns to the FDA for its review andOur sales representatives must provide truthful, non-misleadingcomment before running them. Under our DTC policies and practices,information in their interactions with the medical and scientificthe information provided in our DTC advertising must:community. Our compliance program is consistent with applicable lawsand regulations, and is aligned with the International Federation of • Contain appropriate product benefit and risk informationPharmaceutical Manufacturers & Associations (IFPMA) Code of• Be appropriately balanced, consistent with FDA regulations, and usePharmaceutical Marketing Practices, as well as with regional andappropriate \"taste and tone\"country industry codes, such as the Pharmaceutical Research and• Be approved by our company's Promotion Review Team or DigitalManufacturers of America (PhRMA) Code and the Compliance ProgramEngagement Team, a governing body consisting of a team ofGuidance for Pharmaceutical Manufacturers, published by the Office ofreviewers (including the job owner, an attorney, a physician, athe Inspector General, U.S. Department of Health and Human Services.representative from the Office of Promotion and Advertising Review,The pharmaceutical industry as a whole recognized that more and a product scientific specialist) who ensure that promotionalneeded to be done to address concerns raised by public officials and material is clinically and scientifically accurate, compliant withstakeholders in the health care community. Self-regulating industry applicable laws and regulations, and compliant with company policy.codes of conduct such as the IFPMA, the European Federation ofPharmaceutical Industries and Associations (EFPIA) and PhRMA codesset standards for the industry's sales and marketing practices and helpto ensure that companies have adequate policies and procedures inplace to comply with the codes.Among PhRMA's Code on the Interactions with Healthcare Professionals(the Code) key components is an annual requirement for company CEOsand chief compliance officers to certify personally that they have policiesand processes in place that foster compliance with the Code. The Codealso encourages companies to periodically obtain third-party verificationof their compliance policies and procedures. We complete PhRMA Codecertification every year in compliance with the Code. We also periodicallyobtain third-party verification that our policies and procedures areadequate to support compliance with the Code.Other requirements of the Code have previously been incorporated intoour already strong ethical business practices. For example, our companyfollows the standards for commercial support of continuing medicaleducation established by the Accreditation Council for ContinuingMedical Education, and our ethics and compliance program requires thatcompany representatives be periodically assessed to make sure theycomply with relevant company policies and standards of conduct.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 80"
  },
  {
    "page": 81,
    "source": "text",
    "content": "We try to help consumers achieve better health outcomes by delivering Taxaccurate, relevant and understandable information on diseaseprevention, identification and potential treatment. To remain trueto this goal, we adhere to the letter and spirit of U.S. Food andDrug Administration (FDA) regulations and guidelines governing GRI 207-1 Approach to taxDTC promotion, meet or exceed all Pharmaceutical Research andManufacturers of America (PhRMA) guidelines on DTC advertising, We recognize our role as a responsible taxpayer to pay our full shareand follow a comprehensive set of internal policies and practices when of taxes, including corporate income taxes. We also recognize that ourengaging in DTC advertising within the U.S. contribution is much more than the corporate income tax we pay.We adhere to updated 2019 PhRMA guidelines that all DTC television We pay a significant amount of taxes to national and local governmentsadvertising that identifies a medicine by name should include direction in the form of employment taxes value added taxes, sales taxes, exciseas to where patients can find information about the cost of the taxes, property taxes and customs duties. We also collect numerousmedicine, such as a company-developed website, including the list price taxes paid by our employees. We pay all taxes due in full and on timeand average, estimated or typical patient out-of-pocket costs, or other in the jurisdictions in which we operate. The way we conduct business,context about the potential cost of the medicine. In addition, we include including the economic impact from the taxes we pay, also reflects ourinformation on our U.S. Patient Assistance Program in all new U.S.- commitment to striving to reach those in need with our medicines andbased DTC print and television advertisements for eligible products. vaccines and helping to build robust, durable health systems worldwidethrough partnership, investment and innovation.We inform and educate health care professionals about ourproducts before we advertise them to consumers. We implement Our chief financial officer (CFO) is ultimately responsible for our overallcomprehensive programs to educate physicians and other prescribers tax position. The day-to-day management of tax is performed byabout a new product for an appropriate period of time before starting the company's global corporate tax department, which is led by theproduct-specific DTC broadcast advertising in the U.S. Senior Vice President of Tax. Effective oversight of the tax functionis maintained by at least an annual tax presentation to the AuditThese principles and our practices are reflected in the PhRMACommittee of our Board, and regular meetings with the CFO, SeniorGuiding Principles on Direct-to-Consumer Advertisements aboutVice President, Tax and Treasury, and other executive leaders toPrescription Medicines.discuss emerging tax matters.For more information on our ethical marketing practices, please visitGRI 417 on page 167.Sales and marketing 2016 2017 2018 2019 2020Number of warning letters or untitled letters from OPDP1 0 0 0 0 0or APLB 2 in the U.S.1 OPDP: Office of Prescription Drug Promotion.2 APLB: Advertising and Promotional Labeling Branch (APLB) of the FDA Center for Biologics Evaluation and Research.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 81"
  },
  {
    "page": 82,
    "source": "text",
    "content": "We comply with tax rules and regulations on a worldwide basis andonly engage in tax planning that is aligned with our commercialbusiness activities and reputation. We are committed to thearm's length standard in transfer pricing and OECD guidelines forinternational tax matters. We have a zero-tolerance approach to taxevasion and the facilitation of tax evasion. Where uncertainty exists,and when appropriate, we seek clarification from our external advisorsand/or governmental authorities. This can take the form of tax rulingsor advanced pricing agreements from governmental authorities.We monitor proposals and changes to tax incentives and regulationsin the countries in which we operate in order to assess their impact onour business, and we actively participate in industry groups interactingwith government representatives to support the development ofeffective tax systems that encourage innovation and growth. Weutilize available tax incentives and opportunities, such as Research andDevelopment tax reliefs, in the spirit in which they were intended.The effective income tax rates of 19.4 percent in 2020, 14.7 percent in2019, and 28.8 percent in 2018 reflect the impacts of acquisition anddivestiture-related costs and restructuring costs partially offset by thebeneficial impact of foreign earnings, including product mix.To learn more, please download our Global Tax Strategy from ourcorporate website.For information on our effective tax rates for the last three years,please see GRI 201-1 on page 50.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 82"
  },
  {
    "page": 83,
    "source": "text",
    "content": "EnvironmentalSee our GRI Index on page 171.Materials ProductsWe conduct extensive testing of our products to identify andunderstand any potential safety, health and environmental hazards.We manage and communicate information about hazardousGRI 301 Materialsmaterials to keep our employees, contractors, transporters andother partners safe.By using more efficient and innovative processing methods andtechnologies, we are reducing the amount of energy, water andWe are actively engaged in conversations on product stewardship toraw materials we use to make our products, thereby minimizing theunderstand and act on the issues specific to our industry worldwide.amount of waste we generate.We share best practices within the industry via our membership inWe go to great lengths to ensure that our products are designed,the Conference Board Product Stewardship Council, the Americanmade and used in a safe, effective and environmentally sound manner.Chemistry Council's (ACC) Green Chemistry Initiative (\"CHEMLEG\"),We deliver on this commitment by maintaining a highly trained andthe European Federation of Pharmaceutical Industries andcapable scientific staff and by actively pursuing manufacturing processAssociations (EFPIA), the International Federation of Pharmaceuticalimprovements that minimize environmental impacts.Manufacturers & Associations (IFPMA) and the ACS Green ChemistryInstitute Pharmaceutical Roundtable (ACS GCIPR).We have set environmental sustainability goals to demonstrate thiscommitment with concrete targets and timelines. To ensure that ourOur objective is to maintain compliance and assure supply of life-savingknowledge stays current with that of thought leaders and experts inmedicines as we look to further minimize our environmental footprintthe industry, we also collaborate with external resources and industryin the future.groups, such as the American Chemical Society and the EuropeanFederation of Pharmaceutical Industries and Associations.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 83"
  },
  {
    "page": 84,
    "source": "text",
    "content": "Governance In addition to these critical functions of packaging, there is also theconsideration of the environmental impact of the materials we use.Our efforts in this area are overseen by our Green & SustainableAfter it has served its critical function(s), packaging becomes ourScience Steering Committee and the Environmental Health and Safetycustomer's waste and therefore must be accounted for in our designs.(EHS) Council.We have adopted \"Design for Environment\" practices that helpPrograms and initiatives our engineers design new product packages that are better forthe environment by minimizing package sizes and using moreOur chemists and engineers are trained in green-design principlesenvironmentally friendly materials, where possible.and are provided with tools and resources to help them developmanufacturing processes that use safer chemicals and reducedAs a standard business practice, we review all of our new humanquantities of raw materials. We use innovations like nanotechnologyhealth packaging designs prior to launch to understand and minimizeto make our products more effective, while ensuring that productenvironmental impacts as much as possible, while still providingsafety always remains of utmost importance.adequate protection for our products.Complying with chemical substance and product requirements isTo help us evaluate the differences in environmental impacts betweena top priority for us. We track numerous existing and emergingpackaging options, we use a simplified life-cycle assessment (LCA) toolchemical control regulations that require us to register specific typesthat provides information on the environmental impacts generated byof chemicals with the proper authorities. To meet these requirements,the materials used in our packaging.our scientists complete assessments of the environmental and humanhealth risks of the substances with which we work and submit the In addition, we are working to establish foundational, environmentally-required regulatory notifications. Additionally, we provide details focused packaging principles for the future of our packaging design.on product use and risk-based control measures in accordance with These principles, in addition to our LCA tool, serve to guide decisionapplicable regulations. making for packaging design.We continue to monitor global trends around material use such asPackagingthe New Plastics Economy, and around how we might incorporate\"circular economy\" concepts into the critical functions of packagingOur product stewardship program extends to our customers andfor pharmaceuticals. It is unclear how these trends will impact ourpatients through the design of effective, low-impact productindustry, however, these are important signals of a changing externalpackaging. Our company also supports the development of science-approach to the use and recovery of specific materials like fiber-basedbased, cost-effective and environmentally sound programs thatproducts, plastics such as PVC, metals and others.promote the proper disposal of unused medicines in accordancewith regional requirements. For more information, see our positionstatement on responsible disposal of medicines, which can be found Governanceon our corporate website. Packaging design is managed by the Global Pharmaceutical Operationsarea of the company with oversight from the Environmental Health andThe materials we use for packaging our finished products serve a rangeSafety Council.of important purposes; the foremost purpose is to protect the purity,efficacy and physical integrity of the product. Packaging also provides In 2020, we responded to the CDP forest questionnaire for timberthe customer with information and convenience, the pharmacist products, specifically for paper and secondary and tertiary packaging.or provider with accurate dispensing information at the point of Also in 2020, CDP graded our disclosure with a C \"awareness\" rating,purchase, and our business with marketing value. For some products, indicating that we have \"Knowledge of impacts on, and of, forestspackaging also serves safety functions such as child resistance and issues\". According to CDP, our company is among 50 percent oftampering evidence.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 84"
  },
  {
    "page": 85,
    "source": "text",
    "content": "companies that reached Awareness level in our Activity Group manufacturing sites, we have engineers who are responsible for(Biotech and pharma) for Timber. We performed a gap assessment identifying and driving process-improvement projects. When it isof our questionnaire response and developed a roadmap for not practical to reuse regenerated solvents in our own productionimprovements in this area over the next several years. processes, we either work with suppliers who recover the spentsolvents for resale to other industries, or safely burn them as a sourceWe are in the early stages of our program development and are in the of energy. Any used solvents that leave our site as hazardous wasteprocess of assessing the impact of other forest risk commodities. are managed at offsite facilities that are on our list of approved wastemanagement sites.Solvent useChemical managementSolvents play a key role in the research and manufacturing ofour products, as well as in equipment cleaning. Because of their A comprehensive and effective chemical management program issignificance to our business and the life-cycle impact they represent, critical to the safety and protection of our employees, the communitieswe focus on designing our processes to minimize or avoid their use in which we operate and the environment.where practical. Where we do use solvents, we maximize efficiencyand control them in our emissions, effluents and waste. We have put procedures, systems and processes in place to managethe approval, procurement, inventory, receipt, transfer, storage, useWe have an active Green and Sustainable Science program (see and disposal of chemicals at all of our sites. We provide our employeesfollowing page) to design our new processes using fewer, less toxic, and others with information about the identities and potential hazardssolvents and other hazardous materials, and to reuse and recycle more of the chemicals in our operations and final products through properof the solvents we do use. labeling of chemicals and the creation of safety data sheets.For cleaning our manufacturing equipment, we use water-basedmethods where they are as effective as solvents. At each of ourMaterials and packagingGoal:100% of the packaging for ournew human health products willbe reviewed for environmentalimpact and improvement.Progress:AchievedMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 85"
  },
  {
    "page": 86,
    "source": "text",
    "content": "Green and sustainable science GovernanceOur company's Process Research and Development department isDeveloping innovative, cost-efficient manufacturing processes withresponsible for chemistry development. The progress toward our goals islow environmental impact aligns with our company's environmentaloverseen by various internal bodies including the Scientific Advisory Councilsustainability strategy. Green and sustainable science is the design(SAC), the Development and Commercialization Review Committee (DCRC)of new products and processes that reduce or eliminate the use orand the Environmental Health and Safety (EHS) Council.generation of hazardous substances.The concept applies across the life cycle of a product, including its Strategydesign, manufacture, use and ultimate disposal.Our integrated strategy involves several stages and aims to provideinnovative solutions rather than incremental improvements to historicalThere is a trend towards more regulatory restrictions and increasedpractices. We see science and innovation as critical enablers to developingoversight in many places around the world. Our strategy for greensustainable, low-cost manufacturing processes that provide bothand sustainable commercial chemical route development could helpenvironmental and economic benefits over the life cycles of our products.to avoid potential future issues in the supply chain.We aim to develop the most efficient and sustainable processes at productOur company's overall objective is to be viewed as the leader inlaunch, with the goal of minimizing material use and waste from ourthe industry for the development of innovative, efficient, greencommercial manufacturing. Our company's research laboratories utilizeand sustainable commercial syntheses of our small molecule activean innovative \"green-by-design\" development strategy to progress frompharmaceutical ingredients (API), from sustainable commodity rawan initial early clinical supply route to a fully optimized and sustainablematerials, where feasible. We are also exploring ways to reduce thecommercial manufacturing process. We have developed aggressive Processenvironmental impact of biologics and vaccine manufacturing.Mass Intensity (PMI) targets for our API processes utilizing an internallydeveloped SMART PMI tool and regularly evaluate PMI at every stage ofdevelopment. We use this tool during the development of all our new APIprocesses and achieved our stated goal that by 2020, at least 90 percentGreen and sustainable scienceof our human health API processes will meet internal sustainability targetsat the time of product launch. Nine out of ten of our new processes metthe internal sustainability targets, thus achieving the 90 percent successGoal:rate threshold.By 2020, at least 90% of our new humanhealth API processes will meet internal Programs and initiativessustainability targets at launch. As part of our Green & Sustainable Science program, we calculatethe process mass intensity (PMI) of our human health products. PMIrepresents the number of kilograms of raw materials (including water)used to produce one kilogram of an API or biologic. PMI indicates howProgress: efficiently we convert raw materials into final products. We use this metricinternally to compare different manufacturing methods, identify processAchieved improvement opportunities and track our progress. We are also using life-cycle assessment (LCA) tools to further evaluate the environmental impactsof our processes.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 86"
  },
  {
    "page": 87,
    "source": "text",
    "content": "American Chemistry Society (ACS) GreenChemistry Institute (GCI)We are a founding member of the ACS Green Chemistry Institute®Pharmaceutical Roundtable, a partnership between the ACS GCI andmember pharmaceutical companies. The Roundtable assists withthe development of tools, such as solvent selection, reagent guidesand the PMI calculator, which drive the integration of sustainabilityinto process design. Roundtable members also work together tosupport and advance academic research and education on new waysto apply green and sustainable science to pharmaceutical discoveryand manufacture, which have resulted in several industry publicationson more sustainable processes and technologies. More recently, theACS GCI member companies have developed tools and guidelines forsustainable production practices relevant to bioprocessing.In 2017, 2018, 2019 and again in 2020, our company was honoredby the EPA and the ACS as a winner of the Green ChemistryChallenge Awards.In 2017, our scientists were recognized for the design andcommercialization of a green synthesis of Prevymis™(letermovir) utilizing state-of-the-art approaches to sustainablecommercial manufacturing.In 2018, our scientists were recognized for successfully applyinggreen chemistry design principles to the commercial synthesis ofPIFELTRO™ (doravirine), an antiviral drug approved in 2018 in theU.S. and Europe.In 2019, we were recognized for changing the way we manufactureceftolozane, a component of the antibiotic ZERBAXA® (ceftolozaneand tazobactam).In 2020, we were recognized for the discovery of a catalyst thatimproved the process used to produce certain antiviral drugs used forthe treatment of diseases including hepatitis C and HIV, by reducingthe PMI by 87 percent and eliminating the use of toxic reagents.Since the establishment of the annual Green Chemistry ChallengeAwards in 1996, we have been the only pharmaceutical company tobe recognized with seven Green Chemistry Awards for innovativeprocess improvements.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 87"
  },
  {
    "page": 88,
    "source": "text",
    "content": "EnergyGRI 302 Management approachAs a global biopharmaceutical company, we recognize the importantrole we play in identifying, adapting and responding to the public healthrisks associated with climate change, such as threats to clean air andwater, insufficient food supplies and the spread of disease. We believeour long-standing support of stronger health systems in underservedareas is even more important given the evidence that certain diseasepatterns are associated with changing climate conditions.Our Energy Management Standard requires responsible and efficientenergy management and associated greenhouse gas (GHG)emission reductions.Energy-demand reduction and efficiency will always be part of ourenergy management strategy and will positively impact our efforts toOur company has launched initiatives around the world to improve energyreduce our global footprint.use, reduce GHG emissions from our operations and understand our supplyUtilization of renewable energy is a growing expectation of industry. chain-related impacts.The advancements in renewable technology, incentives throughOur Global Energy & Sustainability Center of Excellence (CoE) identifies,legislation and comparison with conventional technology andshares and standardizes best practices and prioritizes the funding of energyfuel prices have grown the industry and created a robust renewableprojects to reduce energy use across the company. Our manufacturingenergy market.facilities, warehouses, laboratories, offices and vehicle fleet are the primarytargets of our energy-demand-reduction programs, as they represent thePrograms and initiatives majority of our energy consumption.We have made it a priority to reduce our demand for energy and In 2020, our company's Energy Capital fund became the Sustainabilityhave established internal policies and practices focused on reducing Capital Fund, expanding the scope of the funds to water and wasteenergy use at our sites and minimizing GHG generation throughout projects. It is used exclusively for sustainability projects at sites aroundthe company. By taking these steps, we are not only minimizing GHG the world that bring long-term value to the company and focus on carbonemissions, but also reducing our operating costs and mitigating the footprint, water use and solid waste reduction. The fund allocates up tobusiness impacts expected to be associated with future climate $12 million per year to adopt low carbon technology, better positionschange requirements. the company to respond to climate change and supports a morecircular economy.Energy-efficiency and demand-reduction projects will continue tocontribute to reducing both our energy consumption and direct Since 2015, our sites have completed more than 95 projects throughGHG emissions. In addition, we will continue to optimize systems, the Sustainability Capital Fund. This has saved over $9 million per year,consolidate excess facility space when possible and utilize renewable averaging a payback of about three and a half years and avoiding theenergy sources. production of 50,000 metric tons of carbon per year.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 88"
  },
  {
    "page": 89,
    "source": "text",
    "content": "Facilities We require our facilities to have a plan to manage their energy use.Examples of these plans and resources include:We continuously strive to make our facilities energy-efficient. Our• 11 European sites have maintained and/or achieved their certificationGlobal Energy & Sustainability CoE has created an \"energy road map\"of ISO50001:2018 for energy management to comply with the EUto help our facilities reduce energy demand and associated GHGEnergy Efficiency Directive audit requirementsemissions. The energy road map's foundation includes large-scalemetering and monitoring to assess and identify opportunities for • The EU Energy Efficiency Directive (EED) Phase Two compliancecontinuous improvement. As facility energy management programs assessment was completed for all entities in the EU Region and allmature, energy savings are sought by improving the reliability of the qualifying sites are undertaking energy audits to ensure complianceequipment, the efficient operation of utility systems and building• Our Global Energy & Sustainability CoE has provided tools forefficiencies into systems design.facility managers to identify opportunities to reduce energy useand eliminate waste. These tools include facility-wide, three-dayWe have also created a Low Carbon Transition Playbook (LCTP).Energy Treasure Hunts, half-day utility-system assessments (EnergyThe LCTP was a result of a cross-functional company effort thatKaizens), and online Energy Treasure Hunts, which allow for best-pulled together experts into a \"design-thinking\" workshop organizedpractice sharingto develop strategies to reduce GHG emissions throughout thecompany. The LCTP includes a gap assessment for sites to evaluate • All our employees have access to a training curriculum that allowsthe maturity of their energy programs and helps create short- and them to learn more about energy management and energylong-term plans to reduce sites' carbon intensity and build toward a systems. Through this program, employees can earn an Energycarbon-neutral future. Manager Certification. Site energy managers from more than 70 ofour facilities are expected to complete the basic energy efficiencyAll our new facilities are required to comply with our Energy Design training curriculumGuide and Energy Conservation Planner. If we purchase a facility, itis evaluated for energy efficiency and assessed against our energyWork practices and recognitionscorecard as part of its integration into our company.Our company takes advantage of technological advances to saveAll new laboratories, offices and major renovations are built followingenergy, time and money while also reducing emissions.cost-effective and energy-efficient practices and are designed to meetEnergy Efficient Design (EED) Management, Leadership in Energy andThe strategies we employ include:Environmental Design (LEED), or a comparable country standard (e.g.BREEAM, EXEED, HQE, etc.). Offices and laboratories are expected to • Site energy use is tracked monthly by our Global Energy &achieve LEED Gold certification, at a minimum. Sustainability CoE through a centralized system. A global energyscorecard is issued monthly, and sites receive a letter grade based on• Our China Head Office is certified as LEED Goldan internal assessment of their energy intensity and performance.• Our new South San Francisco, CA, office was certified LEED Gold in Our companywide average score has consistently been a top-level2020, and is pursuing WELL Building Standard certification grade of \"A-\".• An operations support facility at our facility in Durham, North • A rollout of Energy Utility Analytics Technology for multiple sitesCarolina, is certified as LEED Silver that will enable continuous commissioning, energy efficiencyimprovements and reliability of assets.• Our lab in Carlow, Ireland, received both LEED Gold and Excellence inEnergy Efficiency Design (EXEED) certification in 2019 • The development of an energy management strategy that seeks toachieve energy savings through continuous improvement, reliability,• Development labs in both New Jersey and Pennsylvania are pursuingoperations and design.LEED Silver certification• Two sites, one in New Jersey and one in Virginia, have received LEEDCampus certificationMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 89"
  },
  {
    "page": 90,
    "source": "text",
    "content": "• A rail-travel option is included in our online business-travel booking Our company recently signed three virtual power purchase agreementstool to make it easier to travel by train when appropriate. Train travel (VPPAs) for utility-scale energy projects based in Texas and Spain.has a smaller carbon footprint than traveling by either airplane or These projects will address approximately 35 percent of our company'spersonal vehicle. Scope 2 emissions by collectively adding 145 megawatts (MW) of solarand wind energy to the grid. These agreements follow a 2018 U.S.We worked with our three largest long-range freight carriers, and evenwind VPPA, which has added 60 MW of new renewable energythough the amount of material shipped by weight was about the samecapacity, while providing our company with the associated renewablein 2020 vs. 2019, our transportation-related GHG emissions intensityenergy credits.decreased by shipment consolidation and by shifting away from airfreight to ocean and overland ground freight whenever practical.Vehicle fleetThe winning projects included:Approximately nine percent of our total Scope 1 and 2 GHG emissions are• A multi-year project that optimized a site's chiller plant in the U.S.associated with our vehicle fleet. We calculate our fleet's GHG emissionsIn addition to energy and financial savings, this site's effort helpedbased on estimated fuel economy and actual total miles driven.create a cultural change among the operations team.• In an ongoing effort to improve fuel efficiency, we have converted• A growing site commissioned state-of-the-art HVAC units andour U.S. sales fleet from cars with six-cylinder engines to cars withincreased the efficiency of the older units. Efficiencies were gainedfour-cylinder engines, replaced eight-cylinder-engine trucks withthrough modified air change rates and the installation of efficientsix-cylinder-engine trucks and introduced an all-wheel-drive (AWD)AHU fans.sedan option to replace AWD sport utility vehicles. This has resulted• Replacement of four HVAC refrigerators that utilize R134A andin fuel efficiency improvements from an average of 22 miles perR404A gas with three air-cooled ammonia chillers.gallon (mpg) in 2008 to an average of 27 mpg in 2020.• 40 percent of our U.S. fleet are now partial-zero-emission vehiclesRenewable energy(PZEV), and we are expanding our use of hybrid vehicles.As part of our new climate goals announced in 2021, we are • Our European fleet continued to convert to the use of more fuel-accelerating by 15 years our previous 2040 goal to 2025 of sourcing efficient vehicles, including the availability of electric or hybrid100 percent renewable energy such as solar and wind for purchased vehicles being offered in over 50 percent of the markets.electricity (Scope 2). Photovoltaic arrays, wind turbines and other • Over 50 percent of the vehicles being utilized in our Asia/Pacificrenewable-energy installations avoid emissions, help reduce energy- markets are hybrids.demand peaks and postpone or preclude adding new power plants.• We have started to introduce hybrid vehicles in Mexico and Peru andWe continually analyze our sites to look for opportunities for new flex fuel vehicles are now being used in Brazil.onsite installations, power-purchase contracts, vendor-suppliedrenewable energy through the electrical grid and VPPA projects.Several sites have incorporated renewable energy installations over thepast several years.In 2020, a new solar array was installed at one of our offices in Australiaand our Singapore operations began the construction of solar arraysacross several sites.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 90"
  },
  {
    "page": 91,
    "source": "text",
    "content": "Energy consumption within the organizationGRI 302-1(Scopes 1+2)GRI 302-4 Energy reductionsTotal energy use 2016 2017 2018 2019 2020Total energy use (GJ) 20,913,432 19,418,800 19,313,900 18,674,800 18,033,385Scope 1 and location-based Scope 2 energy use (% of total)1 2016 2017 2018 2019 2020Natural gas (Scope 1) 61% 60% 63% 63% 65%Purchased electricity (Scope 2)2,3 23% 23% 23% 24% 24%Fleet fuel (Scope 1) 12% 13% 10% 9% 7%Fuel oil (Scope 1) 1% 2% 2% 2% 2%Purchased steam (Scope 2) 2% 2% 2% 2% 2%Bio-Fuel (Scope 1) 0.4% 0.6% 0.6% 0.6% 0.7%Renewable energy generated and used onsite (Scope 1)4 0.04% 0.04% 0.05% 0.05% 0.05%Spent solvents (Scope 1 ) 0.1% 0.0% 0.0% 0.0% 0.0%Coal (Scope 1) 0.0% 0.0% 0.0% 0.0% 0.0%Note: We have defined \"purchased electricity\" as electricity sourced from external suppliers as well as renewable electricity that was generated and utilized onsite where we retained therenewable attributes or where we have obtained renewable attributes through contract. GHG figures have been changed from our 2019/2020 report, due to a collection methodologyupdate since our last report.1 May not add to 100 percent due to rounding.2 Reported using Scope 2 location-based value in accordance with the Greenhouse Gas Protocol.3 Includes solar, wind and other renewables generated onsite where renewable energy credits (RECs) have been sold.4 Includes solar, wind and other renewables generated onsite where renewable energy credits or guarantees of origin have been retained or retired.ERM conducted an independent third-party review of our 2020 greenhouse gas and water inventories and provided limited assurance for the data that we submit to CDP and for inclusion inthis report. To view ERM's limited assurance letter for our environmental data, please visit the Resources link on the Responsibility page of our corporate website. The verification standardused is ISO14064-3.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 91"
  },
  {
    "page": 92,
    "source": "text",
    "content": "Scope 1 and market-based Scope 2 energy use (% of total)1 2016 2017 2018 2019 2020Natural gas (Scope 1) 61% 59% 62% 62% 63%Purchased electricity (Scope 2)2,3 23% 22% 20% 18% 15%Fleet fuel (Scope 1) 12% 12% 10% 9% 7%Fuel oil (Scope 1) 2% 2% 2% 2% 1.8%Purchased steam (Scope 2) 2% 3% 3% 3% 3%Bio-Fuel (Scope 1) 0.4% 0.6% 0.6% 0.6% 0.7%Renewable energy generated and used onsite (Scope 1)4 0.3% 1.1% 3.1% 6.0% 9.1%Spent solvents (Scope 1 ) 0.1% 0.0% 0.0% 0.0% 0.0%Coal (Scope 1) 0.0% 0.0% 0.0% 0.0% 0.0%1 May not add to 100 percent due to rounding.2 Reported using Scope 2 location-based value in accordance with the Greenhouse Gas Protocol.3 Includes solar, wind and other renewables generated onsite where renewable energy credits (RECs) have been sold.4 Includes solar, wind and other renewables generated onsite where renewable energy credits or guarantees of origin have been retained or retired.ERM conducted an independent third-party review of our 2020 greenhouse gas and water inventories and provided limited assurance for the data that we submit to CDP and for inclusion inthis report. To view ERM's limited assurance letter for our environmental data, please visit the ESG Resources page of our corporate website. The verification standard used is ISO14064-3.In 2020, our purchased electricity consumption decreased due to • A data center in New Jersey that obtained a perfect score of 100energy efficiency projects, an increase in renewable energy utilization• A research office in Pennsylvania for the 9th consecutive yearand a temporary shutdown of office spaces in response to COVID-19.Our fleet's fuel usage continued to decrease as well. • Two office buildings in Pennsylvania and New Jersey for the 2ndconsecutive yearIn March 2021, the U.S. EPA again recognized our company with ourOur Puerto Rico facility was awarded the ENERGY STAR Pharma14th consecutive Sustained Excellence Award. This is also the 16thEnergy Performance Indicator (EPI) for superior energy efficiencyconsecutive year in which we have been recognized by ENERGY STARand environmental performance among U.S. pharmaceuticalfor excellence in energy management.manufacturing plants for the 12th consecutive year.In 2020, our company continued to successfully use ENERGY STARFor more information, please see GRI 305-5 on page 102.benchmarking tools such as the ENERGY STAR Portfolio ManagerA link to our CDP Climate Change Questionnaire is available onto obtain the ENERGY STAR Certified Building label for fourthe ESG Resources page of our corporate website.buildings including:Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 92"
  },
  {
    "page": 93,
    "source": "text",
    "content": "• Understanding and controlling our operational water footprintWater• Managing water risk at our facilities and in our supply chain• Reporting publicly on our water use and goalsFor the past four years, we have conducted supplier sustainabilityGRI 303 Management approachsurveys using the Pharmaceutical Supply Chain Initiative (PSCI)As we strive to meet the health needs of our patients, we are Survey. In 2020, the survey was sent to approximately 113 of ourincreasingly operating in regions of the world where access to strategic suppliers, with a 96 percent response rate. Through thisclean water and proper sanitation is under great pressure. Even in engagement suppliers were requested to identify water use reductionestablished markets, our business faces water-related risks. opportunities and goals.Our global water strategy aims to achieve sustainable water We are on track for our 2025 supplier goal, as 45 percent of highmanagement within our operations and our supply chain, which impact suppliers have water use reduction targets.supports UN SDG 6, \"Clean Water and Sanitation.\" To achieve theseFor further information on supplier environmental assessments,strategic objectives, we are focusing on the following commitments:please see GRI 308 onpage 116.• Ensuring that our wastewater discharges comply with local andnational standards, as well as internal company requirementsWe have established water goals to help us manage water-related risksin our operations and supply chain:Internal Internal Supply chain Supply chain Supply chainoperations operationsWe will collect By 2020, we will By 2025, atBy 2020, we will By 2025, we will water use data from engage with those least 90% of ourdevelop water maintain global at least 90% of our suppliers and strategic suppliersconservation plans water use at or strategic suppliers request them to with the highestfor sites in \"high below 2015 levels. with the highest identify water environmentalwater risk\" locations. - environmental use reduction impacts will set3.6 million m3 impact. opportunities. their own water usebelow 2015 levels - reduction targets.(14% reduction). GHG and waterdata collected from96% of high-impactstrategic suppliers.Progress: Progress: Progress: Progress: Progress:Achieved On track Achieved Achieved On trackMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 93"
  },
  {
    "page": 94,
    "source": "text",
    "content": "Governance We report our water security annually through CDP. In 2020, CDPgraded our disclosure with a B \"management\" rating, indicating thatWater management is overseen globally by the Water Center of we \"provide evidence of actions associated with good environmentalExcellence (CoE). This CoE reviews water data to monitor sites' management\", and are \"taking coordinated action on water security.\"progress, and provides assistance as needed to support sites' workIn 2020, we supported the Keystone 10 Million Tree Partnershiptowards meeting these goals. The Environmental Review Committeeproject with funding for 100,000 trees through the organization Oneprovides oversight in establishing our internal Environmental QualityTree Planted. This project is focused on planting trees in PennsylvaniaCriteria (EQC) standards.to help protect the Chesapeake Bay. Over the years, the ChesapeakeEach site is responsible for management of water resources. In many Bay has suffered degradation due to development and changing seacases, the Water CoE partners with sites and provides assistance in levels, as well as pollution. Planting trees will restore degraded areasworking toward meeting the corporate water goal. as well as assist in the restoration and filtration of this sensitive watersystem. Planting of trees upstream of the bay in Pennsylvania willIn 2020, our Energy Capital fund became the Sustainability Capital result in improvements in biodiversity, reduce pollution and benefit theFund, expanding the scope of the fund to water and waste projects. It local community. Our site located in Riverside, Pennsylvania, is withinis used exclusively for sustainability projects at sites around the world the Chesapeake Bay catchment.that have the potential to bring long-term value to the company andfocus on carbon footprint, water use and solid waste reduction. The Our 2019 contribution of $100,000 to the Nature Conservancy'sfund allocates up to $12 million per year, which allows us to adopt low (TNC) Mantiqueira Restoration Fund near our Cruzeiro, Brazil, sitecarbon technology, better positions the company to respond to climate enabled TNC to work with landowners and other decision-makers tochange and supports a more circular economy. In 2020, we allocated advance policies and improve the economic benefits of restoration andapproximately $400,000 to water projects. The completed projects will ecosystem services. TNC developed the science, innovative tools andresult in $148,000 in annual savings. monitoring systems needed to guide restoration efforts. TNC has alsostrengthened local capacity for implementing restoration.For more detailed information on our environmental managementand governance, please see GRI 307 on page 110. Key measures of success of the project were:• Engagement with 200 landowners on restorationStewardship• Development of municipal programs to support restorationWe have endorsed the UN CEO Water Mandate, a public commitment • Leveraging financial support for landowners for restorationto adopt and implement a comprehensive approach to water• Municipal staff trained on writing restoration projectsmanagement, and we have aligned our water program with• Creation and development of the Mantiqueira Portal, a website thatits principles.gathers data about rural properties that have been partially restoredCEO Water Mandate endorsers have a responsibility to make water-• Creation of a regional databaseresource management a priority and to work with governments,UN agencies, NGOs, local communities and other interested parties • Diversification of restoration methods in the Cruzeiroto address global water challenges. We are working to identify Demonstration Unitpartnerships that will help us advance our water stewardship priorities • Formalization of the Paraíba Valley Agroforestry Networkin the areas in which we operate. These projects also support the goals• Support of forest productsof SDG 15, which strives to \"protect, restore and promote sustainableuse of terrestrial ecosystems.\"Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 94"
  },
  {
    "page": 95,
    "source": "text",
    "content": "GRI 303-1 Water as a shared resource GRI 303-2 Water discharge-related impactsAccess to clean water is critical for human health and is a key input to We conduct environmental risk assessments on our products (smallour manufacturing operations. molecules, biologics and vaccines), from the development phasethrough product launch, to understand and manage product impactsIn establishing our public water risk goal, we focused on the sites most both from manufacturing and patient use. We assess productscritical to our operations-those with high water use (i.e. greater than in a manner consistent with the most stringent applicable global100,000 m3 annually) that were located in areas considered to be of regulations, including the regulatory review processes of thehigh risk after assessment. These are our \"priority\" sites. U.S. Food and Drug Administration and the European MedicinesAgency. Product environmental safety profiles are reassessed duringWe use the World Resources Institute's (WRI's) Aqueduct Water Riskperiodic renewals of product filings, and risk-mitigation actionsAtlas tool as an initial step to measure and map our water risks. Sitesare implemented when needed.are categorized using the \"Baseline Water Stress\" indicator, which isthe ratio of total annual water withdrawals to total available annual We use the information from our risk assessments to establish orrenewable supply, and accounts for up-stream consumptive use. update our internal, compound-specific Environmental Quality CriteriaHigher-stress values indicate more competition among water users. (EQCs), which are used to confirm that wastewaters discharged fromour facilities do not contain levels of residual products that presentIn 2020, the WRI Aqueduct tool identified five of our manufacturinga risk to human health or the environment. Our manufacturingand/or research facilities being in areas with \"extremely high\" and ninefacilities are required to use these EQCs, along with industry-acceptedin areas with \"high\" Baseline Water Stress. High water-use sites (i.e.risk-assessment methods, to establish procedures for managinggreater than 100,000 m3 annually) were assessed further through aand controlling active pharmaceutical ingredients (APIs) in theirstudy with WRI, which provided information on the steps and datawastewater. Each facility uses the internal EQC standards to:required to assess exposure to water-related business risks aroundselected catchments and facilities. Sites were deprioritized when • Assess the potential risk from its operations using science-basedresults of the detailed catchment-specific studies with WRI indicated and industry-accepted risk assessment methodslesser risk than was indicated by the Aqueduct tool.• Minimize environmental impacts from wastewater discharges in thelocal watershedThis exercise enabled us to better prioritize facilities and catchmentsfor water stewardship activities and lay the foundation for potential • Establish procedures for managing, treating or controlling APIs infuture water targets in priority locations. Globally, two priority sites wastewater prior to discharge where neededhave been identified through this methodology and have waterOur production facilities have, or will be provided with, API-treatmentconservation plans in place. We work with a third-party water usetechnology such as advanced oxidation where needed, so that ourexpert to evaluate opportunities for water use reductions at prioritywastewater discharges meet both regulatory requirements and thesesites, resulting in site-specific water management plans.internal standards.Existing and acquired sites will continue to be monitored for riskWe also provide EQC information to suppliers that manufactureaccording to the established methodology as general practice. Sitespharmaceutical compounds for us and have initiated detailedwith a rating of \"high\" or \"extremely high\" risk and water withdrawalassessments of our suppliers to better understand and addressof less than 100,000 m3 will also be further assessed and waterpotential impacts.management plans will be put in place as needed.The facilities that use the most water in our network are U.S.-based.Of these, two are in areas of \"high\" Baseline Water Stress according tothe Aqueduct tool but were identified as only medium risk based on theresults of WRI deep-data dive water risk assessment.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 95"
  },
  {
    "page": 96,
    "source": "text",
    "content": "In addition, as a member of the Antimicrobial Resistance (AMR) have worked together to develop the Eco-Pharmaco-StewardshipIndustry Alliance and signatory to the Industry Roadmap for Progress (EPS) initiative. The EPS initiative considers the environmental impactson Combating AMR, we are working to deliver on our commitments of a medicine throughout its entire life cycle and addresses the rolesto reduce the environmental impacts from antibiotic residues in and responsibilities of all parties in managing those impacts. Thiswastewater through implementation of the AMR Alliance Common includes public services, the pharmaceutical industry, environmentalAntibiotic Manufacturing Framework. We have reviewed the experts, doctors, pharmacists and patients.operations of our human health antibiotic chemical synthesis facilitiesFor more information on our supply chain, please see section GRIand third-party human health antibiotic suppliers to assess their102-9 on page 29.wastewater treatment controls and have recommended improvementswhere needed, which we will follow through to completion. WePlease refer to the following resources for additional informationhave developed a mechanism for transparently demonstrating thatrelated to water related discharge impacts on the ESG Resources pageour supply chains meet the standards in this framework, which isof our corporate website:presented in the AMR Industry Alliance 2020 Progress Report.• Public Policy Statement: Water StewardshipWe participate in efforts to address water discharge related impacts• Public Policy Statement: Pharmaceuticals in the Environmentwith various organizations, including the European Federationof Pharmaceutical Industries and Associations (EFPIA) and the • Global Antimicrobial Resistance Action PlanInternational Federation of Pharmaceutical Manufacturers and• CDP-Water Security 2020Associations (IFPMA). The EFPIA, Medicines for Europe and theAssociation of the European Self-Medication Industry (AESGP) • Business Partner Code of ConductGRI 303-3 Water withdrawalWater use by source (million m3)1 2015 2016 2017 2018 2019 2020Groundwater 12.3 10.4 10.2 10.5 10.4 10.3Purchased water 7.7 7.1 6.7 7.7 7.4 7.3Surface water 3.9 3.2 2.7 2.4 2.7 2.9Total2 23.9 20.7 19.7 20.6 20.4 20.51 In accordance with the Greenhouse Gas Protocol, prior-year data have been adjusted to add or remove facilities that have been acquired and sold. Adjustments also reflect changesin methodology to ensure consistency from year to year.2 All values above are rounded to one decimal place. As a result, the total values shown may not equal the sum of the individual source totals.ERM conducted an independent third-party review of our 2020 greenhouse gas and water inventories and provided limited assurance for the data that we submit to CDP and for inclusion inthis report. To view ERM's limited assurance letter for our environmental data, please visit the Resources link on the Responsibility page of our corporate website. The verification standardused is ISO14064-3.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 96"
  },
  {
    "page": 97,
    "source": "text",
    "content": "Water use by risk in the following tables is categorized according to data obtained via the WRI Aqueduct Water Risk Atlas Tool.We understand that following further assessment site water-risk categorization could change.For information on our water risk assessment approach, please see GRI 303-1 on page 95.North America77%Europe, Middle East and Africa15%Asia Pacific6% Extremely high (1.0%)High (15.7%)Latin America Med to high (15.6%)Low to med (51.1%)2%Low (13.7%)Water use and risk by Extremely Med to Low toregion (million m3) high High high med Low N/A % of Total TotalNorth America 0.00 2.28 2.98 10.17 0.29 0.05 77% 15.77Europe, Middle East 0.16 0.83 0.11 0.33 1.35 0.22 15% 2.99and AfricaAsia Pacific 0.02 0.00 0.12 0.00 0.94 0.23 6% 1.31Latin America 0.03 0.11 0.00 0.00 0.24 0.07 2% 0.45Total 0.21 3.22 3.20 10.50 2.81 0.57 - 20.53Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 97"
  },
  {
    "page": 98,
    "source": "text",
    "content": "Water use in areas of high toextremely high water risk by region(million m3) Groundwater Surface Water Purchased Water Total1North America 0.41 0.00 1.87 2.28Europe, Middle East and Africa 0.23 0.00 0.76 0.99Latin America 0.04 0.00 0.11 0.14Asia Pacific 0.00 0.00 0.02 0.02Total1 0.67 0.00 2.76 3.441 May not add up to total due to rounding.Note: ERM conducted an independent third-party review of our 2020 greenhouse gas and water inventories and provided limited assurance for the data that we submit to CDP and for in-clusion in this report. To view ERM's limited assurance letter for our environmental data, please visit the Resources link on the Responsibility page of our corporate website. The verificationstandard used is ISO14064-3.In 2020, we used 20.5 million cubic meters of water globally, versus Our water-use-reduction initiatives include:23.9 million cubic meters in 2015, representing a 14 percent reduction• Consideration of water use in process designin water use.• Cooling-system optimizationApproximately 14 percent of the total water we used in 2020 was• Prompt repairs and maintenance of steam-distribution systemssupplied from surface water sources, and 50 percent was supplied byand trapsgroundwater water sources, with the balance sourced from municipalwater supplies. • Recovery and reuse of steam condensate and \"reject water\"• Process-water purification system optimizationOur sites employ a variety of technologies and techniques aimed atreducing our water footprint and improving operational performance. • Avoiding the use of water in mechanical seals, such asClosed-loop cooling systems, which reduce freshwater use, are those in pumpsemployed at many of our facilities worldwide. Reverse osmosis (RO)\"reject water\" is reused for non-potable and non-process applications For information on the specific water sources affected in areassuch as cooling tower feed water. In all, 1.1 million cubic meters of water experiencing high and extremely-high water risk, please see our CDPwas recovered, reused or recycled at our facilities in 2020, which is Water Security response. For our water assurance letter, please visit theequivalent to five percent of our total water use. ESG Resources page on our corporate website.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 98"
  },
  {
    "page": 99,
    "source": "text",
    "content": "GRI 303-4 Water dischargeTotal water discharge by region(million m3) Surface Water External Treatment Facilities Total1 % of TotalNorth America 10.31 3.69 14.00 78%Europe, Middle East and Africa 1.08 1.88 2.96 16%Asia Pacific 0.07 0.70 0.77 4%Latin America 0.00 0.33 0.33 2%Total 11.46 6.58 18.05 100%1 All values above are rounded. As a result, the total values shown are not equal to the sum of the individual source totals.ERM conducted an independent third-party review of our 2020 greenhouse gas and water inventories and provided limited assurance for the data that we submit to CDP and for inclusion inthis report. To view ERM's limited assurance letter for our environmental data, please visit the Resources link on the Responsibility page of our corporate website. The verification standardused is ISO14064-3.Water discharge in areas of high toextremely high water risk, by region(million m3) Surface Water External Treatment Facilities TotalNorth America 0.49 1.51 2.00Europe, Middle East and Africa 0.02 1.00 1.02Asia Pacific 0.00 0.02 0.02Latin America 0.00 0.11 0.11Total 0.50 2.65 3.15Note: All values above are rounded. As a result, the total values shown are not equal to the sum of the individual source totals.ERM conducted an independent third-party review of our 2020 greenhouse gas and water inventories and provided limited assurance for the data that we submit to CDP and for inclusion inthis report. To view ERM's limited assurance letter for our environmental data, please visit the Resources link on the Responsibility page of our corporate website. The verification standardused is ISO14064-3.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 99"
  },
  {
    "page": 100,
    "source": "text",
    "content": "Wastewater from our facilities is managed and treated to meet Emissionsregulatory standards and minimize environmental impacts prior todischarge. On-site wastewater treatment facilities are operated atmany of our production and research facilities. Where on-site treatmentis not provided, wastewater is discharged to local municipal wastewaterGRI 305 Management approachtreatment facilities that have the technology and capacity to treat ourwastewater. As a company, we currently do not differentiate dischargesScientific data support that climate change is occurring, and we areto freshwater and seawater in our enterprise system. The majority oftaking action to reduce the economic and public health risks associatedour facilities discharge to freshwater environments.with a changing climate.As described in GRI 303-2, many of our production facilities areWe have adopted a set of environmental sustainability goals toequipped with advanced wastewater treatment technologies to ensurehelp position our company to succeed in an increasingly resource-that our facilities meet both regulatory requirements and the internalconstrained world. These were developed to address the risingstandards required by our EQC Program.expectations of our customers, investors, external stakeholders andemployees regarding the environmental impact of our operations andsupply chain.We have made progress on these goals and remain on track to achievethem. We continue to find ways to decrease energy demand andhave increased the amount of renewable energy we purchase. Ourprocurement team is engaging our strategic suppliers in our effortsto reduce the environmental footprint outside of our operations.GHG emissions Renewable energyGoals: Goal:Reduce Scopes 1 & 2 GHG emissions 46%, By 2025, 100% of our purchased electricity willand Scope 3 emissions 30%, by 2030 from come from renewable sources.a 2019 baseline.Progress: Progress:On Track: 8% reduction in Scopes 1 & 2 GHG emissions On Track: 37.7% of our purchased electricity comesfrom renewablesMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 100"
  },
  {
    "page": 101,
    "source": "text",
    "content": "GHG emissions (additional)Goal: Goal: Goal:We will collect GHG data from By 2020, we will engage with By 2025, at least 90% of ourat least 90% of our strategic those suppliers and request strategic suppliers with thesuppliers with the highest them to identify GHG emission highest environmental impactsenvironmental impact. reduction opportunities. will set their own GHG emissionreduction targets.Progress: Progress: Progress:Achieved Achieved On TrackThe World Resource Institute's Greenhouse Gas Protocol defines our company's current actions, and complement our new Scopes 1 & 2Scope 1 GHG emissions as emissions from owned or controlled sources science-based emission target which was determined to be in line withsuch as onsite fuel combustion and fleet vehicles. Scope 2 emissions the 1.5º C trajectory by the Science-Based Targets initiative (SBTi).are those from indirect sources such as purchased electricity. Scope 3includes indirect emissions in a company's value chain. As part of our new goals, we are also accelerating by 15 years ourprevious 2040 goal of sourcing 100 percent renewable energy such asFor the past four years, we have conducted a supplier sustainability solar and wind for purchased electricity (Scope 2).survey through the Pharmaceutical Supply Chain Initiative (PSCI).In 2020, the survey was sent to approximately 113 of our strategicGovernancesuppliers, with a 96 percent response rate. Through this engagementsuppliers were requested to identify GHG reduction opportunitiesOur climate strategy is overseen by our Environmental Sustainabilityand goals.Center of Excellence (CoE) in partnership with our Global Energy &Sustainability CoE and Energy Procurement CoE. The CoEs review andWe are on track to achieve our 2025 supplier goal as 52 percent of ourreport data, monitor progress, and provide assistance as needed, tohigh impact suppliers currently have GHG emission reduction targets.support sites' work towards meeting our goals and review possibleIn 2021, we committed to becoming carbon neutral across our above-site renewable energy projects.operations (Scopes 1 & 2) by 2025, to reducing our Scopes 1 & 2 GHGEach site is responsible for the management of their energy use. Inemissions 46 percent by 2030 from a 2019 baseline (including biogenicmany cases, our company partners with our third-party Integratedemissions and removals from bioenergy feedstocks), and to reducingFacility Management (IFM) providers to manage energy use and workour value chain (Scope 3) GHG emissions by 30 percent by 2030. Wetoward achieving the corporate goals.will achieve carbon neutrality in our operations with ongoing innovationto increase energy efficiency, applying sustainable building standardsFor information regarding our environmental management andand continuing to transition away from fossil fuel use. Remaining Scopegovernance, please see GRI 307 on page 110.1 emissions will be balanced each year by investing in high-qualitycarbon offsets, including carbon removal offsets. These goals expandMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 101"
  },
  {
    "page": 102,
    "source": "text",
    "content": "GRI 305-1 Direct GHG emissions (Scope 1)GRI 305-2 Indirect GHG emissions (Scope 2)GRI 305-3 Other indirect GHG emissions (Scope 3)GRI 305-4 GHG emissions intensityGRI 305-5 Reduction of GHG emissionsGHG Emissions in 2020Scope 1: 738,400 MT CO e2Scope 2 (market-based): 255,400 MT CO e2Scope 3: 7,103,450 MT CO e2Total GHGs (MT CO e)1 2015 2016 2017 2018 2019 20202Scope 1 869,200 861,500 806,200 800,000 799,000 738,400Scope 2 location-based 548,200 503,600 458,100 433,000 413,800 392,400Scope 2 market-based 586,300 536,500 473,000 399,300 318,400 255,400Total GHGs (Scope 1 & 2 market-based) 1,455,500 1,398,000 1,279,200 1,198,300 1,077,100 993,800Scope 3 GHGs 5,586,300 7,975,100 6,586,100 6,239,800 6,965,600 7,103,450GHG intensity2 21.4 20.6 18.5 17.4 15.2 13.4Note: ERM conducted an independent third-party review of our 2020 greenhouse gas and water inventories and provided limited assurance for the data that we submit to CDP and for inclusionin this report. To view ERM's limited assurance letter for our environmental data, please visit the Resources link on the Responsibility page of our corporate website. The verification standardused is ISO14064-3.1 In accordance with the Greenhouse Gas Protocol, prior-year data have been adjusted to add or remove facilities that have been acquired and sold. Adjustments also reflect changes inmethodology to ensure consistency from year to year.2 T otal Scope 1 & Scope 2 market-based metric tons COe per employee.2Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 102"
  },
  {
    "page": 103,
    "source": "text",
    "content": "Scope 3 GHGs details (MT CO e)1 2015 2016 2017 2018 2019 20202Purchased goods and services1 3,864,900 6,204,000 4,997,600 4,595,600 5,155,100 5,403,700Capital goods1 112,700 224,000 192,900 229,200 339,900 470,200GHG emissions from fuel and energy-related 276,200 304,500 262,100 243,400 240,700 203,250activities not included in Scopes 1 & 22, 3Upstream transportation and distribution1 222,200 255,500 267,100 274,100 271,200 263,100Waste generated in operations 20,600 16,800 16,000 18,200 19,500 22,000(excluding recycled & composted waste)4, 5GHG emissions related to employee 283,300 265,400 218,200 301,100 340,400 217,100business travel6, 7Employee commuting8 302,400 301,500 262,200 264,400 272,000 127,600Downstream transportation and distribution9 211,000 118,000 121,900 120,800 133,200 145,100GHG emissions from use of sold products10 255,000 248,400 205,800 148,100 142,100 205,500End-of-life treatment of sold products11 38,000 37,000 42,200 44,900 51,500 45,900Total12 5,586,300 7,975,100 6,586,100 6,239,800 6,965,600 7,103,450Note: Limited Data Assurance was granted for emissions calculated from primary travel vendor data and employee reimbursable travel mileage data. The total reported here includes non-primary travel vendor data emissions which were based on our 2020 third-party spend data and an Economic Input-Output Model performed by Climate Earth, Inc.1 Based on third-party spend data and an economic input-output model performed by Climate Earth, Inc.2 Emission factors from Argonne National Laboratory's GREET Model (https://greet.es.anl.gov/) were used in conjunction with primary fuel and energy-use data.3 Data as reported historically, not baseline adjusted.4 Primary-waste data were used with the U.S. EPA's WARM Model (https://www.epa.gov/warm).5 Including recycled and composted waste in these calculations, would result in negative emissions in), 2015 (-40,200 MT CO₂e), 2016 (-60,200 MT CO₂e), 2017 (-41,200 MT CO₂e), 2018(-43,700 MT CO₂e), 2019 (-62,400) and 2020 (-48,900 MT CO₂e).6 B ased on primary travel vendor data, employee-reimbursable mileage and United Kingdom Defra factors (https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting#conversion-factors-2015).7 Emissions are based on primary vendor data where available and economic input-output modelling performed by Climate Earth, Inc., using spend data.8 2020 reduction caused by shift to remote working due to COVID-19.9 Emissions were calculated using our \"Upstream transportation and distribution\" spend data as a worst-case estimate entered into the WRI Quantis tool. We assumed that all \"downstream\"material would first have been stored, transported and handled \"upstream.\"10 A ssumes that all HFC-containing devices shipped for sale were consumed. The amount and identity of HFC in each product is calculated and multiplied by the appropriate global warmingpotential (GWP) to determine the CO₂e released as a result of product use.11 Calculated assuming that all primary, secondary and tertiary packaging purchased was disposed of by our customers. Packaging material data was used with the U.S. EPA's WARM Model.12 May not add up to total due to rounding.ERM conducted an independent third-party review of our 2020 greenhouse gas and water inventories and provided limited assurance for the data that we submit to CDP and for inclusion inthis report. To view ERM's limited assurance letter for our environmental data, please visit the Resources link on the Responsibility page of our corporate website. The verification standardused is ISO14064-3.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 103"
  },
  {
    "page": 104,
    "source": "text",
    "content": "Reduction of GHG emissionsFrom 2019 to 2020, we reduced our year-over-year Scope 1 and GRI 305-6 Ozone-depleting substances (ODS)Scope 2 market-based GHG emissions by eight percent due to ourGRI 305-7 NOx, SOx and other emissionscontinued focus on energy efficiency and an increased utilization ofrenewable energy. Where possible, office buildings utilized energy set We are committed to controlling air emissions from our facilities tobacks in response to the low occupancy due to COVID-19 protocols. reduce local, regional and global environmental impacts.We have analyzed and reported our Scope 3 impacts using primary Air emissions are generated by our manufacturing and researchoperating data, accepted emission factors and an economic input- operations, as well as by burning fuel in on-site equipment and fleetoutput model based on our third-party spend. In 2020, our Scope 3 vehicles. Our Air Management Standard requires our facilities toGHG emissions increased slightly as compared to 2019. While our quantify and control air emissions to comply with both applicablebusiness travel decreased sharply due to the pandemic and many regulations and emission standards.employees were able to work from home offices, we continued ourmanufacturing and research operations, as well as continued the Any increase in production can negatively impact our emissions trends.execution of many on-going capital projects. Though there are efforts to minimize solvent use in production,solvents are needed for cleaning and disinfecting purposes. As theOur analysis shows that our Scope 3 GHG emissions impacts are nearly company transforms from manufacturing of pharmaceuticals tothree times greater than our combined Scope 1 and Scope 2 emissions. biopharmaceuticals, mandatory cleaning and disinfection protocolsWe are working to reduce those impacts through activities such as associated with biologics and vaccines are increasing solventreducing waste in our operations, creating more sustainable packaging, based emissions.and changing the way we commute to work and travel for business. Weare also engaging with our strategic suppliers to identify ways to reduce The Montreal Protocol mandates phase-out of refrigerants thatGHG emissions in our supply chain. These actions not only reduce our are ozone depleting substances (ODS) per schedules approved forenvironmental impact, but benefit the business by reducing costs. individual countries. Our facilities strive to maintain compliance withapplicable regulatory requirements that have been established inWe report our GHG emissions as required by regulations in certain accordance with each country's commitments.countries and annually through CDP (formerly Carbon DisclosureProject). In 2020, CDP graded our disclosure as a \"B\" or a rating of Our company's Air Center of Excellence (CoE) provides assistance as\"management\", indicating that we are \"taking coordinated action on needed to our facilities to obtain appropriate environmental permits,climate issues.\" and to quantify and control air emissions to comply with applicableregulations and emission standards.For more information on our initiatives, policies andaccomplishments, please see Section GRI-302 energy and the followingProduction and research emissionsresources on the ESG Resources page of our corporate website.• Corporate Policy: Respect for Environmental Health Many of our pharmaceutical manufacturing processes, cleaning/and Safety (EHS) disinfection operations and research laboratories require the use ofsolvents. Evaporation of solvents into the air is our primary source• Public Policy Position Statement: Climate Changeof volatile organic compound (VOC) emissions. In an effort to reduce• Business Partner Code of ConductVOC emissions, reduction in solvent usage has been incorporated as anelement of our Green & Sustainable Science program (see GRI 301 onpage 83 for more information).Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 104"
  },
  {
    "page": 105,
    "source": "text",
    "content": "Key elements of the program include designing efficient processesthat use fewer and less-hazardous organic solvents and using water-based methods for cleaning our process equipment where they areas effective as solvent-based methods. To reduce emissions fromprocesses where organic solvents are used, we use pollution-controltechnologies such as conservation vents, carbon filters, thermaloxidizers, condensers and scrubbers.Fossil fuel combustion emissionsAir emissions are also generated by burning fuel in our boilers andpower-generation turbines (for heat and energy), and by othercombustion processes, such as thermal oxidizers (for treatingair emissions) and incinerators (for destroying waste). Our fleetvehicles and aircraft also burn fuel and generate air emissions.These combustion processes result in emissions of carbon dioxide(CO₂), nitrogen oxides (NOx), sulfur oxides (SOx) and volatileorganic compounds (VOCs). We strive to make our facilities moreenergy-efficient through our energy-management programs andto improve the fuel efficiency of our fleet vehicles. By making theseimprovements, we also reduce emissions of CO , NOx, SOx and VOCs2from our operations.Air pollutant emissions by type (MT)1 2016 2017 2018 2019 2020Nitrogen oxides (NOx) 460 487 504 395 396Sulfur oxides (SOx) 37 37 31 27 23Volatile organic compounds (VOCs) 440 384 411 399 383Ozone-depleting substances (ODS) 0.7 0.1 0.3 0.7 0.3Note: Previously reported data have been restated per our methodology, which includes adding facilities that have been acquired and removing facilities that have been soldas operating sites.1 Data are estimated using conservative assumptions and factors, not measured or weighed.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 105"
  },
  {
    "page": 106,
    "source": "text",
    "content": "Our 2020 NOx emissions remained consistent with 2019 levels despite The amount of waste we generate reflects the efficiency of ourthe use of emergency generators at our Puerto Rico facility that were manufacturing processes. Our facilities track and report the amountrequired during an extended power outage caused by earthquakes of operational waste they generate and how it is managed.and Tropical Storm Laura. However, this increase in emissions wasWe continuously strive to reduce the amount of operational wastecounterbalanced by a reduction in emissions throughout our networkwe generate and to maximize the use of environmentally beneficialdue to a decrease in emissions from our jet and fleet operations as adisposal methods such as recycling, composting and waste-to-energy.result of the COVID-19 pandemic.The decrease in SOx emissions from 2019 to 2020 can be attributed toGovernancethe use of fuel with a lower sulfur content.Waste management is overseen globally by our Waste and DangerousVOC emissions decreased from 2019 to 2020 due to variations inGoods Center of Excellence (CoE). This CoE reviews waste data toproduction and because of continuous data collection improvementsmonitor sites' progress, and provides assistance as needed to supportwith the adoption of more accurate emission-tracking methods.the sites' work toward these goals.Emissions of ozone-depleting substances are the result of non-routineEach site is responsible for the management of its waste. In manyreleases from temperature-control and fire-suppression systems andcases, we partner with our third-party Integrated Facility Managementcan vary from year to year.(IFM) partners to manage site waste and work toward realizing theFor more information, please refer to the other sections of GRI 305 corporate waste goals.and GRI 307 (pages 100 and 110).For information regarding our environmental management andgovernance, please see GRI 307 on page 110.Effluents & waste1Waste minimization begins with the upfront evaluation of our productdesigns and manufacturing processes. Through our Green andSustainable Science program (see GRI 301 on page 83), we designGRI 306 Management approach processes that use safer chemicals, consume less energy, use lesswater and other resources and generate less waste. Our processThe proper management of waste from our facilities is important development biologists, chemists and engineers have the expertise toto the communities in which we operate and is the focus of our create more sustainable ways to make our products.environmental permits and other regulatory requirements.To ensure our waste is managed in an environmentally responsibleOur waste management standard requires our facilities to comply manner, we use only approved waste disposal facilities. Approvedwith applicable generation, management and disposal regulations facilities demonstrate that they have the systems, technologies andand standards. practices to manage our waste streams responsibly and in compliancewith all applicable requirements. We routinely audit these facilities toTo minimize our environmental footprint and align with the U.N.verify the acceptability of their systems and practices.Sustainable Development Goals (SDGs), we look for opportunitiesto avoid the use of hazardous materials, to reuse or recycle materials Waste types are defined differently in various parts of the world. Forand to prevent the generation of waste. When prevention, reuse this report, we have divided our operational waste into two categories:and recycling are not practical or feasible, we apply controls andtreatment technologies to prevent human health impacts and minimize Hazardous waste: Highly regulated or high-risk waste streams thatenvironmental impacts. need to be neutralized, treated or destroyed to address a particularhazard such as toxicity, flammability, corrosivity, radioactivity,1 D ata for this section are captured in corporate managed data systems. Data from the pharmaceutically active or infectious.Merck Animal Health Intelligence (MAHI) facilities, which were acquired in 2019 andthereafter, are not yet included. These metrics will be reported in the future as these Non-hazardous waste: This includes all other operational waste.sites become fully integrated into the company internal reporting processes.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 106"
  },
  {
    "page": 107,
    "source": "text",
    "content": "The amount of construction project related waste can vary significantly footprint, water use and solid waste reduction. The fund allocates upfrom year to year based on the number and size of projects. to $12 million per year which allows us to adopt low carbon technology,Therefore, our definition of operational waste does not include better positions the company to respond to climate change andconstruction or demolition waste from construction projects. supports a more circular economy. In 2020, we allocated approximately$262,500 to waste projects.Over the past few years, a number of countries in Asia have enactedlegislation restricting the acceptance of solid waste from othercountries. Historically, a large percentage of recyclable waste collectedin the U.S. has been shipped to Asia for recycling, so this change had GRI 306-3 Waste generatedand continues to have the potential to affect the percentage of ournon-hazardous waste sent for recycling. However, this change hadminimal impact on our recycling rates in the past year. The percentage A \"significant environmental event\" is defined as an environmentalof our non-hazardous waste sent for recycling decreased from release that results in environmental harm to humans, aquatic40 percent to 39 percent from 2019 to 2020. organisms or wildlife.In 2020, our Energy Capital fund became the Sustainability Capital We experienced no significant environmental events in 2020.Fund, expanding the scope of the funds to water and waste projects.It is used exclusively for sustainability projects at sites around theworld that bring long-term value to the company and focus on carbonWaste managementGoal: Goal:By 2025, no more than 20% of our global By 2025, at least 50% of our sites will send zerooperational waste will be sent to landfills and waste to landfills.incinerators (without energy recovery).Progress: Progress:On Track: 28% to landfills and incinerators On Track: 48% of sites(without energy recovery)Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 107"
  },
  {
    "page": 108,
    "source": "text",
    "content": "GRI 306-4 Waste diverted from disposalGRI 306-5 Waste directed to disposalAmount of product accepted for takeback, reuse,SASB 250a.4or disposalGlobal operational waste 2016 2017 2018 2019 2020Incinerated (without energy recovery) 20% 19% 24% 19% 23%Landfilled 10% 10% 9% 7% 5%Total 30% 29% 33% 26% 28%Hazardous waste (MT) 2016 2017 2018 2019 2020Incinerated (without energy recovery) 13,186 13,462 17,639 14,025 16,649Energy recovery 9,871 9,538 10,300 13,655 15,330Recycled 6,135 7,979 6,827 8,034 8,685Other 2,425 2,423 2,221 1,865 1,662Reused 2,132 1,505 695 1,147 480Landfilled 1,492 745 731 938 198Composted 5 0 0 0 0Total 35,246 35,652 38,413 39,674 43,004Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 108"
  },
  {
    "page": 109,
    "source": "text",
    "content": "Non-hazardous waste (MT) 2016 2017 2018 2019 2020Incinerated (without energy recovery) 1,361 426 374 477 1,124Energy recovery 10,342 8,576 9,273 10,030 8,280Recycled 14,636 15,188 12,975 14,188 13,537Other 445 212 209 1,025 1,717Reused 972 1,071 2,204 660 963Landfilled 5,826 6,633 5,684 4,603 4,061Composted 3,771 4,668 4,798 4,843 4,892Total 37,353 36,774 35,517 35,826 34,574Hazardous and non-hazardous waste (MT) 2016 2017 2018 2019 2020Recycled, energy recovery, reused or composted 47,864 48,525 47,072 52,557 52,167Landfilled and incinerated (without energy recovery) 21,865 21,265 24,428 20,053 22,032Incinerated (without energy recovery) 14,547 13,887 18,013 14,512 17,773Landfilled 7,318 7,378 6,415 5,541 4,259Other 2,870 2,635 2,430 2,890 3,379Total1 72,599 72,426 73,930 75,500 77,5781 May not add up to total due to rounding.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 109"
  },
  {
    "page": 110,
    "source": "text",
    "content": "In 2020, we managed approximately 77,578 metric tons of waste Environmental compliancefrom our operations, a three percent increase from 2019. Of this total,43,004 metric tons were hazardous waste.Of the hazardous waste we generated in 2020, 57 percent was GRI 307 Management approachbeneficially reused in some way (reused, recycled or sent for energyrecovery), down from 58 percent in 2019. Approximately 20 percentProtecting our people, our communities and the environment isof our hazardous waste was sent offsite for recycling and was eitherfundamentally important to the way our company operates.returned to us for reuse or sold to other industries. Another 36 percentwas burned to generate power, up from 34 percent in 2019. Regarding Our company strives every day to conduct business in a safe andthe hazardous waste that could not be recycled or beneficially reused, environmentally responsible manner. We are committed to providing39 percent of the total hazardous waste generated was incinerated a safe and healthy workplace for our employees and to reducing thewithout energy recovery, up from 35 percent in 2019. Less than one environmental impact of our operations around the world. Our corepercent was sent to hazardous-waste landfills. values are focused upon promoting the health and safety of ouremployees and respect for the environment. This is reflected in ourWe beneficially reused 80 percent of the 34,574 metric tons of non-Corporate Policy: Respect for EHS.hazardous waste we generated in 2020. We are evaluating and refiningthe programs currently in place at our manufacturing, research and In addition to complying with all applicable country, regional, state,office sites to reduce waste generation and increase recycling. provincial and local safety and environmental laws, we strive for EHSperformance that is among the best in the pharmaceutical industry.Approximately 48 percent of our facilities sent zero operational wasteto landfill in 2020, up from 46 percent in 2019, and the percentage of We also adhere to the following key operating principles:waste sent to landfill dropped two percentage points, from 7 percent in• Maintain a safe and healthy working environment for all employees,2019 to 5 percent in 2020.contractors and guestsWe continue to work to identify alternate methods of waste• Foster a culture of EHS excellence that is built on science, integrity,management that will reduce the amount of waste sent to incineratorsaccountability, personal responsibility, collaboration and active(without energy recovery) and landfills.employee participationWe do not collect data on the amount of product accepted for takeback, • Seek to continuously improve our EHS systems, processesreuse or disposal. and standards• Minimize our impact on the environment by identifying andFor additional information on this topic, please review theimplementing approaches to reduce the resources we use during thefollowing documents located on the ESG Resources pagedesign, development and manufacture of our productsof our corporate website:• Understand the potential hazards associated with our products and• Corporate Policy: Respect for Environmental Healthtake action to minimize any potential risks or adverse impactsand Safety (EHS)• Promote EHS excellence in our supply chain by entering into• Public Policy Position Statement: Responsible Disposalbusiness relationships with partners that share our commitment toof Medicines in the Householdresponsible EHS stewardship• Sharps Management Plan-CalRecycle1 Data for this section are captured in corporate managed data systems. Data from the Merck Animal Health Intelligence (MAHI) facilities, which were acquired in 2019 and thereafter,are not yet included. However, environmental NOVs and fines from these facilities are included in this section.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 110"
  },
  {
    "page": 111,
    "source": "text",
    "content": "The Global Safety and Environment (GSE) department is responsiblefor the global EHS Management System which is based on the \"Plan,Do, Check, Act\" model. This enables us to assess and continuallyimprove our practices over time. The model is implementedglobally through a set of interwoven business processes that spanthe corporation:• Our planning process includes developing goals, objectives andmetrics based on a review of our company's performance, EHSprograms, applicable regulations and external factors that mayimpact our business (PLAN)• Activities are performed by using standards, guidelines and toolsthat are integrated into the EHS Management System and includespecific expectations for sites and operating organizations (DO)• Governance committees, from the executive-level EHS Councilthrough site-based compliance committees, review business unitperformance and progress against objectives throughout the year.EHS audits and self-assessments are also performed throughout theyear (CHECK) • EHS professional training designed to expand technical expertiseand improve our EHS capabilities around the world• Corrective actions and continuous-improvement initiatives areestablished to resolve EHS concerns that have surfaced during • Employee training covering the specific information our employeesperiodic assessments, audits and routine surveillance of the need to perform their jobs in a safe and environmentally compliantregulatory landscape. We track our corrective actions centrally to manner, focusing on hazards they encounter on the job and theensure proper oversight (ACT) corresponding control measuresWe have robust programs and initiatives to address global challenges Site EHS professionals complete an assessment of the activitiesand opportunities related to achievement of our short- and long-term performed at their sites and ensure that relevant topics are includedenvironmental management and compliance objectives. in their site-specific training plans. They develop employee trainingcurricula to comply with both regulatory and internal trainingrequirements specific to their country. These training programsTrainingare updated when there are changes to our EHS Standards and/or applicable national, regional, state or local requirements, and areTraining is critical to building worldwide employee competenciesreviewed periodically to ensure that they remain current. Our EHSthat will improve compliance, reduce risks and drive continuoustraining program materials are available in both instructor-led andperformance improvement.e-learning formats. We also conduct periodic web-based seminarsto inform EHS professionals of changes in regulations, standards andWe have a global standard that defines the EHS training expectationscompany practices.for employees in three categories:• Manager training covers specific management responsibilities with Recently, we developed a new e-learning course to build organizationalregard to safety and environmental compliance and promoting a awareness about Environmental Sustainability. The training's objective\"safety first\" culture is to help employees understand how they might be able to promoteMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 111"
  },
  {
    "page": 112,
    "source": "text",
    "content": "environmental sustainability in their role at the company. It defines the material issues. In addition, the VP of GSE partners with businessconcept of environmental sustainability and then takes a closer look leaders to establish long- and short-term goals and performanceat what environmental sustainability means for business, our industry metrics to drive EHS excellence.and our company.Safety and environmental performance targets are included indivisional management objectives.Environmental Health and SafetyLearn more about corporate governance at our company in(EHS) governanceGRI 102-18 on pages 40-42.Our commitment to the environment and employee health and safetyOur corporate EHS organization is responsible for:begins with the company's Executive Team, which has established thecorporate EHS Council. • Developing corporate policies, procedures, guidelines,standards, tools and programs to set expectations and toThe EHS Council comprises senior-level executives representing all support EHS compliancebusiness units, and is responsible for overall EHS governance, as well as• Providing technical and regulatory support to site-based EHS stafffor leading and driving enterprise-wide excellence in EHS managementand operating organizationsand performance. In 2020, the EHS Council formally met four times,with additional off-cycle communications as needed. • Managing and implementing an internal audit program chargedwith understanding the current state of compliance and identifyingThe Council's responsibilities include: potential issues• Establishing EHS strategy, policy and business risk • Tracking and communicating internal and external trends that shouldmitigation controls be addressed• Ensuring cross-divisional engagement in the design • Anticipating, tracking and commenting on new regulationsand implementation of EHS business processes affecting our business and, where appropriate, developing plansto address them• Sponsoring and implementing a sustainability strategy• Tracking EHS performance of individual sites, divisions and the• Monitoring the EHS performance of the company andcompany as a whole, and communicating performance versusestablish continuous improvement targetsestablished targets• Enhancing visibility and transparency of EHS risks, processesand issues Our site-based safety and environmental professionals around theworld support the EHS needs of their business areas, which includeAn EHS Standards Committee has been chartered by the Council tomanufacturing, research operations, sales and administrativeprovide stewardship over our EHS Standards and enable businessactivities by:engagement in the development of new or revised Standards.Each area of the business is responsible for executing against these • Ensuring that line management fully understands EHSStandards, contributing to the development of programs, supporting requirements, including applicable regulations, permit requirementsinternal audits and communicating significant EHS events. Divisional and company EHS StandardsEHS compliance committees have also been established to manage, • Establishing, assessing and improving programsexecute and resolve EHS issues as they arise.• Providing regulatory and technical support to employees and theThe vice president (VP) of GSE is responsible for communicating to the operating areascompany's Board of Directors, Executive Team and the EHS Council• Routinely assessing performance against our company standards,regarding progress on goals, objectives and metrics, as well as otherregulatory requirements and performance targetsMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 112"
  },
  {
    "page": 113,
    "source": "text",
    "content": "• Findings from our audit program are communicated to appropriateparts of the organization so that learnings may be shared andpreventative actions can be taken.• Audit performance and key program metrics are reviewed as partof our governance process.We use multiple factors to determine the audit frequency of ourfacilities, including facility size, operational complexity, compliancestatus and performance history. Our most complex operations areaudited every year, and all manufacturing and research operations areaudited at least every three years. Less complex facilities, such as salesand business offices are audited less frequently. In 2020, we performed13 corporate EHS audits of our facilities, involving 212 auditor days ofremote review activities.In 2020, the conventional EHS audit process was significantlyinterrupted by the COVID-19 pandemic, resulting in the creation of aremote audit methodology and procedure. Remote audits were thenrestarted in the 3rd quarter of 2020 using technology tools such asvideo conferencing, use of electronic document repositories and bothreal-time and recorded videography.• Acting as the primary liaison with local regulators and inspectors• Investigating incidents and near-miss events to identify root A recent survey by the National Association for Environmental, Healthcauses and developing corrective and preventive actions to & Safety and Sustainability Management (NAEM) found that remoteprevent recurrence EHS auditing has increased since the onset of the pandemic for thecompanies responding to the survey. Most companies (68 percent)responded that they were currently piloting or conducting virtualInternal auditingaudits in some capacity.1We have a detailed and rigorous EHS audit program. Our globalRegular-internal Quality Assurance Reviews of the program arecorporate EHS audit program is one way in which we identify andperformed by Corporate Audit and Assurance Services at least everyresolve compliance and performance issues within the company.three years. The most recent review of the EHS auditing program was• Our audit leaders are full-time professional EHS auditors with performed in March 2021, and resulted in a rating of \"Effective,\" withextensive experience in auditing a broad range of EHS programs controls and practices deemed to be in line with company requirementsapplicable to the company. The individual audit teams consist of EHS and expectations.professionals with extensive site and subject-matter expertise. InIn addition to our corporate EHS audit program, our sites regularlymany cases, particularly outside of the U.S., our internal auditorsperform self-inspections, and review compliance with permitwork with independent consultants who have regulatory expertise inconditions, regulatory requirements and company EHS Standards,the laws of the host country.with all programs being evaluated at least once every three years.• All audit findings are addressed through the development ofcorrective and preventive action plans (CAPA), which are reviewed,approved by the audit leader and regional EHS leader, and tracked to1 Sean Mason, Research Manager, NAEM, \"The Emergence of Virtual EHS Audits\",completion. This process includes senior management oversight. NAEM Research, February 2021Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 113"
  },
  {
    "page": 114,
    "source": "text",
    "content": "Certification For additional information on this topic please review the followingdocuments located on the ESG Resources page of our corporate website:Our company is certified in the Responsible Care® Management• Corporate Policy: Respect for EHSSystem Technical Specification RCMS Technical Specificationis RC101.06, 2019. The RCMS® recertification occurred on • Public Policy Position Statement: Pharmaceuticals in the EnvironmentDecember 4, 2019.• Public Policy Position Statement: Responsible Disposal of MedicinesAdditionally, our corporate EHS management system is generally in the Householdaligned with the requirements of the International Standards • Global Antimicrobial Resistance Action PlanOrganization (ISO), but we do not pursue certification under theEnvironmental (ISO 14001) or Safety (ISO 45001) frameworks at theglobal level. Some of our facilities have individually achieved ISO 14001certification to meet customer requirements.RemediationEnvironmental management practices have evolved significantly overthe past 30 years.With research and manufacturing operations dating back more than100 years, some of our facilities operated at a time when there werefew regulations and little understanding of good environmentalpractices. Because our company has responsibility for remediation ofthese sites, we have launched investigations, developed science-basedremediation plans and implemented cleanup projects to protect thehealth and safety of our neighbors, communities, employees and theenvironment, and comply with all applicable requirements.Over time, we have acquired properties and manufacturing facilitiesthat may not have been subject to the same EHS managementstandards that we have in place today. We are also investigating andremediating those properties where necessary.We spent $11 million in 2020 for remediation and environmentalliabilities, including those at formerly owned and operated sites.Our company has an environmental liability reserve of approximately$67 million to fund the continued remediation of these sites intothe future. In addition, we are a potentially responsible party at16 multi-party Superfund sites in the U.S.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 114"
  },
  {
    "page": 115,
    "source": "text",
    "content": "Safety and environmental performance targets are included indivisional management objectives. In addition, all employees areNon-compliance with environmental lawsGRI 307-1 eligible for special recognition for innovative ideas and projects relatedand regulationsto improving EHS aspects of our operations.Our centralized EHS information system allows us to collect, manage,learn from and share our safety and environmental performance data Notices of violations, fines and settlementsmore efficiently.We report all forms of EHS compliance notices using the term NoticesWe collect and analyze data in both leading and lagging metrics toof Violation (NOVs), which includes citations, letters of warning andlook for potential trends and identify opportunities that can help drivenotices of noncompliance from environmental and safety-focusedperformance improvement. We continuously explore new ways to learnregulatory agencies.from and report on our performance.In 2020, the company had 156 EHS-related regulatory agencyinspections of our facilities around the world. We received threesafety-related and nine environmental-related NOVs and paid$21,022 in fines in 2020.Notices of violations (NOVs) and citations 2016 2017 2018 2019 2020Environmental 12 5 6 9 9Safety 2 3 1 4 3Fines 2016 2017 2018 2019 2020Environmental fines paid $33,906 $0 $0 $17,690 $21,022Number of environmental fines 2 0 0 3 3Safety fines paid $0 $0 $0 $0 $0Number of safety fines 0 0 0 0 0Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 115"
  },
  {
    "page": 116,
    "source": "text",
    "content": "Supplier environmental products are screened for Environmental Health and Safety (EHS)compliance, in addition to quality, supply and technical competenceassessment requirements. The EHS screening and onsite assessment is ledby Global Safety and the Environment (GSE) and includes asurvey covering such topics as regulatory compliance, fatalitiesand major incidents.GRI 308 Management approachBased on the screening results and activities undertaken by thesupplier, certain external manufacturers are subject to a more detailedEnvironmental sustainability principles are integrated in each stage ofonsite assessment conducted by a multidisciplinary team, which mayour supplier management program. Our Global Supplier Managementinclude our company's Quality, GSE, Global Technical Operations andGroup (GSMG) drives the program and maintains the associatedGSMG representatives.standards and processes by which suppliers are identified, qualified andmanaged. The environmental sustainability program is integrated withThe external manufacturers we contract with are periodicallysocial responsibility and economic inclusion and supplierreassessed using a risk-based approach; higher-risk externaldiversity (EI&SD).manufacturers are subject to more frequent onsite assessments.We expect that observations made during the audit process will bePlease visit GRI 102-9 on page 29 for additional informationremediated by our external manufacturers, and we monitor and trackregarding our integrated approach with our suppliers.corrective actions through completion.External manufacturing The 2020 schedule was impacted by the COVID-19 pandemic. Ourpriority was given to new supplier reviews (due diligence) versusWe understand that our external manufacturers pose a higher current supplier reviews, in our support of the supply chain. Wheneverrisk compared to most supplier categories. As a result, external possible, assessments were completed in person. However, somemanufacturers of active pharmaceutical ingredients and finished assessments were completely virtual or a combination thereof.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 116"
  },
  {
    "page": 117,
    "source": "text",
    "content": "Pharmaceutical Supply Chain Initiative In 2020, we updated the survey to include questions related to science-based targets (SBT) for greenhouse gas emissions reductions. Please(PSCI) Environment Task Teamsee the following table for the 2020 survey response rate.Our company co-leads the PSCI Environment Task Team and works In addition to the survey, below are a few examples of additional itemstogether with GSE and peer organizations to develop supplier completed by the Environment Team in 2020:survey(s), training, tools and maturity modeling.• 10 environmental sustainability guidesSince 2016, this team has been working together to standardize their• 14 responsible sourcing guides for key materialsenvironmental supplier data request to reduce the different requests tosuppliers and minimize data fatigue. The survey covers greenhouse gas • Responsible Sourcing of Raw Materials trainingemissions, energy, waste and water, and is in four sections: • Sustainable Packaging training• Established program: alignment with the Code of Conduct • Revised PSCI Principles training• Manage impact: data for each environmental indicator We worked with PSCI to provide environmental training to our• Reduce emissions: environmental targets suppliers. These initiatives ensure a consistent message and approachwith our suppliers across the industry. Working together with PSCI,• Apportion emissions: supplier emissions that are specificwe provide these tools and resources on PSCI's platform and into our companywebinars. We also provide these tools for our employees on an internalGSMG webpage.External manufacturing EHS assessments 2016 2017 2018 2019 2020Prospective external manufacturers 34 37 65 43 50Current external manufacturers 85 53 61 48 27Total 119 90 126 91 77PSCI environmental metrics 2017 2018 2019 2020Supplier personnel trained in environmental topics 1 N/A N/A N/A 885Environmental Survey response rate 87% 96% 96% 96%1 Formal training was created in 2020 and conducted as a joint effort with PSCI.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 117"
  },
  {
    "page": 118,
    "source": "text",
    "content": "SocialSee our GRI index on page 171.Employment We are:• Committed to fostering development and rewarding talent• Dedicated to diversity and inclusion at every level ofthe organizationGRI 401 Management approach• Adept at recognizing unique skill sets and nurturingemployees' talentsWe recognize that our ability to excel depends on the integrity,Throughout 2020, we invested in programs to drive positiveknowledge, imagination, skill, diversity and teamworkcultural and talent changes at our company. Our values representof our employees.the very core of our character and they guide every decision andaction we take.A positive, inclusive and high-performing work environment isessential for employees to feel welcomed and valued, and to fullyAt the same time, we recognize that we must continue evolvingachieve their business objectives.our culture and ways of working to fortify the company's future andtruly achieve our vision of becoming the premier biopharmaceuticalHarnessing the knowledge and insights of a globally diversecompany. To that end, we embarked on a collaborative effort toworkforce requires leadership, a corporate culture of respect and fullcreate the behavioral and mindset shifts needed for our company'sengagement, and a thoughtful and strategic approach to workplacefuture. As part of this initiative, we asked our employees to join usinclusion and employee development and wellbeing - physical,in writing the next chapter for our company. Ways of Working is theemotional, social and financial.name of the journey to transform our company culture and create aWe value global diversity and inclusion at every level of the working environment that is stimulating and motivating to get theorganization and strive for inclusiveness in every aspect of work. best out of our talent.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 118"
  },
  {
    "page": 119,
    "source": "text",
    "content": "Behavioral and mindset shiftFrom Silos to Networks From Knowing to LearningThe cultural transformation journey encompassedby Ways of Working builds on the foundation of ourvalues, and encourages colleagues to engage in fivebehavioral and mindset shifts:Build partnerships, break down barriers and Challenge ourselves by continuously learning from othercollaborate across the enterprise in a positive way. people, industries and organizations. Foster a culture ofcuriosity, discovery and openness to new ideas.Engage and align multiple internal and externalstakeholders toward a common goal.From Controlling to Empowering From Planning to Experimentation From Withholding to Sharing1 23 4Foster an environment of autonomy at all levels of Make effective and rapid decisions for the business based Proactively collaborate in cross functional teams tothe organization. on incomplete information or without being certain of share capabilities, ideas, resources and innovation.the outcome. Experiment with courageous new ideas,Appropriately put decision rights where they belong Lead change by being candid and sharing criticalapproaches and improvements to current process. Beregardless of hierarchy and allow for innovation. information that people need to know to performaccountable for extracting lessons learned from failurestheir best.and mistakes.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 119"
  },
  {
    "page": 120,
    "source": "text",
    "content": "At the end of 2020, the Ways of Working culture journey was well Changing collaborationunderway: more than 29,000 employees had accessed the internalRealizing the risk of feeling disconnected while working from home,Ways of Working social media site. Approximately 16,000 employeesemployees rapidly shifted to go from silos to networks by using thecompleted a self-assessment on the Ways of Working as an initialdifferent channels of the Ways of Working to share stories about howexploration of where they were on the journey. Colleagues were alsoto cope and be productive at working from home. In a matter of weeks,using our internal recognition platform, INSPIRE, to recognize othersteams around the world shifted learning programs, physician forumsin their Ways of Working journey: more than 300,000 recognitionsand key customer meetings to virtual formats over more appropriatewere made in the platform to celebrate how one of those five Ways ofperiods of time. Virtual events and summits became the new normal.Working were being demonstrated.The COVID-19 pandemic created a high degree of disruption to our Enabling inclusionwork and personal lives. Our company's grassroots adoption of theWorking from home involved going from withholding to sharing more ofWays of Working provided a means for employees to not only managepeople's personal side. Success stories about how people brought theirbut thrive amidst the challenges around them. Employees postedwhole selves (as well as their families and pets) to work contributed toexamples from the five Ways of Working on several company channelsa greater sense of inclusion and belonging.to highlight the changes that made the greatest impact on them:As some parts of the world began preparing for a return to theAdopting new technology workplace, the learning and networks inherent in the Ways of Workingallowed practices like office-booking applications to be shared for thoseBy engaging in experimentation, learning and sharing, teams around theseeking support. At a time of great disruption, employees went fromworld were able to quickly adopt technologies that allowed them to docontrolling to empowering to create solutions that allowed them to betheir work. These technologies include videoconferencing applications,successful in their own unique ways.virtual whiteboards, polling and podcasting tools and cloud-basedproductivity suites. Visit our culture and values page for more information on ourinitiatives, policies and accomplishments.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 120"
  },
  {
    "page": 121,
    "source": "text",
    "content": "2020 Turnover (global)GRI 401-1 New employee hires and turnoverTalent recruitment and retention efforts for Overall turnover rate 1 Voluntary turnover rateSASB 330a.1R&D personnel8.5% 5.9%Voluntary and involuntary turnover rate for:SASB 330a.2 executives and senior managers, midlevel managers,professionals and all others1 Includes all types of turnover of regular employees.Turnover by Overall Voluntary Turnover by Overall Voluntary Turnover Female Maledivision (2020) turnover turnover region (2020) turnover turnover distributionrate 1 rate rate 1 rateby gender andAnimal Health 7.1% 4.6% Asia Pacific 8.1% 6.8% region (2020)Corp Compliance 5.1% 3.0% Latin America 8.9% 3.1% Overall 47% 53%Global Services 5.5% 4.4% EEMEA 8.9% 6.1% Asia Pacific 50% 50%Global Human 14.4% 9.0% Japan 11.4% 2.1% EEMEA 59% 41%HealthEurope 6.9% 3.6% Latin America 39% 61%Human Resources 7.8% 5.7%U.S. 5.8% 4.9% Europe 49% 51%Legal, Security, 6.2% 5.3%Safety & China 22.3% 19.3% Japan 18% 82%EnvironmentCanada 10.1% 9.1% U.S. 47% 53%Manufacturing 5.3% 3.8%China 51% 49%Division 1 Includes all types of turnover, including restructuring.Canada 49% 51%Research 6.7% 5.5%LaboratoriesStrategic 5.0% 2.5%Communications,Global PublicPolicy &Public Health1 Includes all types of turnover, including restructuring.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 121"
  },
  {
    "page": 122,
    "source": "text",
    "content": "Employee hires by region 2016 2017 2018 2019 2020Asia Pacific2Number of hires 1,732 1,909 3,071 2,727 597Hire rate1 14.8% 16.1% 24.4% 20.8% 8.9%EEMEANumber of hires 382 378 505 605 360Hire rate1 13.5% 13.7% 16.7% 18.8% 10.7%Latin AmericaNumber of hires 380 1,246 714 558 459Hire rate1 8.0% 23.8% 13.1% 10.5% 8.4%Europe and Canada3Number of hires 1,636 1,865 2,495 2,624 1,754Hire rate1 8.9% 9.8% 12.3% 12.3% 8.4%JapanNumber of hires 196 109 153 121 143Hire rate1 5.0% 2.8% 4.3% 3.4% 4.4%U.S.Number of hires 1,937 2,173 3,019 2,654 3,193Hire rate1 8.3% 9.1% 12.4% 10.5% 11.9%ChinaNumber of hires NR NR NR NR 2,149Hire rate1 NR NR NR NR 29.5%CanadaNumber of hires NR NR NR NR 50Hire rate1 NR NR NR NR 7.5%NR: Not reported1 Percentage of new hires in the total onboard head count; regular employees only.22020 data excludes China. Separate reporting for China began in 2020.32 020 data excludes Canada. Separate reporting for Canada began in 2020.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 122"
  },
  {
    "page": 123,
    "source": "text",
    "content": "We use a comprehensive approach to ensure recruiting, retention Our benefits and wellbeing programs are designed using guidingand leadership development goals are systematically executed principles that focus on consumer experience, a core set of programsthroughout the company. We hire talented leaders to achieve improved for everyone and flexible offerings to support our diverse workforce,gender parity and representation across all dimensions of diversity. We financial stability for both our company and our employees, andprovide training to our managers and external recruiting organizations providing high-quality programs that reflect our business, valueson strategies to mitigate unconscious bias in the candidate and culture.selection and hiring process. In addition, we utilize a comprehensivecommunications strategy, marketing outreach, social media andHealth and wellbeingstrategic alliance partnerships to reach a broad pool of talent in ourcritical business areas.Employees across the world enjoy comprehensive health coverage,which varies by region and country, and are also provided access to our2020 was a highly unusual year due to the global pandemic. Turnovercomprehensive wellbeing initiative called Live it. Through Live it, ourwas lower in most markets, which may reflect employees not makingemployees can utilize a wide variety of programs and resources that arejob changes in such an uncertain environment for personal health andfocused on prevention, physical health, nutrition and mental health.economic concerns.In the U.S., we generally offer health, life, disability and business travelOur hiring practices pivoted seamlessly to almost all virtual. Hiring didinsurance as well as retirement income benefits to all employees.slow down in most ex-U.S. markets consistent with lower turnoverEmployees also can opt to contribute to tax-free flexible spendingrates. But in the U.S., our highest volume hiring market, hiringaccounts for reimbursement of certain health spending and/orincreased in 2020 versus 2019 by 20 percent, largely due to growthdependent care costs.and investment in our U.S. Manufacturing division plants and theexpansion of clinical trials in our R&D division.Outside the U.S., while benefits may vary by region and country, weoffer health, life and injury, disability and business travel insurance,China is another market that remained on pace with hiring in 2020,along with retirement income benefits. In addition to coveringto support the growth strategy in that market in Oncology andemployees' eligible dependents, in the U.S. and many countriesVaccines across Human Health and in our Research & Development(subject to local law) we extend health care and various insurancedivision. While some companies across the pharmaceutical industrybenefits to employees' domestic partners and their partners' eligiblemay have scaled back their hiring in 2020 as a result of the pandemic,dependent children.we continued to move forward on hiring plans to fulfill our strategicgrowth plans. We were successful at attracting and securing talentReview our Wellbeing Report on Merck.com.during a highly unusual year and significantly increased our focuson creating a diverse workforce through our sourcing, branding andselection processes.GRI 401-2 Benefits provided to full-time employeesWe recognize that our employees are vital to the company's missionof improving and saving lives around the world. One way we recognizethe importance of our people is to provide a valuable suite of programsand resources that support professional achievement and personalwellbeing at every stage of life.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 123"
  },
  {
    "page": 124,
    "source": "text",
    "content": "Health advocacy (U.S.) Other programs to support wellbeing (U.S.)Within the U.S., our medical plan helps support our members with Our company offers many programs to help make it easier foran advocacy solution, which is designed to help employees and their employees to balance their various responsibilities. The following is afamilies navigate the health care and health insurance system. The non-exhaustive sampling:program is designed to make employees' lives easier by saving hours of• Caregiving supporteffort with activities such as:• Transportation services• Helping to resolve complicated medical and dental insurance claims• Backup dependent care• Finding doctors, providers and facilities• Childcare support• Scheduling appointments for physicians, treatments and tests• K-12 educational guidance• Securing expert second opinions• Special-needs counseling• Connecting with fertility advocacy• Adoption and surrogacy assistance• Getting cost estimates for medical procedures• High-quality mental health network• Assisting in the transfer of medical records• Fast access to high-quality cancer care• Researching and locating the latest treatments• Employee assistance and work-life services program• Managing complex or chronic conditions with clinical experts• Summer hoursCommitment to mental health • Paid parental time offEvery employee and their household members have access to • Disaster relief benefitsour global Employee Assistance Program, which provides:• Breastmilk shipping• In-the-moment telephone support for daily relationship• Tobacco-free policychallenges, work issues and everyday stress• Professional counseling sessions How we have helped employees through COVID-19• Work-life services for everyday help and everyday needs, During the pandemic, we updated and added programs to assistsuch as finding assisted living for an aging parent or support employees and their families with the many challenges resultingwith childcare services from COVID-19.• Crisis support for unanticipated eventsOutside the U.S., we support 100 percent coverage of COVID-19-Our company provides a wide variety of resources to all employees related testing, diagnosis and treatment, as well as paid leavesuch as mental health awareness training, webcasts by world-class during quarantine.speakers on important topics such as resilience, men's mental healthand happiness, live and recorded exercise classes, mindfulness sessionsand a network of mental-health champions that provide local support.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 124"
  },
  {
    "page": 125,
    "source": "text",
    "content": "In the U.S., we have offered: Outside the U.S., we have more than 80 pension plans (includingdefined benefit, cash balance, and defined contribution plans) in over• 100 percent coverage for testing, diagnoses and treatment of40 countries. These plans often supplement government-sponsoredCOVID-19 and telemedicine for any reason through the medical plansocial security pension benefits to improve employees' financial security• Onsite daycare centers with expanded safety protocols through added retirement income.• Regular and backup childcareIn the U.S., we offer a defined benefit pension plan as well as a 401(k)• Remote tutoring plan with company matching contributions. U.S.-based employees whoare at least age 55, and those who have at least ten years of service• Caregiving coordinator for employees and their loved onesafter age 40, are eligible for subsidized medical benefits at retirement.• Flexible Spending Account updates (e.g., allow rollovers and mid-year changes) Also in the U.S., we offer:• Free online fitness classes • Comprehensive financial planning through Ernst & Young (EY), a• High-quality mental health provider network valuable benefit provided to employees at no cost to them, whichoffers assistance with budgeting, saving, investing, estate and tax• Mental health training for managers and employeesplanning, as well as help selecting benefit options and other financial• Cares Act 401(k) withdrawals planning guidance• Expanded vacation carryover • Educational assistance, which provides financial support forhigher educationFinancial security• Access to student loan consolidation and refinancing optionsWorldwide, our company offers core and ancillary financial security and• Banking through our company's credit union, which offersretirement benefits that routinely rank amongst the most valuable andcompetitive interest rates on savings accounts and lendingprogressive of other large multinational corporations.Employees and compensation 2016 2017 2018 2019 2020Total compensation paid to employees/payroll, $7.77 $8.65 $8.98 $9.56 $10.18including benefits (in billions)Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 125"
  },
  {
    "page": 126,
    "source": "text",
    "content": "Global flexible work arrangementsWe believe flexible work arrangements offer a different way of workingand have the potential to enhance employees' commitment to thecompany, foster teamwork, increase productivity and support work-lifeeffectiveness. The company has had a global flexible work arrangementpolicy since 2008.In developing our global flexible work arrangement policy, we'vechallenged traditional assumptions about where and how work canand must be done. Flexibility reflects our belief that job effectiveness isdetermined by employee performance and results, not by the numberof hours one is seen in the office. What is produced or accomplished ismore important than when or where the work is done.Time off and leave policiesFor employees outside the U.S., time off and leave benefits arebased on local laws and market practices. We are in the process ofimplementing global paid parental time off with a 12-week minimum.For U.S.-based employees not subject to a collective bargainingagreement, we offer paid time off, leaves of absence and otherbenefits to help employees manage work-life issues. For U.S.-basedemployees who are subject to a collective bargaining agreement,time off and leave benefits are offered in accordance with the collectivebargaining agreement.Disclaimer: Benefits vary based on region and country, employee groupand status, collective bargaining agreements and local legal requirements.Employee volunteeringEach year, our employees around the world take an active role in givingback to their communities by donating thousands of volunteer hoursto help improve health and wellbeing through a range of volunteeractivities. However, the COVID-19 pandemic impacted the totalnumber of hours volunteered as employees were unable to participatein traditional, in-person volunteering and the Fellowship for GlobalHealth was paused in 2020.Fellowship for Global HealthOur mission to save and improve lives underpins the idea behind theFellowship for Global Health.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 126"
  },
  {
    "page": 127,
    "source": "text",
    "content": "The Fellowship for Global Health is a three-month, corporate pro bono Skills-based volunteer programprogram designed to leverage the skills and talents of our employeesOur skills-based volunteer program offers employees the opportunityworldwide. The company continually seeks innovative ways to increaseto donate their professional skills through virtual, short-term projectsaccess to health around the world while also growing and developingthat provide important capacity-building support for nonprofitour talent. The Fellowship for Global Health is one way that we canorganizations. The program expands opportunities for employees toaccomplish both objectives. Due to the COVID-19 pandemic, we pausedgrow and develop, while giving back to the community.the Fellowship program in 2020. However, the program has returned in2021 as a virtual opportunity.Pro bono legal programLearn more about how our Fellows are helping communities.Our company's pro bono legal program has been serving the poor anddisadvantaged for 26 years and is led by our Legal department. Theprogram provides opportunities for our legal professionals to providetheir expertise, free of charge, to members of the community whowould otherwise be unable to access legal advice on a range of issuesincluding family law, veterans' affairs, child advocacy and others.Throughout 2020, attorneys, paralegals and administrative associatesprovided more than 2,600 hours of pro bono legal services.2,600+ hours Medical volunteering-COVID -19of pro bono legal services In response to the pandemic, our company changed its volunteerin 2020 policy to support employees with medical backgrounds. Recognizingthe need for additional health care professionals, including doctors,nurses and medical laboratory technicians, to assist in regions whereCOVID-19 had spread, we removed the cap of 40 hours of paid time off1,224 hoursto volunteer for these individuals. In the U.S. for example, employeeswith a medical background reported volunteering 1,224 hours in 2020.volunteered through COVID-19In 2021, we will continue this policy.medical volunteering programin 2020Employee giving summary volunteering1 2016 2017 2018 2019 2020Employees who volunteered 2 16,446 6,560 6,557 14,395 985Employees who used paid time off (PTO) 3 14,376 4,870 4,795 7,301 411Total recorded volunteer hours (TRVH) 1 214,862 114,903 114,393 136,014 46,279Skilled volunteer hours 4 16,726 19,468 18,317 19,907 3,9771 T he Employee Giving Summary table has been simplified to reflect data that is most meaningful to stakeholders and reflects the performance of our company's volunteering initiatives.2 2 020 figures are based on employee self-recorded volunteer hours and volunteer hours communicated directly to the Office of Social Business Innovation for certain countries.3 F igures based on estimated data.4 F igure includes aggregate reported hours from our major skills-based volunteer initiatives - the MSD Fellowship for Global Health, SkillShare and Pro Bono Legal program. It also includeshours recorded for U.S. employees with a health care background who volunteered to assist with the COVID-19 pandemic.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 127"
  },
  {
    "page": 128,
    "source": "text",
    "content": "employees such as partners and contracted workers) must follow thestandards and requirements of our EHS management system or haveGRI 401-3 Parental leave equivalent programs. Compliance with these requirements is measuredthrough the site audit processes for employees and non-employees,and through peer reviews for construction.We are in the process of implementing up to 12 weeks of paid parentaltime off for employees who become parents through the birth,Information on our management approach to occupational healthadoption or surrogacy of a child regardless of the employee's sex,and safety, specifically our key operating principles, EHS governance,marital status, sexual orientation or gender identity.internal auditing and certification is included in GRI 307 on page 110.For more information regarding the occupational health and safetyIn addition to parental leave, U.S. employees receive separate, paid,expectations in our value chain please refer to our Business Partner Codeunpaid and job-protected leave to care for a newborn child, adoptedof Conduct.child or child placed in foster care following the child's birth.International standardsOccupational health & safetyWe are committed to providing a safe and healthy workplace for ouremployees and contractors, and to complying with all applicable safetylaws and regulations. In addition, we aim for EHS performance that isGRI 403 Management approach among the best in the pharmaceutical industry.Our company has processes in place that are consistent with theInternational Labour Office (ILO) Code of Practice on RecordingAs a global health care company, we strive to provide a safe andand Notification of Occupational Accidents and Diseases (the Code)healthy workplace.where governments have adopted the Code. In countries that haveWe seek to eliminate work-related injuries, illnesses and unplanned not adopted the Code, we report to governments as required byevents from all aspects of our operations through comprehensive applicable law.safety programs that are part of our Environmental Health andFor consistency across the company, and to enable us to compareSafety (EHS).our injury rates with those of other multinational companies, weEach year, we set targets for leading and lagging safety metrics, use the U.S.-based OSHA record-keeping criteria for recording andincluding safety observations, near-miss reporting, peer safety audits, tracking work-related injuries and illnesses. We require all injuries,recordable injury rates and days away and reassignment or transferred illnesses and incidents involving our employees to be reported and(DART) rate. investigated to determine their cause. We also require actions be takento prevent recurrence.Please see GRI 403-9 on page 137for performance on all metrics.We have reviewed the ISO 18001 Standard but have not pursuedEveryone who works at our sites (i.e., all employees, and non- certification at the corporate level because we believe that ourcurrent EHS management systems are robust and will help us to drivecontinuous improvement in our EHS programs and achieve our desiredlevels of EHS performance.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 128"
  },
  {
    "page": 129,
    "source": "text",
    "content": "GRI 403-1 Occupational health and safety management system Hazard identification, risk assessment, and incidentGRI 403-2investigationWe seek to eliminate work-related injuries, illnesses and unplannedOur process safety program identifies and controls risks associatedevents from our operations through comprehensive safety programswith manufacturing our human and animal health products. Thethat are part of our EHS management system. We also work toprogram applies not only to operations that are subject to processminimize the frequency and severity of safety and environmentalsafety regulations, but also to our pilot plants, manufacturingincidents by focusing on proper facility design, process controls,operations and utility areas where process hazards may exist. Inoperation and maintenance procedures, protection systems andaddition, we have implemented a structured chemical-reaction-emergency-response capabilities.hazard review program for our research laboratories.Our global safety program is designed to drive a proactive safetyIn the early stages of product development, we conduct chemicalculture and reinforce the link between our leadership behaviors and ourreaction and thermal testing of our intermediate materials andsafety and environmental objectives. We believe that through visibleproducts to identify potential reactivity, fire and explosion hazardsmanagement, leadership and employee engagement, we can increaseand environmental risks. This testing continues throughoutthe awareness of hazards and help employees make the right choiceseach product's life cycle to assure that we are aware of andwhen it comes to safety, health and the environment - both on and offcan appropriately manage process risks. Global process safetythe job.professionals work with operations and engineering personnel toOne example of leadership and employee engagement is our active conduct process hazard analyses and hazard and operability studiessafety committees that drive program implementation and address to thoroughly evaluate our operations. These structured reviews takesafety issues collaboratively between management and employees. place during process design, initial start-up and throughout the life ofthe process to ensure that our facility design, equipment, operatingWe address the following areas in our approach to employee and controls and maintenance procedures are effective in controllingcontractor safety, which are discussed in more detail in GRI 403-2 on process-related hazards.page 129 and GRI 403-3 on page 132:Process safety (403-2) Non-routine hazardous workNon-routine hazardous work (403-2)In recognition of industrial safety trends and our own internalCapital projects construction safety (403-2) assessments, we have refined our global approach to managingsafety during non-routine maintenance and repair activities, as theseSafety for non-company personnel (403-2)work activities are a leading cause of serious and fatal injuries acrossMotor-vehicle safety (403-2) industries. We have developed global safety standards to minimizeEmergency preparedness and response (403-2) the potential for serious incidents when our employees are working atheights, entering confined spaces and working on or near machinery,Loss prevention (403-2)piping and electrical systems. This global effort is focused on creatingIndustrial hygiene (403-3) a rigorous, error-free and safe approach to performing these non-routine, high-hazard work activities.Biological safety (403-3)Ergonomics (403-3)For information on our Global Safety and Environment (GSE) EHSManagement System, please visit GRI 307 on page 110.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 129"
  },
  {
    "page": 130,
    "source": "text",
    "content": "Capital projects construction safety performance and adherence to company EHS requirements on anongoing basis, including through the IFM partners' scorecard.We have a strong construction safety program with a focus onThese IFM partners are required to follow our company's EHSzero harm to people, property and the environment. Our Globalstandards and site level procedures. They are required to identify andEngineering Solutions (GES) group oversees hundreds of contractorsmonitor compliance activities associated with their scope of servicesand thousands of skilled craftworkers on our construction projectsand meet safety-related performance objectives.worldwide. Safety is integrated into all stages of our constructionprojects, beginning with the concept and design phases and carriedOur IFM partners prequalify the contractors that they use at our sites,through to detailed design and construction.ensure those contractors are trained, perform EHS inspections andmonitor EHS performance.Our construction safety program mandates pre-job planning, hazardassessments and daily safety audits. We also conduct monthly peerIFM partners proactively follow a continuous improvement processreviews by bringing together in-house engineers, contractors, EHSwhereby each year, on top of our company requirements, additionaland other partners to conduct thorough project safety evaluationstargets are set up and monitored at the governance level.and sharing of best practices. We completed 78 peer safety reviewsin 2020, covering 91 percent of our active projects. Contractors working at our sites who are not managed by our IFMpartners are prequalified using the same process as our embeddedWithin the last two years the construction industry has seen acontractors, including verification of safety training. These contractorsnegative trend related to availability of contractor and craft resources.are assigned internal company liaisons who monitor safety andThe impacts of this trend are management of resource availabilityenvironmental compliance, perform observations of their work andissues, varied levels of experience and safety competencies.verify that necessary corrective actions are taken.GES uses a hyper-care program adding additional supervisionand safety oversight to new contractors, high-risk work scope All above referenced contractors are required to report and investigatecontractors and less experienced contractor craft. all incidents and near-miss events. They also work with site based EHScontacts to identify and implement corrective and preventive actions,Additionally, GES uses a rigorous prequalification program throughwhich are tracked to completion. Contractors are monitored forConstructSecure (external prequalification service/program) tocompliance with all EHS requirements.evaluate, score and prequalify every contractor and subcontractor.ConstructSecure evaluates contractor safety programs, pastperformance, incident rates, experience modifier rate (EMR), training Motor vehicle safetyverification of craft and reviews any regulatory citations prior toallowing them to bid on any projects. The aim of our motor vehicle safety program is to promote astrong safety culture for our employees who operate vehicles whileconducting company business. Our program is designed to reduce theSafety for non-company personnelfrequency and severity of motor vehicle injuries and reduce the numberof collisions, violations and vehicle-related incidents across our globalWe frequently work with integrated facility management (IFM)network. We have implemented a global motor vehicle safety standardpartners whose employees perform work at our sites. Currentand adopted programs, such as telematics that provide real-timeIFM partners were selected at the global level following a detailedcontinuous feedback, to support safe driving skills and behaviors ofsourcing process and are managed through a specific governanceour sales and marketing employees who operate the majority of ourprocess. The governance process includes dedicated company EHSbusiness-use vehicles.oversight that measures, monitors and evaluates IFM partner EHSMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 130"
  },
  {
    "page": 131,
    "source": "text",
    "content": "Risk management Many of our manufacturing plants have trained emergency responseteams, and mobile fire and rescue apparatus that can respond to onsitefires, medical emergencies, technical rescues and spills/releases. MostEmergency preparedness and responseof our emergency response teams interact directly with their localWe prioritize the prevention of incidents through equipment and community-based emergency responders, and in some cases, assistfacility design, operational and maintenance procedures and employee off-site when requested.training. Because we recognize that incidents can still occur, our EHSstandards require emergency preparedness and response capabilities Processes for workers to report work-related hazards and hazardousat all of our facilities worldwide. situations, investigate work-related incidents and determinecorrective actions and improvements needed in the occupationalOur priorities for emergency response include: health and safety management system are included in EHS emergencypreparedness and response and incident investigation standards and• Ensuring the safety and wellbeing of our employeestraining. These standards also include information on how employees• Preserving the environment and nearby communities are protected against reprisal.• Protecting our physical assetsLoss preventionSite-specific emergency-response procedures include incidentreporting and management, personnel evacuation, medical/first-aid Protecting our people, facilities, production processes andresponse and incident response and control. We routinely conduct product supply chains from threats such as natural catastrophesemergency response drills and train employees in both job- and site- (i.e., hurricanes, floods, windstorms and earthquakes) and firesspecific emergency-response duties. is critical to ensuring that our products reach our customerswhen needed. We proactively assess and manage these risks atWe conduct pre-emergency planning for credible emergency scenarios our facilities andat several of our strategic third-party manufacturerssuch as process upsets, fires, spills, releases, severe weather and and warehouse providers.security-related incidents.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 131"
  },
  {
    "page": 132,
    "source": "text",
    "content": "Our loss-prevention program focuses on eliminating or reducing the Health quality and productivityimpact of potential loss events by:Our employees are our most valuable asset, and we commit every• Providing appropriate facility and process designsday to preserving their health. We assign employees only to jobs that• Implementing inspection, prevention and maintenance procedures they are physically able to perform. When employees become ill orinjured, we support their recovery so they can return to work as soon• Installing fire suppression, detection and specializedas they are medically able to perform their jobs. When an employeeprotection systemsexperiences an occupational injury or illness, we promote and facilitate• Executing emergency response and business continuity programsappropriate treatment and rehabilitation.We also engage the services of globally recognized loss preventionengineering service providers to routinely inspect facilities and review Prevention and risk minimizationnew designs and facility modifications. This helps us to maintain a highstandard of loss prevention that corresponds to the level of operational Reducing risk and preventing illnesses and injuries are the best waysrisk, monetary value and supply-chain importance. to maintain the occupational health of our employees. We collaborateclosely with Global Safety and the Environment organization to identifyand evaluate potential impacts of our operations on the health of ouremployees to reduce adverse impacts. We take proactive steps toGRI 403-3 Occupational health services prevent occupational injury and illness through our Medical Surveillanceprogram. This program evaluates new and existing workplace hazardsand develops and implements procedures and clinical protocols toOccupational health principles apply to all employees and directlyeliminate them and prevent future occurrences. In the event of ansupervised contingent workers at all levels, and across all divisions inoccupational injury or illness, we perform joint follow-up investigationsthe company. We promote compliance with both the letter and thewith Global Safety and the Environment and conduct analyses tospirit of applicable occupational health laws, company policies andfurther refine our preventive efforts and reduce avoidable risks.requirements. We prioritize continuous improvement and assess ourimprovements objectively through internal measurement, externalbenchmarking, incorporating best practices and participating in Performance managementoccupational health research where appropriate.Our occupational health programs are not static, and we driveTo meet the company's objectives, we focus on eight key areas: continuous improvement in their performance. We establish programs,policies and procedures that tie our occupational health performance• Health quality and productivityto corporate and divisional goals and objectives. We regularly report• Prevention and risk minimization our progress against our goals to management and refine them asnecessary at regular intervals.• Performance management• Global standards and communicationGlobal standards and communication• Education and training• Management We adhere to and promote company goals, programs, procedures andpolicies designed to provide a high level of respect for the health of• Safetyour employees globally. In communication, we foster openness and• Global employee health. respectful dialogue with our employees, anticipating and responding toconcerns about our operations.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 132"
  },
  {
    "page": 133,
    "source": "text",
    "content": "Education and training Global employee healthWell-informed and trained employees provide the backbone for The Executive Vice President of Human Resources is the seniormaintaining employee health in the workplace. We assist in providing company official who advises the Executive Team on occupationalappropriate education and training programs for our employees, so health strategies, policies and programs, and reports to the committeethey understand potential health hazards and necessary precautions on occupational health matters that impact employee health andrelated to their job duties. To achieve this effectively, we invest in our human performance. Together, this position and the Vice President ofoccupational health team's professional growth to foster business Global Safety and the Environment promotes effective collaboration onexcellence in conscientious execution of their responsibilities. occupational health and safety matters. Their mission is to achieve thecompany's occupational goals and other relevant safety policies, and toprovide expert subject matter advice to management.ManagementLeaders of employees or managers of other resources are responsible Global Health Center of Excellence (CoE)for implementing and adhering to local and regional occupationalhealth policies. They may also provide input into Global Employee Our Global Health CoE includes our company's industrial hygiene,Occupational Health policy and strategies that promote the company's biological safety and ergonomics programs. By integrating theseoccupational health leadership in accordance with our mission and disciplines into a single organization, the company more effectivelyvalues. Similarly, we expect division and business unit leaders to make manages worker safety and promotes employee health. The Globalsure their teams provide input to occupational health strategies, Health CoE improves worker safety and employee health by focusingpolicies and programs, as appropriate. Above all, they make sure on four vital areas:their organization provides adequate resources to support and track• Governanceoccupational health performance.• Risk managementSafety • Implementation and operation• Program managementGlobal Safety and the Environment provides input into GlobalEmployee Occupational Health policy and strategies that promote Through the Global Health CoE, we protect employees, customers,the company's occupational health leadership in accordance with our vendors, partners and neighboring communities by identifyingmission and values. Activities include development and implementation chemical, physical and biological hazards and assessing and properlyof Occupational Health Programs, assessing potential workplace controlling risks. By systematically maintaining rigorous attentionhealth hazards (chemical, biological and physical), preventing adverse to sustainable risk management principles and controls, we protecthealth effects from hazards, evaluating employees' ability to perform our stakeholders worldwide, enabling the organization to focus onjob tasks, identifying causal factors associated with injuries and discovering, developing and providing innovative products and servicesillnesses, and working with site health professionals to track the safety that save and improve human and animal lives around the world.performance of the company.To accomplish this, we require and expect our stakeholders, executiveteam and ourselves to anticipate hazards, evaluate risks and provideeffective and sustainable solutions to control both.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 133"
  },
  {
    "page": 134,
    "source": "text",
    "content": "Industrial hygieneOur industrial hygiene program protects employee health throughoutall stages of research and manufacturing. Our professionals identifychemical, physical and biological hazards to assess exposures andcontrol risks.Based on industry-leading best practices, we accomplish this through ahierarchy of controls.These are:1. Prevention2. Substitution3. Engineering4. Administrative 12 million+disposable masks5. Personal protective equipment (PPE)delivered to workers aroundFor example, when designing new processes and facilities, we buildthe globe in 2020safety into our designs organically by eliminating risks, substituting lesshazardous processes or materials and installing effective engineeringand operational controls. We also confirm the ongoing effectiveness ofthese controls after installation through a robust monitoring program. 315 new alternate PPE products were evaluated with an approval rateof 79 percent. Twenty-one percent were rejected as unapproved orWhen addressing existing processes and facilities we use a similar counterfeit devices.approach. First, we seek to eliminate hazardous materials and processes.When not possible, we use less hazardous substitutes and then evaluate We developed performance specifications, selected and deliveredpotential engineering controls to mitigate the remaining risk. Where nearly 4 million reusable cloth masks to our workers and their familiesengineering controls are insufficient or not feasible, we establish during the COVID-19 pandemic. Wearing reusable masks supportseffective work practice controls including those that may require our mission to preserve surgical masks and respirators for healthselected types of PPE. care workers who need them, and to reduce waste by minimizingdaily discard of disposable masks. We contributed our mask designNearly 9,000 data points were collected and used during 2020 to and performance experience with ASTM International to supportevaluate risk or to confirm effectiveness of risk reduction investments, publication of the new ASTM F3502-21 Standard Specifications forand 129 risk reduction actions were completed. Barrier Face Coverings to benefit the global community.Working as a focused cross-functional team, we achieved businessBiological safetycontinuity and uninterrupted supply of products to patients byproviding pandemic response procedures, supplies and approved Our biological safety program protects our employees, customers,protective equipment to on-site essential workers. More than vendors, partners and neighboring communities by systematically1,800 inventory items were actively managed with more than identifying, assessing and controlling biosafety and biosecurity risks1,000 shipments of essential supplies shared across the company. associated with the research, development and manufacture of ourMore than 12 million disposable masks were delivered to workers vaccines and therapeutic proteins. Our biological risk managementaround the globe. In response to PPE scarcity during the pandemic,Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 134"
  },
  {
    "page": 135,
    "source": "text",
    "content": "team drives safety by setting high performance expectations for clinicians, manages risk assessment lifecycle and communication withingovernance, controls, strategy, planning, management, reporting, the company and provides a comprehensive suite of assessments forpolicies, processes and corporate culture. different units of operation. BAR evaluates biosafety and biosecurityrisk associated biological materials and establishes risk controlWe strive to integrate biosafety considerations into the culture- strategies that protect human health and the environment.for our internal and external stakeholders. For example, in 2020, wepartnered with Global Engineering Services to update our engineeringErgonomicsdesign standard that governs fit-for-purpose, large-scale biologicalfacility design. Our global ergonomics team reduces employee injuries by improvingprocess efficiencies and human performance while advancingThis enabled our company to establish multiple, production-ready worker wellbeing through adaptation of conditions relating to tasks,facilities for safe development and manufacturing of vaccines and equipment and the work environment. The ergonomic programtherapeutics to combat endemic or emerging infectious diseases focuses on the identification and prioritization of highest-risk/highest-like COVID-19. exposure work task in all areas of the organization (manufacturing,warehousing, research, sales and support services) to drive downWe demonstrate leadership in the field of biosafety by partnering withinjuries and worker discomforts. We also provide standards to ensureour community of public and private sector biosafety professionals, inergonomic design requirements are incorporated into construction oforder to develop guidelines that protect human and animal health andnew or renovated facilities to maximize worker comfort and health andthe environment. For example, in 2020, we helped the CDC develop,minimize ergonomics hazards and risk factors.\"Appendix M, Large Scale Biosafety,\" in the CDC/NIH publication,Biosafety in Microbiological and Biomedical Laboratories (BMBL), 6th Approximately 15 percent of our company's global, recordable injuryedition, and contributed to the article \"Promoting Biosecurity by cases are ergonomic-related; in 2020, the number of recordableProfessionalizing Biosecurity\", in Science, published February 21, 2020. ergonomic cases decreased 30 percent versus 2019. We haveachieved a sustainable ergonomic program focused on utilizing aWe promote a safe environment for our workers and protect theteam/participatory approach to reduce risk by encouraging employeehealthy living conditions of our neighboring communities. For example,participation in workplace assessments and risk identification,our biological safety professionals facilitated 418 biorisk assessmentsand implementation of sustainable engineering controls. Whereto support research and development and manufacturing activitiesengineering controls are unavailable, administrative and behavioralacross all company divisions. By developing an asset called Bioriskcontrols are implemented, including but not limited to, job rotation,Assessment and Repository (BAR), we believe that we have set newjob hazard identification and body mechanics training, to reducebiorisk management standards in the industry. The tool provides arisk of ergonomic injury until an engineering control can be identifiedcomprehensive repository of biological processes in the company,and implemented.collates lifesaving information that supports first responders andIn response to the pandemic, non-essential employees workedremotely. To support this change, a remote worker ergonomicassessment process was developed and deployed with collaborationfrom IT, Procurement and Live It (Health and Wellbeing group). Thisnew process provides worker access to resources that guide proper$5.3 millionhome office workstation setup and identify appropriate equipment andworth of PPE and supplies donated in 2020 including: solutions needed to maintain a healthy work from home environment.• Disposable masks • Gloves• N95 respirators • Sanitizers• Goggles • CoverallsMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 135"
  },
  {
    "page": 136,
    "source": "text",
    "content": "GRI 403-5 Worker training on occupational health and safety GRI 403-6 Promotion of worker healthTraining is critical to building worldwide employee competenciesGlobal Employee Health Services provides worker access tothat will improve compliance, reduce risks and drive continuousnonoccupational medical and health care services to addressperformance improvement.major nonwork-related health risks. The team operates bothglobally and locally.We have a global standard that defines the EHS training expectationsfor employees in three categories:Global Employee Health provides services that range from the• Manager training covers specific management responsibilities with administrative-such as medical clearances for job placement andregard to safety and environmental compliance and promoting a evaluations to assess capability to perform a job task, to regulatory\"safety-first\" culture assessments for potential health hazards and reproductive healthhazards, to consultations that prevent injury and illness like those• EHS professional training is designed to expand technical expertiserelated to travel and unique workplace hazards, to outright care forand improve our EHS capabilities around the worldthose suffering a serious injury or illness at work.• Employee training covers the specific information our employeesneed to perform their jobs in a safe and environmentally compliant Locally, Global Employee Health supports the company's peoplemanner, focusing on hazards they encounter on the job and the through on-site employee health services clinics. These facilities,corresponding control measures located on many sites, are staffed by dedicated Global Employee Healthpersonnel or contractor employees. All facilities provide occupationalSite EHS professionals complete an assessment of the activities and preventive health services that keep employees healthy, on the job,performed at their sites and ensure that relevant topics are included and functioning at optimal capacity. Global Employee Health supportsin their site training plans. They develop employee training curricula many of the programs, including biometric screenings for employeeto comply with internal and regulatory training requirements specific personal health assessments, flu and other vaccinationsto their country. These training programs are reviewed periodically to and mammograms.ensure that they remain current. Our EHS training program materialsare available in both instructor-led and e-learning formats. We also Our most vital occupational health services relate to medical adviceconduct periodic web-based seminars to inform EHS professionals of and consultation, medical evaluations, medical surveillance, care ofchanges in regulations, standards and company practices. occupational injuries and illnesses, identification and reporting of newpotential hazards and adverse health effects, emergency medicalIn 2020, with the COVID-19 pandemic, the company ensured social response and-most importantly-prevention.distancing during training by modifying classroom training formatswhen in-person training was required, and shifting to web-based To develop and maintain awareness of all workplace health hazards,interactive training modules, where possible. Global Employee Health services maintains a close functional workingrelationship with site Management, Safety and Industrial Hygieneprofessionals. We are also responsible for maintaining employee healthrecords in accordance with local regulatory requirements. Employeehealth is a vital priority at our company so we continuously improveour programs globally and at each site. These efforts range fromcommunications for our global policies, procedures and protocols; toadministering regulatory and compliance audits; to providing criticaloversight for our occupational health programs.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 136"
  },
  {
    "page": 137,
    "source": "text",
    "content": "In 2020, 29 percent of our recordable injuries were related to slips,trips and falls, with \"struck-by/caught-in\" and ergonomic-relatedGRI 403-9 Work-related injuries injuries accounting for 37 and 15 percent of the total number of injuries,respectively. We continue to focus our efforts on reducing these typesGRI 403-10 Work-related ill healthof injuries. In addition to our focus on the safe design of new facilities,we proactively address existing risks through the hierarchy of controls,focusing on eliminating high-risk tasks, improving engineeringIn 2020, we placed additional emphasis on proactively assessingcontrols, and performing coaching and training to our workforce to aidexisting processes and equipment that presented ergonomic risks.in identification of risks.Formal plans drove risk assessments and an engineering controlfeasibility process was established to better mitigate risk factors In 2020, we experienced a 27 percent reduction in the collisions perfollowing the hierarchy of control principles. million miles (CPMM) indicator. This was due to a 41 percent reductionin the number of collisions and 18 percent reduction in miles drivenWe have worked steadily to drive down our workplace injury rates.due to the COVID-19 pandemic restrictions. In 2020, we focused thedriver safety program to help our employees to return to work safely,In 2020, our lost-time incident rate (LTIR) was 0.05, a 56 percentincluding vehicle pre-inspections, vehicle and mobile devices hygienedecrease from 2019. Our recordable incident rate (RIR) was 0.16, aand COVID-19 related safety precautions among others. Our global47 percent decrease from 2019. This is our fourth consecutive year in thevehicle safety program includes a standard duty of care by holdingfirst quartile when compared against our pharmaceutical industry peers.both employees and managers accountable for achieving safeThere were no fatalities in 2020. The substantial decrease in the 2020driving expectations.LTIR and RIR was due to a large percentage of our workforce workingfrom home for the majority of the year due to COVID-19 precautions.Lost time injuries/ Lost Time % of Lost Recordable injuries/illnesses % of Total1illnesses by cases Time cases1 by casual factors (total:132)casual factorsSlips-trips-fall 28.8Slips-trips-fall 16 39.0Struck by/caught in 37.1Struck-caught 11 26.8Motor vehicle 3.0Motor vehicle 4 9.8Ergonomic 15.2Ergonomic 4 9.8Chemical/biological exposure 6.1Chemical exposure 3 7.3Other 7.6Other 1 2.4Non-ergonomic 1.5Non-ergonomic 1 2.4Physical/environmental exposure 0.8Phys/env exposure 1 2.4Biological exposure 0 0Total 411 M ay not total 100 percent due to rounding.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 137"
  },
  {
    "page": 138,
    "source": "text",
    "content": "Construction construction safety performance. Our injury rates continue to improveand be significantly better than construction industry averages.In 2020, we received one safety excellence award for our EMEA/AP Construction projects also set a record with 160,000 Tap Ins (safetyprojects safety management program (3-year period from 2018-2020) observations) being reported in 2020.from the construction user round table (CURT). CURT is a globalIn 2020, we had two high consequence work-related ill healthorganization that provides an international forum for the exchangeinjuries involving one hot-work incident in the Asia-Pacific region.of information and expertise to improve safety, productivity andTwo workers were burned significantly in the event and suffered dayscompetitive advantage for the construction industry.away from work. In 2020, 95 percent of injuries were injuries sufferedIn 2020, we logged 11 million construction hours globally and achieved in low risk/routine tasks. The top two 2020 injury categories includedzero injuries on 95 percent of our capital construction projects. Our slips, trips and falls from the same elevation, and hand and finger cuts2020 construction safety RIR of 0.60 reflects an increase over our requiring stitches.2019 rate of 0.42 and just over our 2020 target of 0.55. Our capitalconstruction projects also achieved a DART rate of 0.24, which wasNon-employeesslightly above our 2020 target of 0.23.In 2020, our IFM partners had a total RIR of 0.35 and a LTIR of 0.26.In 2020, we had a 2 million hour increase in the number of constructionOur major IFM providers' injury rates continue to be significantlyhours, and more capital projects in all regions of the world. In addition,better than industry averages.the COVID-19 impact, while massive in 2020, did not affect theGlobal safety performance1, 2 2016 2017 2018 2019 2020Workplace safetyRecordable incident rate (RIR) 0.35 0.33 0.30 0.30 0.16RIR percentage change -27% -6% -9% 0% -47%Lost-time incident rate (LTIR) 0.13 0.13 0.10 0.11 0.05Fatalities3 0 0 2 0 0Motor vehicle safetyCollisions per million miles (CPMM)4 9.48 7.29 6.93 7.01 5.07Note: Injury rates are subject to change over time, as new cases are added and case classifications change in accordance with our own requirements and applicable regulatory requirements.We report injury/illnesses together in our rates and analyses.1 LTIR/RIR: Calculated per OSHA methodology.2 T he company metrics presented in this table are captured from the corporate managed data system. Newly acquired facilities are not included in this data set. However, based onconservative estimates of this not yet included data, the company would still fall within the first quartile of performance when compared with its peer member companies in thePharmaceutical Safety Group (PSG).3 I n 2018, one of the fatalities was transportation-related and the other was high-risk work related.4 CPMM: Reflects both personal and business use of company-owned or -leased vehicles.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 138"
  },
  {
    "page": 139,
    "source": "text",
    "content": "Cases by business area Lost-time cases Recordable casesFacility Management 2 5Global Human Health (GHH) 15 25Global Support Functions (Legal, HR, IT, S&E, et al.) 2 7Animal Health 3 10Manufacturing (MMD) 16 77Research (MRL) 3 8Total 41 132Capital projects construction safety1, 2 2016 2017 2018 2019 2020RIR 0.53 0.59 0.73 0.42 0.60DART 3 0.26 0.32 0.28 0.15 0.24Fatalities 0 0 0 0 0Facility management contractor safety4 2016 2017 2018 2019 2020RIR N/A N/A 0.71 0.55 0.35LTIR N/A N/A 0.47 0.42 0.26Fatalities N/A N/A 0 0 0NA: Not Available.Note: Incident rates are subject to change over time, as new cases are added and case classifications change in accordance with our own requirements and applicable regulatory requirements.1 LTIR/RIR: Calculated per OSHA methodology.2 Primarily reflects capital projects over $100,000 managed by our global engineering group.³ DART: days away, reassigned or transferred, calculated per OSHA 300 methodology.⁴ Incident rates for IFM partners; reporting initiated in 2018.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 139"
  },
  {
    "page": 140,
    "source": "text",
    "content": "Training & educationGRI 404-1 Average hours of employee trainingPrograms for upgrading employee skills andGRI 404-2transition assistance programsGRI 404 Management approachTools and resourcesWhether we are inventing the next breakthrough treatmentor simply challenging and supporting one another for ongoingOur current talent management practices provide company-development, we lead through a culture of applied curiosity.wide performance management, leadership development, talentThe Global Learning and Development (GL&D) organization's primary assessments, talent reviews and succession planning. Talentfocus is to enable a diverse and accessible environment in which management designs and implements the enterprise-wide talentall can learn and thrive. We accomplish this by collaborating with development and leadership strategy aligned to business strategybusiness partners across the company to understand and align to in order to retain and attract talent, support and develop a diversecritical business challenges. Then we design, develop and execute workforce and create a strong succession pipeline. Talent practicesinnovative learning solutions and experiences to strengthen our are supported by a human capital management system which enableshuman capital strategy. managers and employees to keep track of business and developmentpriorities, performance ratings, career aspirations, job experiences,GL&D ensures all learning opportunities are developed to allow skills, language proficiency, certifications and education.for diversity of thought, experience and an enriched accessiblelearning environment. We identify learning needs of our globally Managers and employees are encouraged to meet throughout thediverse employee population through extensive discovery of learner year to discuss progress and accomplishments against their priorities.personas, requirements and environments. Our strategy allows us to Emphasis is placed on creating a culture of ongoing coaching andidentify, prioritize, design and develop learning solutions that drive future-focused feedback. At year-end, colleagues summarizeresults and impact. Solutions include, but are not limited to, building their achievements and assess the impact they have had on theleadership and management capability, technical and functional organization, their team and their own development. Managersreskilling and upskilling. conduct annual performance reviews of employees at all levels (exceptthose subject to collective bargaining agreements) to guide individualGL&D understands employee skills and capability must support the decisions relating to development, compensation and rewards.company's vision and mission. As a result, we continuously evaluateour organizational capability needs and retool the learning culture and Employee performance is measured, in part, by how well employeesstrategy to support. demonstrate the company's aspirational culture and Ways of Working.We seek to emphasize not just what an employee achieves, but alsohow he or she achieves it. Managers gather feedback about theircolleagues and write performance reviews describing the ways in whichtheir team members demonstrated the company's Ways of Working intheir accomplishments.Transition assistance programs may be provided to support employeeswho are exited as part of a company workforce restructuring. Suchbenefits which may include the following, however, are subject to localplans, laws and country guidelines:Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 140"
  },
  {
    "page": 141,
    "source": "text",
    "content": "• Severance benefits which may include severance pay based on In addition, we offer programs for experienced managers focused onemployee level and service areas like strategic planning, innovation and influencing others.• Outplacement job transition assistanceTeam and individual development• Continued health and wellness benefits for a defined period of timeWe have programs that provide skill trainings and tools that supportBuild the Best Teams & Talentbuilding and maintenance of effective teams, including Building HighPerformance Teams, Virtual Teaming offerings (for example: DealingThis global program is intended to help the organization learn, growwith Change, Building Trust and Shifting your Mindset throughand achieve. Based on neuroscience, it gives employees practicalImprovisation), Assessing Team Performance through an online surveystrategies and tools they can use to effectively share and receive moretool and Insights Discovery.frequent feedback from diverse stakeholders and increase the qualityof performance conversations. In addition, individual developmental assessments may be used toidentify strengths and developmental areas as a way to prepareemployees for higher-level positions or accelerate performance inManagement and leadership programstheir current job. These assessments prioritize developing leadersManagement Foundations is a comprehensive program that focuses who will create a positive work environment and inspire their teamson building core, common and critical knowledge and skills for new to contribute to the company's goals. Based on an individual'smanagers. Using a variety of learning methods, new managers are observed behavior, personality or skills these assessments providetrained on what they need to know and do to be effective in their role comprehensive feedback that is used to create an action plan andand to establish foundational management skills. individual development goals.Training and education1 2016 2017 2018 2019 2020Total course completions for all 4.2 5.3 4.4 5.3 7.2employees (in millions)Hours of training for all 2.1 2.6 2.2 2.7 3.6employees (in millions)2Average course completions 60 48 43 55 69per employee1 T raining requirements are not based on gender or other employee categories; thus, data is not broken down as such.2 B ased on average of 30 minutes per course.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 141"
  },
  {
    "page": 142,
    "source": "text",
    "content": "Individuals may also drive their development by accessing subscribed The Business Leadership Programresources found on an internal, central platform. These resourcesA global, nomination-based program on advanced concepts in businessinclude, but are not limited to:and financial management and cross-functional leadership at an• Harvard Management Mentor enterprise-wide level. The program develops leadership capabilities tohelp manage external environmental trends and their potential impact.• Get Control!Participants experience the language of finance through simulated• AchieveForum experiences focused on the fundamentals of a company's balancesheet, income statement and cash flow, how to integrate long-term• Cultural Navigatorplans with short-term action and how to create a strategy that willEmployees can register for free events and webinars to drive their drive decisions.development in areas of Leadership, Teaming and Professional Skills.Training can be done on the learner's time and focus can be set toBusiness Leadership Program 2020close areas of development or to further strengthen skills of interest.The various platforms offer multi-modal resources with trainings toPost-program retention 87%accommodate all schedules.Lateral moves 39%Key talent focusPromotions 38%We advance the learning and development of our global key talent atall levels of the organization to support the advancement of our talentpipeline and diversity and inclusion strategy.Leadership PathwayThe learning experiences include:The Leadership Pathway focuses on director-level key talent.The purpose is to develop individuals to be change makers whoGeneral Management Acceleration Program (GMAP) engender inclusion and trust; inspire experimentation, feedbackand learning; and achieve aspirational business outcomes for theOur flagship, application-based program to develop future global,company today and tomorrow.enterprise-wide leaders. The objective of GMAP is to create a robustglobal acceleration program for internal and external talent, providingthe right experiences and learning opportunities to help meet our Leadership Pathway 2020future business demand. Successful participants broaden theirexperience and perspective, enhance their leadership abilities and are Post-program retention 100%well positioned to move into areas of greater responsibility followingLateral moves 21%their rotations.Promotions 28%GMAP performance 2020Post-program retention 99%Lateral moves 26%Promotions 38%Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 142"
  },
  {
    "page": 143,
    "source": "text",
    "content": "The Women's Leadership Program RiseA global, nomination program focused on enhancing women's key An exclusive experiential program leveraging some of the best-in-classcapabilities to recognize and seize strategic career opportunities by institutions from around the world, designed for our executive directorsdeveloping critical capabilities and confidence while contributing to and associate vice president talent. This program increases ourcore objectives of our company. Areas of focus include strengthening company's talent pipeline and succession planning for critical roles withthe ability to navigate within the organization while maintaining an focus on critical leadership capabilities. This program submerges leadersauthentic leadership style, increasing cultural competence regionally, into creative and critical thinking environments, while cracking real-advancing skills in influencing and storytelling, advancing the ability to world challenges to amplify their enterprise view in preparation forrecognize and manage gender differences and subtle \"micro-inequities\" future upward succession. The participants have influence to driveby leading through courageous action. productive change, to attract, retain, lead and develop diverse talent,and ultimately to drive business results. We view this talented group aschange agents who can lead the organization into the future.Women's Leadership Program 2020Post-program retention 83%Rise 2020(formerly Enterprise Leadership Program)Lateral moves 41%Post-program retention 77%Promotions 32%Lateral moves 39%Promotions 45%Diverse Leader Program (U.S. only)This thought-provoking nomination program is an interactiveleadership journey designed to create a safe place where participants Executive Acceleration Experiencecan hone their leadership skills while exploring what it means to beAn inspiring and actionable learning experience designed to helpa person of color in a leadership role within the company. Whileour company's senior leaders further embed and amplify theirbuilding leadership proficiency, participants investigate the similaritiesleadership capabilities. The experience involves small cohorts beingand differences of leaders from other racial and ethnic groups, andimmersed in a variety of leadership principles, looking outside thedeepen relationships with their mentors through hands-on activitiescompany for broader inspiration and devising experiments they canand conversations.run with their teams.Diverse Leader Program 2020Post-program retention 90%Lateral moves 34%Promotions 32%Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 143"
  },
  {
    "page": 144,
    "source": "text",
    "content": "Our partners • Saïd Business School and the University of Oxford• Cornell UniversityThrough careful consideration, partnerships have been formed withglobal diverse thought leaders to support the Key Talent Portfolio. We • Center for Creative Leadershipwork with these external partners to provide the highest quality and • Stanford Universityimpactful learning experience.For more information on our training and education efforts andExamples of our partnerships include: programs, please see GRI 102-17 on page 38.• Duke Corporate EducationPromotion metrics1 2019 2020Men 47% 48%Women 53% 52%1Breakdown by gender, of all regular employees promoted during the fiscal year. \"Regular employees\" is defined as full and part-time employees only.Percentage of employees receiving regularGRI 404-3performance reviewsPerformance reviews 2016 2017 2018 2019 2020Executives1 100% 100% 100% 100% 100%Middle management 100% 100% 100% 100% 100%Line supervisors 100% 100% 100% 100% 100%Non-managers2 94% 93% 94% 94% 95%1\"Executives\" refers to the first two organizational levels below the chief executive officer.2All \"non-managers\" (previously \"individual contributors\") including those who are subject to a collective bargaining agreement (unions).Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 144"
  },
  {
    "page": 145,
    "source": "text",
    "content": "In 2020, as in years past, the percentage of performance reviewshas held steady for managers and employees. As a company wecontinue to utilize our current talent management system whichsupports company-wide performance management, development,talent reviews and succession planning. It helps ensure that ourworkforce is aligned with company objectives and focused on theirongoing professional development. The system allows managersand employees to keep track of business and development priorities,performance ratings, career aspirations, job experiences, skills,language proficiency, certifications and education.Throughout the year, managers are encouraged to discuss with each oftheir employees his or her strengths and development opportunities toalign on ways to grow capabilities and skills.Promotion metrics1 2019 2020Men 47% 48%Diversity and equal opportunityWomen 53% 52%$2 billion+GRI 405 Management approachin supplier diversity spend in 2020In 2020, our strong foundation in global diversity and inclusion (GD&I)uniquely positioned us to address the needs of employees, customersOur business objectives for diversity and inclusion are fully alignedand the patients we ultimately serve. We took necessary steps duringto drive long-term, sustainable business performance. In addition,uncertain times to accelerate and amplify our company commitment toour objectives for diversity and equal opportunity support the SDGscreate a more diverse and inclusive workplace. From supporting ourof advancing gender equality, providing decent work and economicemployees through the pandemic, addressing the increased attentiongrowth, reducing inequalities within and among countries andgiven to racial justice issues, continuing our work to address pay equity,Performance reviews 2016 2017 2018 2019 2020 and fostering disability and LGBTQ inclusion, we met the challenges of strengthening global partnerships.2020 with purpose, integrity and strategic intent.Our GD&I strategic framework focuses on the following priorities:Executives1 100% 100% 100% 100% 100%• Continue to build the diversity and inclusion capabilities of ourOur ability to accomplish our objectives is linked to the GD&Iglobal workforceStrategy-our framework for sustainable competitive advantage.Middle management 100% 100% 100% 100% 100%Through it, we align with our mission to save and improve lives, and • Ensure accountability at all levels of the organizationour purpose to create an environment of belonging, engagement,• Integrate diversity and inclusion into our business practices toLine supervisors 100% 100% 100% 100% 100% equity and empowerment that compels a globally diverse and inclusivedrive performanceworkforce which works to improve patient health.• Work to influence the environment, culture and business landscapeNon-managers2 94% 93% 94% 94% 95%to help achieve a more inclusive and sustainable worldMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 145"
  },
  {
    "page": 146,
    "source": "text",
    "content": "GD&I ambassador teams Governance and commitmentsOur GD&I CoE oversees diversity and inclusion across all business GD&I is a strategic business lever for performance-endorsed at thepractices and systems. The CoE leverages five diversity ambassador highest levels of the organization. Diversity and inclusion represent ateams to ensure integration into our business and people strategies. key dimension of our commitment to our ESG goals.Our Board of Directors has a clearly stated Diversity Policy, whichThe Global Disability Inclusion Strategic Councilrecognizes that maintaining a truly diverse membership, includingThe Council recognizes and values the importance of a disability- educational and professional background, gender, race, age, sexualconfident workforce and understands how full inclusion of people orientation, ethnic and national background and other differentiatingwith disabilities increases creativity and innovation for its employees, personal characteristics promotes inclusiveness, enhances the Board'scustomers, external partners and suppliers. deliberations, and contributes to the Board's overall effectivenessto better represent the long-term interests of the company andThe GD&I Extended Human Resources Leadership Team its shareholders. We stand ahead of our industry peers in therepresentation of women on the board.This team of Human Resources professionals supports the globalorganization by ensuring the successful adoption and integration Our commitment to GD&I is further reinforced by our CEO. Ourof diversity and inclusion capabilities into all practices, programs, company's CEO advocates for diversity and inclusion as a strategicprocedures and systems. A key outcome is to enable a diverse and business imperative through the following commitments:inclusive culture - one that attracts, engages, develops, motivates• Approving diversity metrics and reviewing progress againstand retains top talent globally.aspirational talent goals for women and under-represented ethnicgroups (UEGs)Employee Business Resource Group (EBRG) Executive• Driving accountability through meetings with the company's leadersLeadership Counciland engaging employees in company-wide events to review keyWith ten EBRGs representing different constituencies, the Council ofstrategic initiatives centered on GD&Iglobal EBRG leaders work together to support over 21,000 members• Conferring with the company's vice president of human resourcesworldwide, strengthen and diversify the global leadership pipeline andand chief diversity officer on innovation opportunities andprovide culturally relevant insights that drive our success.business solutionsGD&I Business Consortium • Leading authentic listening sessions with employees to engageon topics related to social injusticeThis Consortium, comprised of members from Business Strategy,Supplier Diversity, Clinical Trials and other key business functions,Equitable payenhances our business performance through GD&I bestpractices - creating a competitive business advantage and drivingWe have had a longstanding commitment to diversity and inclusionshareholder value. Our company's chief finance officer acts as theand fair and equitable pay. This commitment is consistent with ourConsortium's executive sponsor.core values of integrity, fairness, and treating all people with dignityand respect. Having the right culture, systems and practices for talentGD&I Line Advisory Councilrecruitment and development are critical in driving our company'sServing as an advisory role to the vice president, GD&I CoE, the ability to compete in global markets where talent is increasingly scarceCouncil provides input and feedback on the GD&I strategy and key and increasingly diverse. Diversity, equity and inclusion are ethical andinitiatives and offers perspectives on areas of progress, as well as strategic imperatives.opportunity, in relation to integrating GD&I into the company'sbusiness and people strategies.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 146"
  },
  {
    "page": 147,
    "source": "text",
    "content": "Pay equity is a very important principle at our company. We regularly Initiatives to help build a moremonitor and evaluate our pay practices and policies to ensure that weinclusive workforceare paying equitably.We chartered a Pay Equity Council which is chaired by our chief We focus our efforts to create a work environment wherediversity and inclusion officer and our SVP of Global Compensation and everyone has access to the same opportunities.Benefits and is comprised of leaders across GD&I, Compensation andGender equality is addressed at all levels of the organizationBenefits and Employment Legal.and a number of resources and development programs areWe have developed guidance to assist our recruiting team in making provided including:hiring pay decisions based on skills, work experience and other job-The Merck Women's Network, one of ten Employee Business Resourcerelated factors.Groups (EBRGs) at the company, is designed to develop and empowerWe look for opportunities to train our managers on our compensation women within the organization.strategy and programs to ensure their decision-making process isThe Women in Leadership Program is a global, nominationbased on legitimate job-related criteria and not personal characteristicsinitiative designed to support the advancement of women intosuch as gender, race or ethnicity.senior leadership ranks.Pay equity is a topic that is rightly receiving a great deal of attentionThe Emerging Women's Leadership Program is designed for femaleand scrutiny. While many other organizations have only recently begunprofessionals to begin to develop their capabilities to take on criticalto explore how to pay their employees equitably, providing fair andleadership roles in the future.equitable pay is one of the pillars of our compensation philosophy.The Re-invent Program recognizes that a disproportionate numberWe have engaged external experts and legal partners to conductof women take breaks throughout their career and that re-enteringannual pay equity studies in the U.S., and we are conducting similarthe workforce can sometimes mean taking a step back. In partnershipstudies in multiple countries around the world. These studies allow uswith the Society of Women Engineers (SWE), our company offersto make any necessary adjustments in order to ensure we continuethe Re-Invent Program, where individuals who have taken a pause into pay our employees equitably and fairly. By the end of 2021, wetheir careers can return in an internship role to a new position in theexpect that our pay equity studies will cover 75 percent of our globalcompany. This provides the individual with new work experience andpopulation, and we have plans to further expand the scope of theseenables a manager to assess performance of the individual, as well.studies in the coming years.Our Diverse Leaders Program is an interactive leadership journeyOur continuing focus on pay equity furthers our goal of being thedesigned to create a safe place where leaders of color-both men andemployer of choice for employees of diverse backgrounds, and itwomen-can hone their leadership skills while exploring what it meanssupports our efforts to attract and retain the best talent and rewardto be a person of color in a leadership role within the company.performance consistent with our Leadership Standards. These areclear business imperatives for our company and we remain firmlyOur company's external commitments to pay equity and gendercommitted to them.equality include the following:2020 Bloomberg Gender-Equality IndexOur company was named to the 2020 Bloomberg Gender-EqualityIndex (GEI) which recognizes companies committed to transparencyin disclosing gender-related metrics and investment in workplacegender equality.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 147"
  },
  {
    "page": 148,
    "source": "text",
    "content": "Paradigm for Parity D&I capability building, networkingIn 2018, we signed on to support Paradigm for Parity-a call-to-action and mentorship opportunitiesand model for gender equality. The goal of the coalition is to achievefull gender parity by 2030, with a near-term goal of women holding at In 2021, to support the learning and development of global employees,least 30 percent of senior roles. We have deepened our engagement we launched the Understanding your Role in Creating a Diverse andwith P4P through our implementation of the five-point action plan to: Inclusive Workplace myLearning course to strengthen our diversityand inclusion focus by continuing to build capabilities, awareness and• Minimize or eliminate unconscious biaseducation so we can nurture and grow a more inclusive culture within• Significantly increase the number of women in senior operating roles our company.• Measure targets at every level and communicate progress andresults regularly Support for working parents and caregivers• Base career progress on business results and performance,Using multiple listening methods-from employee focus groups, tonot on presencefrequent pulse checks, to employee surveys-we created a pathway• Identify women of potential and give them sponsors,to hear directly from the workforce on issues and challenges ofas well as mentorsimportance so that we could leverage employee input in the design anddevelopment of resources and benefits to best support their needs.United Nations Women's Empowerment PrinciplesTo learn more about how we support employee wellbeing,We continue tracking our progress against the United Nationsplease see GRI 401-2 on page 123.Women's Empowerment Principles. These principles reflect sevenareas of focus designed to promote gender equality in business.Research shows that at the current rate of progress, it will take Zero-tolerance policy against violence and202 years for women to achieve economic parity. The full economicharassment at the workplaceparticipation of women in the workforce will generate $12 trillion to$28 trillion in GDP.1In 2020, our company's policy for Prevention of Harassment,Discrimination and Bullying in the Workplace was updated toWe remain committed to equity across gender, race and ethnicityinclude a section on Workplace Violence in the U.S. versionas a strategy to drive business results and advance our mission. We(including Puerto Rico), as well as other applicable regional policies.continue to establish leadership programs to promote equality andpublicly report on our progress to achieve gender equality. Examples ofhow we achieve this objective, and our broader diversity and inclusion Opportunities for people with disabilitiescommitment, are as follows:We reinforce this potential through a culture of transparency andpledge alliance with external organizations that have a shared visionGender sensitive recruitment and retentionfor full disability inclusion.Talent acquisition plays a pivotal role in sourcing and attractingdiverse talent and in consulting with hiring managers to eliminateunconscious bias in the selection process. Using a gender decodertool for job postings, biased language is highlighted with suggestedalternative wording, helping to create gender neutral and inclusivejob descriptions.1The power of parity: How advancing women's equality can add $12 trillion to global growthMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 148"
  },
  {
    "page": 149,
    "source": "text",
    "content": "Disability: IN a common set of standards and procedures. The Web ContentAccessibility Guidelines (WCAG), the international standard fromOur company was recognized by Disability:IN® as the 2020 Employerwhich the new company-wide policy is based, details how to designof the Year for our exemplary policies, strategies and initiatives thatand develop our web enabled products and services, electronichave resulted in measurable results in areas of disability inclusivenessdocuments and software for digital accessibility. These guidelinesin the workplace, marketplace and supply chain.allow people with disabilities to equally perceive, understand,navigate and interact with our company's websites and tools.Valuable 500Our company announced its membership in The Valuable 500 inAddressing injustice and disparityJanuary 2020. The Valuable 500 is dedicated to unlocking thebusiness, social and economic value of people living with disabilities,Systemic racial injustices and disparities were among the polarizingensuring women and individuals with disabilities are provided ampleand major news events characterizing 2020. These events, promptedresources to thrive in the workplace.by the widely publicized incidents of racism and discrimination,enabled our employees to leverage our ongoing efforts to provideMental health a psychologically safe place for employees to have bold, inclusiveconversations and engage in constructive dialog with peers andteams about the significance of these events.One Mind at Work - Mental HealthWe responded in several ways:Our company's CEO signed the One Mind at Work Charter pledgingto make mental health a priority by protecting, supporting and• Kenneth C. Frazier was among the first CEOs to address theirenhancing employee wellbeing in the workplace. Through Oneemployees about racial injustice, and also make a public statementMind at Work, which leverages the support of The Kennedy Forum,about systemic racismwe collaborate with One Mind at Work to enable broad-scale• Leaders participated in listening, learning and action sessions totransformation in how mental health is viewed and approached inaddress unconscious bias, discrimination and exclusion, whilethe workplace, and how we can gain equity, collaboration and parityasking their employees to do the samebetween physical and mental health.• Updates were provided to the Board of Directors on our ongoingR U OK? Mental Health and Wellness efforts to address social injustice both internally and externallyDuring 2020, and in response to struggles with stress and emotional • Chapter leaders from our EBRGs, including the League ofwellbeing, particularly due to the global pandemic, we introduced a Employees of African Descent (LEAD), Alianza and the Asianew program, R U OK? Day Mental Health and Wellness e-Learning Pacific Association (APA), met with members and leaders to hostfor Managers. The e-Learning program, R U OK?, provides facts, courageous conversations in a safe, open settingtalking points and tips managers can use with team members to • In response to the anti-Asian events, we created space for dialoguediscuss emotional wellbeing and mental health. It is one more way we about how each of us can work to create a safer and more equitableare promoting a culture of wellbeing and inclusiveness as part of LIVE company community and societyIT, our holistic approach to wellbeing.• We provided Resources for Living, an employee assistanceprogram, to help our employees cope with trauma andDigital accessibility anxiety associated with social and racial unrest during asocially isolated timeWhile teams across the company have been practicing digital• Delivered weekly Bold & Inclusive Conversations training sessionsaccessibility with varying capabilities and methods, in 2020 a newto build capabilities of managers and employees globallycompany-wide policy was launched to aligns these teams underMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 149"
  },
  {
    "page": 150,
    "source": "text",
    "content": "We enhanced collaboration and alliances with key external partners Year-Upon diversity and inclusion, including:Our company is among the more than 250 corporations partneringwith an innovative nonprofit organization, Year Up. This nonprofitCEO ACT!ON for Diversity and Inclusion® ensures equitable access to economic opportunity, education andOur company has been among the earliest members of this justice for all young adults-no matter their background, income ororganization, pledging in 2017 to reach diversity and inclusion goals. zip code. They accomplish this goal by closing the opportunity gapWith the elevated social media unrest and news prompted by the in the job market for economically disadvantaged youth by offeringkilling of George Floyd in 2020, we deepened our engagement six months of intensive training and a six-month corporate internshipwith this organization to drive change. We participated in \"A Day in information technology, financial operations, sales and customerof Understanding,\" candid dialogue to bring people together, support, business operations or software development and supportand offer unconscious bias education to all employees within the at major corporations. To date, 24 student internships have beenglobal enterprise to build awareness of ways to mitigate bias in the provided through Year-Up by our company.workplace and foster inclusion.Expanding our pipeline of diverse talentIn response to external unprecedented events, we renewed andreaffirmed our commitment to accelerating representation in areasIn 2020, we greatly expanded outreach to Historically Black Collegeswhere there was underrepresentation for various populations,and Universities (HBCUs) by partnering with several organizations,including women, Asian, Black/African American and Latinoincluding the College Diversity Network and the National Urbanpopulations. We accelerated our commitment to Black/AfricanLeague, to focus on building deep partnerships with colleges, students,American and Latino talent, and deepened our investments andfaculty and alumni of HBCUs.outreach with Black and Latino populations. We worked diligentlyto build the pipeline of African American/Black and Latino executiveand emerging leaders to reflect the availability of external talent.These investments include strategic alliances with thefollowing organizations:MANRRSOur company's Animal Health Division partners with Minorities inAgriculture, Natural Resources and Related Sciences (MANRRS)to identify diverse talent from the agricultural sciences and relatedfields and to expose them to the variety of career paths available inaddition to the veterinarian field. Technology, animal intelligence,smart data products and services for the management andwellbeing of livestock, fish and pets-areas where MerckAnimal Health Intelligence (MAHI) is a global, world-classleader-are examples of exciting career paths that are availableto today's talent, but where awareness is low. To deepen itsinvestment with MANRRS, Merck is a platinum sponsor of theorganization conferences.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 150"
  },
  {
    "page": 151,
    "source": "text",
    "content": "We also focus on systemic barriers that limit the candidate pool based Fostering a culture of inclusionon geographic location of open positions and talent residency, and jobLeaders and managers are held accountable for maintaining anprerequisites of having prior pharmaceutical experience. To broadeninclusive culture across the business enterprise. We acknowledgeour access to diverse talent, we post some positions with an optionthose who excel in demonstrating inclusive behavior through theto work virtually, offer relocation services and are agnostic to priorcompany's INSPIRE Awards. Launched in 2019, INSPIRE fosters apharmaceutical experience. We leverage key partnerships such as:culture of recognition and engagement by empowering all employees• Executive Leadership Council (ELC) to recognize others. By the end of 2020, INSPIRE recorded over300,000 recognition moments across 85 countries.• INROADS College Links• National Urban League Learn more about how we engage with employees in GRI 401on page 118.• ALPFA• National Action Council for Minorities in Engineering (NACME)Economic inclusion, health equity and• Ascendworkforce development• Out & Equal• Disability:IN In 2020, a cross-functional working Council was chartered to improvecoordination of the company's longstanding global efforts in health• Best Buddiesequity, economic inclusion and external workforce development.• The International Labour Organization (ILO) Global Businessand Disability Network (GBDN)Economic inclusion• Women of Color In Pharma (WOCIP)Our commitment to diversity and inclusion includes providing decentwork and economic inclusion for diverse suppliers, including minority,Measuring for impact women, veteran, LGBT and people with disability-owned businesses,as well as small business enterprises. During 2020, the company's 35thWe establish clear, measurable goals with our leaders and throughout anniversary of the Economic Inclusion & Supplier Diversity (EI&SD)the business enterprise in the following areas: program, we exceeded our corporate goal of $2 billion in the U.S. andachieved an economic impact of $4.8 billion, with over 30,000 jobsWomen and under-represented ethnic group (UEG) being sustained and created by our diverse suppliers.representationWe further deepened access for economic inclusion during 2020 byLeaders and managers are highly encouraged to incorporate clear introducing the first virtual engagement Opportunity Fair, entitled,diversity and inclusion goals as part of their annual performance \"It begins with Me.\" More than 2,000 U.S. and global companypriorities and reviews. In addition, we utilize specific, time-bound category managers and stakeholders participated in this Opportunityaction plans with aspirational targets to increase the representation Fair to, \"Meet a supplier, Mentor a supplier or Measure impact.\"of women globally and UEGs in the U.S. leadership positions. We have As a result of the Opportunity Fair, 426 capability statements fromdiversity metrics and review progress against aspirational talent goals diverse suppliers were obtained, representing further opportunity forfor women and UEGs at the most senior levels of the organization. economic inclusion development and growth.For more information on our supplier diversity program, please seeGRI 414 on page 157.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 151"
  },
  {
    "page": 152,
    "source": "text",
    "content": "Health equity that have prevented many Black Americans from the opportunity toearn success, OneTen has set out to change the way companies provideU.S. clinical operationsmore equitable environments to drive better business outcomes andWe have set goals to ensure appropriate diversity representation of benefit all employees.patients participating in clinical trials in relevant therapeutic areas.Learn more about the OneTen initiative here.Learn more about our commitment to diversity in clinical trialson Merck.com.INROADS College LinksWorkforce development Since 2019, we have partnered with INROADS, an internationalOneTen nonprofit organization that prepares talented, diverse youth forcorporate and community leadership, and launched a yearlong CollegeIn 2020, Kenneth C. Frazier, our company's chairman, signed on asLinks program for high school students in Newark, New Jersey, toco-chair for OneTen, a new initiative that aims to close the opportunityincrease college and career readiness.gap for Black women and men in America and to make a meaningful,measurable and lasting systemic impact on racial and economic justice. To learn more about our training and development programs forRecognizing that the current system has reinforced systemic barriers employees, please see GRI 404 on page 140.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 152"
  },
  {
    "page": 153,
    "source": "text",
    "content": "GRI 405-1 Diversity of governance bodies and employeesFemale representation, 2016 2017 2018 2019 2020by job category (global)Board 23% 23% 33% 46% 46%Executives1 22% 22% 20% 20% 33%Senior management2 25% 25% 27% 30% 31%All managers3 39% 39% 41% 42% 42%All employees 48% 49% 49% 49% 49%New hires 51% 49% 51% 51% 50%Promotions 51% 52% 52% 53% 52%Underrepresented 2016 2017 2018 2019 2020ethnic group (UEG)representation, by jobcategory (U.S.)Board 23% 15% 17% 23% 31%Executives1 33% 33% 30% 40% 25%Senior management2 15% 17% 19% 21% 20%All managers3 19% 20% 22% 23% 24%All employees 25% 26% 28% 29% 30%New hires 33% 37% 36% 35% 40%Promotions 25% 28% 28% 30% 32%Note: Our company has publicly disclosed EEO-1 information since 1999. Our 2020 data is available on the ESG Resources page of our corporate website.All Board figures above are derived from our proxy statement filed the following year. All other figures are as of December 31, 2020.1 \"Executive\" is defined as the executive team who reports to the chief executive officer.2 \"Senior management team\" is defined as vice presidents and above, not on executive team.3 \"Management role\" is defined as all other managers with at least one direct report.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 153"
  },
  {
    "page": 154,
    "source": "text",
    "content": "Underrepresented ethnic group (UEG) Total Black/ Latino/ Asian All Otherrepresentation, by ethnicity (U.S.) African HispanicAmericanBoard 31% 31% 0% 0% 0%Executives1 25% 20% 0% 5% 0%Senior management2 20% 3% 5% 11% 1%All managers3 24% 5% 5% 13% 1%All employees 30% 8% 5% 15% 2%New hires 40% 11% 7% 19% 3%Promotions 32% 9% 6% 15% 2%Note: Our company has publicly disclosed EEO-1 information since 1999. Our 2020 data is available on the ESG Resources page of our corporate website .All Board figures above are derived from our proxy statement filed the following year. All other figures are as of December 31, 2020.1 \"Executive\" is defined as the executive team who reports to the chief executive officer.2 \"Senior management team\" is defined as vice presidents and above, not on executive team.3 \"Management role\" is defined as all other managers with at least one direct report.Human rights assessmentGRI 412 Management approachAs stated in our Human Rights Public Policy Statement-we strive toavoid causing or contributing to adverse human rights impacts throughour own activities and seek to prevent or mitigate adverse impacts thatare directly linked to our operations and products.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 154"
  },
  {
    "page": 155,
    "source": "text",
    "content": "Human rights issue Policies / standards GovernanceLead functionHealth & safety X X X X Global Safety & EnvironmentForced labor & human trafficking X X Human ResourcesDiscrimination & harassment X X X Human ResourcesChild labor X X Human ResourcesFreedom of association X X Human ResourcesWorking hours X Human ResourcesPrivacy X X X Global Privacy OfficeSecurity X X X Global SecurityAccess to Grievance Mechanisms X X X X X X X X X X Office of EthicsSuppliers & Business Partners X X X Global Supplier ManagementsthgiRnamuHyciloPcilbuP namuHyciloPsecruoseRnamuH& robaLyciloPsthgiR & htlaeHyciloPytefaSreilppuS& tnemerucorP yciloPsnoitaleRrentraPssenisuBtcudnoCfo edoCtnemeganaMnoitamrofnIyciloPnoitcetorP&ataD& ycavirPyciloPnoitcetorPgnidnopseR&gnitropeRyciloPtcudnocsiMotniecneloiVfonoitneverPdradnatSecapkroWsmraeriFfonoissessoP dradnatSWe've put in place appropriate policies, processes, training and monitoring systems to address key human rights issues. Support and respect for theprotection of human rights is embedded and reflected in our operational policies and procedures, as summarized in the table below.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 155"
  },
  {
    "page": 156,
    "source": "text",
    "content": "RemedyEmployee training on human rights policiesAs part of our efforts to protect against business-related human rights GRI 412-2and proceduresabuses, we have established a company-based grievance mechanismthat allows employees and workers to report concerns in a confidentialBusiness-related human rights issues are embedded within ourmanner without fear of retaliation (see the Speak Up section in ourinternal training programs to help maintain employee awareness andhuman rights policy).understanding of our company's expectations. Examples of humanOur company-based grievance mechanism and associated reporting rights related topics covered by existing training programs includechannels are fundamental to ensuring that employees and workers health and safety, privacy and data protection, harassment andhave access to effective remedy whenever human rights impacts occur. discrimination, diversity and inclusion, as well as training that explainsand how to confidentially report concerns, emphasizing the importanceWe expect our suppliers to encourage all workers to report concerns of speaking up. Completion of assigned training is closely monitoredor suspected illegal activities without threat of reprisal, intimidation or and reported.harassment, and to investigate and take corrective action if needed. Inaddition, we expect them to provide workers with information on how For more information on our training and development programs,to confidentially report concerns, and ensure that reporting workers please see GRI 404 on page 140.are protected from retaliation.Governance Investment agreements and contracts that includeGRI 412-3human rights clauses or underwent screeningOur oversight and monitoring of business-related human rights risks issupported by relevant internal functions and business units, includingHuman Resources, Global Safety & Environment; Global Supplier Agreements and contractsManagement; Supply Chain Management, Ethics & Compliance;Our Global Supplier Management Group (GSMG) function overseesGlobal Security, Global Privacy Office, Information Risk Management;contract development and execution activities associated withEnterprise Risk Management, Office of Ethics and the Office of Socialthe sourcing and selection of our suppliers of goods and services.Business Innovation.(See Supplier Social Assessment section.)Through our standard contracts and agreements, we seek a writtenOperations that have been subjected to human commitment from suppliers to respect and abide by the principles setGRI 412-1rights reviews forth in our company's Business Partner Code of Conduct (BPCC).Our Business Partner Code of Conduct states that businesspartners are expected to uphold the human rights of workers andWe perform supplier labor and human rights audits (using independenttreat workers with dignity and respect the protection of internationallythird-party service providers) at select direct material suppliers'proclaimed human rights and ensure that they are not complicit infacilities located in countries that are known to present an increasedhuman rights abuses.risk of human rights abuses (See Supplier Social Assessment section).For more information, please see GRI 414 on page 157.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 156"
  },
  {
    "page": 157,
    "source": "text",
    "content": "Supplier social assessmentGRI 414 Management approachSupplier due diligence assessment for laborpractices and human rightsWe respect human rights and support transparency in our supplychain. We are committed to upholding the Pharmaceutical SupplyChain Initiative (PSCI) Principles, and we require our suppliers tooperate in compliance with all applicable laws. We have a formalprogram led by our Global Supplier Management Group (GSMG) toevaluate the risks for labor and human rights (LHR) in our supply chain.Our policiesOur policies serve as our standards of conduct for engaging withstakeholders. They are founded on our Code of Conduct (Our Values &Standards) and are used to navigate and guide our decisions. They helpus identify, address and mitigate risks.For information on our policies, please visit our Policies & Positionsand ESG Resources pages of our corporate website.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 157"
  },
  {
    "page": 158,
    "source": "text",
    "content": "Human rights and labor risks Suppliers' responses are used to judge whether that supplier hasprograms and/or procedures in place to address potential risks for laborWe recognize that companies with supply chains that extend into high- and human rights, including modern slavery and human trafficking.risk countries potentially face greater LHR risks. Our company can be The information gathered as part of due diligence is used to determineexposed to these risks through our supply chain, as some of our third the acceptability of suppliers' local practices. Results are then appliedparty suppliers and service providers operate in higher-risk countries. by GSMG to inform our supplier selection and risk managementprocesses.To help manage and address potential risks associated with third-partybusiness relationships, GSMG has an established a cross-functional, Contracts: Seeking written commitment from suppliers to respect thethird-party risk management committee and program. LHR risks are principles set forth in our Business Partner Code of Conduct throughconsidered as part of our third-party risk management activities. We our contracts/agreements. Our contract templates contain a BPCCalso recognize that potential risks may exist beyond Tier 2 suppliers. compliance clause, that includes provisions related to modern slavery.During 2020, we worked to detect and address the risks in our supplychain by: Auditing: Performing LHR audits at select supplier facilities to verifytheir conformance with our company's expectations (as stated inSupplier selection: Selecting suppliers that are socially responsible our BPCC), and by working with them to address identified non-and who share our company's commitments to ethics and integrity. We conformances. We use independent third party audit firms to performstrive to obtain the services, goods, active ingredients, components, announced LHR audits at suppliers' facilities. When preparing ourfinished goods or other products in a way that is lawful and fair. audit schedule, we consider the industry risk, the category of materialssupplied, the country in which the supplier operates and results of pastExpectations: Setting and communicating our expectations of due diligence.suppliers, including those related to child labor, forced labor andhuman trafficking. We use our Business Partner Code of Conduct to Remedial actions: Tracking and reporting (to senior management) oncommunicate our expectations. It has been translated for all counties the closure of remedial actions taken by suppliers to address identifiedin which we operate. non-conformances (gaps/concerns) revealed by supplier LHR auditing.Supply chain mapping: Mapping our supply chain to identify which Monitoring: Assigning relationship managers from within GSMG toof our suppliers operate in countries that are known to present a oversee and monitor the performance of key suppliers. We continue tosignificant risk of LHR issues. We use this information to help us decide hold suppliers accountable for meeting their contractual obligations.upon the level of due diligence that may be necessary.Governance: Using our Third Party Risk Committee to help governDue diligence: Conducting appropriate supplier due diligence to help and oversee the management of risks associated with third partydetermine the level of risk presented by suppliers, including potential relationships. This committee is chaired by our company's SVP fornew (prospective) suppliers as well as our existing suppliers. Global Procurement. The role of our Third Party Risk Committee(and associated Third Party Risk Team) is to assist senior leadershipOur supplier due diligence process for LHR targets direct materials by providing independent and objective oversight, monitoring andsuppliers, including external manufacturing suppliers and contract reporting in relation to the risks presented by third parties.manufacturing organizations, regardless of their geographic location. Aself-assessment questionnaire is used to gather information on freely Engagement: Engaging and seeking input from relevant stakeholders,chosen employment, child labor, employment practices, employee including GSMG, Ethics & Compliance, Legal, Global Safety anddisclosures, fair treatment, wages, benefits and working hours. Environment and Office of Social Business Innovation.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 158"
  },
  {
    "page": 159,
    "source": "text",
    "content": "Collaboration: Working with PSCI to develop training, tools and • Holding suppliers accountable for addressing non-conformancesmaturity models and share knowledge across our industry and with revealed by LHR auditsour suppliers.• Conducting a Human Rights Compliance Assessment (HRCA) usingDanish Institute assessment toolTraining: Training GSMG professionals with responsibility for supplierselection, oversight and monitoring, including the assignment of • Participating in the activities/initiatives of PSCI's Human Rights andonline courses: Labor Sub-Committee• Business Partner Code of Conduct• Mitigating Modern Slavery Risks in Supply ChainsGRI 414-1 New suppliers screened using social criteria• Third Party Risk ManagementIn 2020, we worked with PSCI to develop and providePlease see GRI 102-9 on page 29 for additional information on oursuppliers training:supply chain risks and associated KPIs.• Forced Labor & Modern Slavery• Operationalizing the PSCI Human Rights Principles• Human Rights RisksPublic policy• Responsible Sourcing of IngredientsIn addition, 14 Material Specific Human Rights and EnvironmentalImpact Assessment guides were developed. The training and toolsGRI 415 Management approachare provided to suppliers through PSCI and to our employees on aninternal webpage.The Merck Political Action Committee (PAC) engages in the politicalprocess, at both the federal and state levels, to educate policymakers,Next stepslawmakers and candidates on policy issues critical to our industry andour company's core mission to invent new medicines and vaccines toWe will continue working on our efforts to identify, assess andsave lives. The Center for Political Accountability has recognized theaddress LHR risks within our operations and supply chains. TheseMerck Political Action Committee as a Trendsetter in their annual CPAefforts will include:Index of Corporate Political Disclosure & Accountability report.• Investigating all reported concerns promptlyWe continue to make bipartisan contributions that are carefully• Conducting supplier labor and human rights due diligence toconsidered on a case-by-case basis. In establishing our PAC politicalidentify and address risksgiving priorities, our Contributions Committee considers various• Auditing select suppliers to verify conformance with standards factors to prioritize candidates' who support policies that enhancefor LHR innovation and patient access to health care.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 159"
  },
  {
    "page": 160,
    "source": "text",
    "content": "government-affairs activities made the recommendations for specificcontributions based on the budget and priorities approvedGRI 415-1 Political contributionsby the Contributions Committee.Outside legal counsel conducted a thorough review of all proposedWe are committed to participating constructively and responsiblycontributions to ensure that they were permitted under state law.in the political process, and to providing clarifying analysis andFinal approval was provided by the Corporate Secretary.information regarding the issues that affect our business andpatient care. The only other country in which we provide corporate contributionsto candidates or political parties is Australia. These contributions areIn 2020, we contributed a total of $985,450 to support thesubject to the same policies and governance procedures discussedcampaigns of 562 candidates for state-level offices in 27 states plusabove.the District of Columbia. We also supported state legislative leadershipcommittees of both parties, industry-affiliated PACs and national For more information on our political contributions, please visit ourorganizations representing elected state officials that meet periodically Transparency Disclosures page on Merck.com.to discuss policy issues. Our representatives involved in state-Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 160"
  },
  {
    "page": 161,
    "source": "text",
    "content": "Customer health & safety We provide appropriate and ongoing training on cGMP for ouremployees, so they are prepared to perform their duties effectively.Our quality system not only ensures that all applicable employees aretrained, but also monitors the effectiveness of the training provided.GRI 416 Management approach Our company's medicines and vaccines are widely tested beforethey are approved for marketing. This testing is governed by acomprehensive regulatory scheme and by our research policies. WeOur quality strategy is focused on maintaining sustained assess the safety of our products in rigorous nonclinical and clinicalquality and compliance excellence through a digitally enabled trials prior to seeking regulatory approval. Following approval of ourQuality Management System (QMS), oversight and periodic review of drugs, vaccines, or devices the company continues to monitor theirour quality performance, a Quality Management Maturity (QMM) safety profiles.mindset and a learning culture. Our quality strategy is a key enablerto ensuring patient safety, and the overall quality and continuous Our company's chief medical officer (CMO) holds overall responsibilitysupply of our products. for the benefit:risk determination of our pipeline and marketedproducts, provides medical oversight for all clinical programs,We operate in a highly complex and ever-changing regulatory supervises the development and implementation of medical policieslandscape driven by many different factors, including novel scientific (including those related to data transparency and the sharing ofdiscoveries and technological advancements. Specifically, we are using clinical data) and has responsibility for the design, execution andand exploring new technological advancements such as integrated IT implementation of pre-registration expanded access (\"compassionatetools, artificial intelligence (AI) and streamlined digital platforms to use\") programs.further enhance how we manufacture high-quality products.Our company's Global Clinical Safety and Pharmacovigilance (GCS&PV)We apply and adhere to a strict set of quality standards, and we have function manages a global system for the collection, review andpolicies and procedures in place to identify, measure, control and reporting of Adverse Experience (AE) reports received by our companysustain product quality excellence. worldwide, and for the continuous assessment of product safety. Ourcompany's chief safety officer holds overall responsibility for the safetyOur Global Quality Compliance organization is responsible forof our products.establishing the standards to ensure that all of our company's productsare manufactured, tested, released and distributed in compliance with Our industrial hygiene risk assessments require evaluation of theregulatory requirements. effectiveness of control measures. Risk-based exposure monitoringis also conducted to verify the effectiveness of installed engineeringWe continuously strive to improve these standards in order to enhancecontrols, and improvements are made as needed. We use conservativeprocedures and ensure ongoing compliance with current Goodsafety factors to set low de minimis levels for environmental releasesManufacturing Practices (cGMPs).until we have sufficient data to fully understand their impacts onaquatic organisms. Levels are reviewed and updated as new databecome available.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 161"
  },
  {
    "page": 162,
    "source": "text",
    "content": "Incidents of non-compliance concerning the healthGRI 416-2and safety impacts of products and servicesProducts listed in the FDA's MedWatch Safety AlertsSASB 250a.1for Human Medical Products databaseFatalities associated with products as reported inSASB 250a.2the FDA Adverse Event Reporting SystemSASB 250a.3 Recalls issued, and total units recalledQuality and product safety 2016 2017 2018 2019 2020Number of product recalls in the U.S.1 1 0 2 1 2Percentage of sold units recalled during a given year 0.01% 0.01% 0.14% 0.01%0.50%(recall rate globally)11 Definition of Recall Classifications.Counterfeit products In 2020, we continued our commitment to increasing our focus in thisarea and have strategically enhanced our ability to make a long-termWe invest in an industry-leading, rigorous and intelligence-led product- impact on patient safety through various education campaigns.integrity strategy that is solely focused on protecting patients from theWe are committed to cooperating with relevant government agencies,harm associated with counterfeit, diverted and other illicit medicines.other pharmaceutical manufacturers, wholesalers, distributors,Our company's Global Security Group oversees the global Producthealth professionals, consumer groups and key related organizationsIntegrity strategy and leads its execution. The strategy seeks toin fighting the problem of counterfeit pharmaceutical products and inprotect our patients and our company's reputation from the negativeeducating the public about the risks of counterfeit products and how toimpacts of counterfeit and illicit medicines using a three-prongedprotect against them.strategy focused on:• Securing the supply chain This effort includes a multipronged approach to communicatingthe threat that counterfeit medicines pose and to mitigating this• Investigations and enforcementthreat as effectively as possible, while recognizing that it cannot be• Raising public and stakeholder awareness entirely eliminated.Our efforts in public and stakeholder awareness involve raisingCollaboration and information-sharing in order to raise public andawareness of the risks posed by counterfeit medicines, and advocatingstakeholder awareness of the issue and risks are a crucial focus of ourfor increased enforcement to shape relevant regulatory requirements.Product Integrity program. Through active partnerships with otherMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 162"
  },
  {
    "page": 163,
    "source": "text",
    "content": "Anti-counterfeiting1 2016 2017 2018 2019 2020Investigations of suspected counterfeit products1 134 137 274 560 572Substantiated cases of counterfeit products 102 76 226 210 711 Prior-year data have been adjusted to reflect the current status of each event as of April, 2021.2 Evidence from ongoing investigations of suspected counterfeit products can result in recategorization.pharmaceutical companies, and with organizations focused on security, intelligence and understanding of the counterfeiters and the threats topatient safety and public health, we provide effective advocacy on public health. Our company also has forensic detection devices in theQuality and product safety 2016 2017 2018 2019 2020 high-priority anti-counterfeiting policy initiatives. field to analyze and detect counterfeits in regions around the world.Number of product recalls in the U.S.1 1 0 2 1 2 These collaborative efforts support the production of reports, As counterfeiters improve their skills and techniques, our forensicwhitepapers and data-circulation initiatives, as well as promote scientists have pioneered the use of several analytical tools for thePercentage of sold units recalled during a given year 0.01% 0.01% 0.14% 0.01% 0.50% the intelligence sharing necessary to combat threats from detection and characterization of counterfeit medicines and continue(recall rate globally)1 counterfeit medicines. to explore new analytical tools that would increase their forensictesting capabilities. Lab findings are shared with regulatory and/orThe above table details the number of new suspected and law-enforcement agencies, and may be used to support subsequentsubstantiated counterfeit events in 2020, as well as the number of enforcement actions and legal proceedings.events introduced in previous years and the subsequent outcome forthese events. The data below reflects the current status of each event, There were 402 unique questioned samples received as evidence andas of April 2021. prepared for forensic testing in relation to active events in 2020. Aspart of our proactive awareness program, throughout 2020, GlobalThroughout 2020, Global Security addressed 1,947 product integrity Security trained approximately 4,730 law-enforcement personnel inevents in 86 countries, involving counterfeit, diversion, supply chain more than 50 countries regarding the patient safety danger related tosecurity, tampering, financial integrity and brand security (non-MSD, counterfeit and diverted medication.unapproved generic product). Approximately 23 percent of theseevents have been proactively investigated by Global Security to identify Global Security also launched an internal training program on thenew or emerging product integrity threats, or to further characterize Counterfeit, Diversion and Tampering (CDT) reporting process in lateand mitigate known threats. 2017. To date, more than 67,000 employees and contractors havecompleted this training globally.We enable meaningful enforcement actions as a key strategic priority,and in 2020, our product integrity activity led to 52 arrests and theSupply chain security and serializationseizure of more than 2,300 units of counterfeit or illicit products of ourcompany. There were 23 prosecutions resulting from product integrityOur proactive focus on managing supply chain security risk is basedinvestigations in 2020.on our careful implementation and management of strict policiesAnother crucial aspect of investigations is the forensic analysis of and procedures designed to protect the legitimate distribution of ourquestioned products. This forensic testing is aimed at concluding company's products. We require customers to purchase our productswhether a questioned product is counterfeit, diverted or otherwise directly from our company or from authorized distributors listedillicit. Counterfeit products are characterized in order to gain further publicly on our corporate website.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 163"
  },
  {
    "page": 164,
    "source": "text",
    "content": "We maintain our commitment to ensure compliance with established Nigeria, India, Saudi Arabia, the Middle East, the U.S., EU,company policies, standards and procedures throughout the supply United Kingdom, Norway, Iceland, Switzerland, Liechtenstein andchain by identifying vulnerabilities and threats to the supply network. Russia, and will soon be required in Indonesia, Brazil, South AfricaResources are positioned globally to monitor and manage our security and Pakistan. Each country's regulations are different, making it veryprograms and investigate incidents when they occur. challenging for our packaging sites and distribution networks to meetthese diverse and intricate requirements with additional complexity asAs a certified Importer under the Customs Trade Partnership Against reporting requirements are phased in.Terrorism (CTPAT) Program, we are validated by U.S. Customsand Border Protection as an elite Tier 3 Member recognized as We launched the Global Product Serialization Initiative in 2012,implementing best practices in supply chain security. This adds an with the goal of meeting these varying requirements in a robust,important layer to the security of our products and materials imported standardized and effective way based upon GS-1 standards. We areto the U.S. working with industry associations and regulatory authorities to helpshape these new requirements, and advocate for simple, standardizedSerialization-adding a 2D barcode with a unique identification and common-sense regulations that can be effective at protectingnumber on each package that goes to market-is one of the tools against counterfeit medicines.we are investing in to secure our supply chain and prevent or detectcounterfeiting. A serial number on individual packages will enable In addition to our compliance with regulatory requirements related toanyone along the supply chain-from a distributor to a pharmacist serialization, we are also exploring opportunities to deploy voluntaryto a patient-to scan the code and verify it as a serial number serialization and secondary authentication technologies to furthercorresponding to a genuine product of our company. Serialization enhance the security and traceability of our products. These multi-adds a robust layer to the company's product security platform. factor authentication systems would be enabled by blockchain nodesWhen associated with a regulatory mandate that specifies effective and applications that allow for secure and immutable product tracingimplementation and reporting to a national database, this method of that could be accessed by all supply chain partners and end users.product tracking can become a more meaningful product security tool. We are currently running several proof-of-concept and pilot studiesinvolving these emerging technologies, as well as participating in activeMany jurisdictions around the world are requiring serialization industry associations, such as PharmaLedger, to further develop andon pharmaceutical packages or are considering such mandates. apply these digital solutions.Serialization is required today in China, Turkey, Argentina, South Korea,Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 164"
  },
  {
    "page": 165,
    "source": "text",
    "content": "Clinical trial site monitoring, design, conduct In accordance with our public policy position statement, allinvestigational studies in human subjects are conducted in aand oversightmanner consistent with laws, regulations and guidelines forthe protection of human subjects, including those issued by theOur company has long been committed to sharing the results ofInternational Council for Harmonisation Good Clinical Practiceour clinical trials, regardless of their outcome, in a timely manner.(ICH GCP). However, individual country regulations and guidelinesIf a clinical trial of a marketed product is terminated early for safetyshould remain the primary determinant of specific requirements forreasons, we will promptly disclose medically important informationthe conduct of medical research.to regulatory authorities and the public, update the status on clinicaltrials.gov within 30 days and submit a manuscript to a journal (or post We have a commitment, where appropriate, to the study of diversea summary online) within 12 months after the last patient's last visit patient populations, including underrepresented groups, women andoccurs. If the trial was terminated for efficacy reasons, the results will children, in our clinical trials in all regions of the world. As a result,be disclosed within 12 months after the last patient's last visit occurs. we strive to obtain information among diverse populations, ensuringSummaries of terminated trials will provide information about patient a thorough evaluation of the safety and efficacy of our medicinesdisposition, safety and adverse experiences, as well as an explanation and vaccines. These efforts allow us to seek regulatory approvalsas to why the trial was terminated early. throughout the world and thereby offer our medicines globally topatients who need them.We comply with all applicable laws and regulations associated withthe registration of clinical trials in publicly accessible registries and In addition to complying with our company's global standards, thesubsequent posting of the results from these trials. We have put into conduct of our clinical trials adheres to the International Council forplace the processes necessary for compliance with the Food and Drug Harmonisation Good Clinical Practice standards and to the principlesAdministration Amendments Act of 2007 and the European Clinical that have their origin in the Declaration of Helsinki.Trial Directive 2001/20/EC, including those related to clinical trialregistration and posting results. When appropriate, an internal standing Data-Monitoring Committee(DMC) of our research laboratories' senior managers reviews unblindedFor those who analyze, report or publish the results of clinical trials, data from ongoing trials in a pre-specified, scientifically acceptablea clinical trial registry also provides information on trials in progress manner. The goals of the DMC are to protect the safety of trialand the ability to track such trials over the course of development. participants and assess whether the risk/benefit profile is favorable.Company-sponsored and -conducted clinical trials involvingpatients assigned treatment with investigational and marketed The DMC's recommendations are communicated internally to relevantproducts are registered at trial initiation on www.clinicaltrials.gov, scientists and can be distributed externally to clinical investigators,www.clinicaltrialsregister.eu and www.encepp.eu. review boards or regulatory agencies, as appropriate.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 165"
  },
  {
    "page": 166,
    "source": "text",
    "content": "Phase II-V clinical trials patients by region 2016 2017 2018 2019 2020Asia Pacific 25% 15% 22% 28% 42%Central & Eastern Europe, Middle East & Africa 12% 7% 7% 8% 8%European Economic Area 36% 43% 21% 33% 20%The Americas 10% 6% 9% 7% 15%U.S. 17% 29% 41% 24% 15%Trial disclosures activities 2016 2017 2018 2019 2020Manuscripts of clinical trial results and related papers submitted 152 133 153 290 156to peer-reviewed journalsNumber of GCP/PV inspections conducted by regulatory 103 128 96 99 52agencies worldwideGCP/PV inspections 2016 2017 2018 2019 2020GCP/PV inspections by regulatory agencies of the company or 0 0 0 0 0clinical trial investigators that led to significant fines, penalties,warning letters or product seizuresMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 166"
  },
  {
    "page": 167,
    "source": "text",
    "content": "Please visit the U.S. Food & Drug Administration's (FDA) MedWatchPhase II-V clinical trials patients by region 2016 2017 2018 2019 2020website for more information on product safety alerts. You may visitRequirements for product and service informationthe FDA's Adverse Event Reporting System (FAERS) website for up- GRI 417-1Asia Pacific 25% 15% 22% 28% 42% and labelingto-date information on fatalities associated with product use.Incidents of non-compliance concerning product andCentral & Eastern Europe, Middle East & Africa 12% 7% 7% 8% 8% GRI 417-2For more information on our approach to clinical trials, please visit service information and labelingEuropean Economic Area 36% 43% 21% 33% 20% the Clinical Trials page on our corporate website. GRI 417-3 Incidents of non-compliance concerning marketingcommunicationsThe Americas 10% 6% 9% 7% 15% Monetary losses as a result of legal proceedingsSASB 270a.1associated with false marketing claimsU.S. 17% 29% 41% 24% 15%Marketing & labeling Code of ethics governing promotion of off-label useSASB 270a.2of productsThe label in our product packaging contains information on possibleGRI 417 Management approach side effects and, if appropriate, how to avoid some potential healthTrial disclosures activities 2016 2017 2018 2019 2020problems. We include contact details in our product packaging and onour corporate website for patients, caregivers and health professionalsManuscripts of clinical trial results and related papers submitted 152 133 153 290 156Our company's chief medical officer (CMO) holds overall responsibility to report adverse experiences in the U.S. Outside the U.S., adverseto peer-reviewed journalsfor the benefit:risk determination of our pipeline and marketed events are reported in accordance with any additional local countryNumber of GCP/PV inspections conducted by regulatory 103 128 96 99 52 products. In addition, the CMO provides medical oversight for all laws and practices.agencies worldwide clinical programs, supervises the development and implementation ofDepending on labeling revisions and their context, our company ormedical policies (including those related to data transparency and theregulatory authorities may determine, in consultation with regulatorysharing of clinical data), and has responsibility for the design, executionauthorities, that more extensive communications are appropriate. Inand implementation of pre-registration expanded accessthose situations, we work with regulatory authorities to communicate(\"compassionate use\") programs.to health care professionals in a timely manner so that they can informGCP/PV inspections 2016 2017 2018 2019 2020Our company's Global Clinical Safety and Pharmacovigilance (GCS&PV) patients through appropriate mechanisms. Communications to healthfunction manages a global system for the collection, review and care professionals may include \"Dear Health Care Provider\" letters andGCP/PV inspections by regulatory agencies of the company or 0 0 0 0 0reporting of Adverse Experience (AE) reports received by our company media statements.clinical trial investigators that led to significant fines, penalties,worldwide, and for the continuous assessment of product safety. Ourwarning letters or product seizurescompany's chief safety officer holds overall responsibility for the safetyProduct label reviewsof our products.The ongoing oversight and monitoring of our product labels are a majorClinical safety and risk management focus of our safety efforts. Our label review teams monitor informationon our products and work with our product Risk Management & SafetyClinical Safety and Risk Management (CSRM) leads the Risk (RMS) teams to develop or update product labeling. We regularlyManagement & Safety Teams (RMSTs) teams for all products, from communicate relevant information to regulatory authorities worldwide.the beginning of Phase 2b through the end of the product life cycle.CSRM is responsible for the development of a proactive clinical safetyHealth literacyrisk-management strategies, including the Risk Management Plan,which is a regulatory requirement in many countries for marketedThere are many examples of health literacy in action across ourdrugs and vaccines.company's product lifecycle as seen in our approaches to clinicaltrials, informed consent, diversity in trials, medication labeling forMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 167"
  },
  {
    "page": 168,
    "source": "text",
    "content": "patients, instructions for use, packaging and patient education. Customer privacyBeginning in 2019, new clinical trials addressed cultural competenceand included training for investigators in teach-back, a way to confirmunderstanding by asking participants to repeat information in theirown words. Early in 2020, our commercial organization launched aGRI 418 Management approachprocess to integrate health literacy reviews more consistently across alltherapeutic areas.We have nine FDA approved health literate patient labels which Information about our company, products and people is one of ourwere developed with input from patients across a range of health most valuable assets. We are committed to ethical use, managementliteracy levels. and protection of information.Our commitment applies not only to our company's information, butU.S. Merck Medical Forums also to the information entrusted to us by others. Our tools, processesand procedures ensure that we appropriately collect, use and safeguardWe deliver balanced medical and scientific information to health care information throughout its life cycle to ensure integrity of informationprofessionals within the U.S. through our company's promotional and to prevent unauthorized access and disclosure. We have developedMerck Medical Forums, which are conducted by contracted external and continue to improve upon a comprehensive, global, state of thespeakers. Speakers are selected based on defined, objective criteria art information security and cyber resiliency program to enable ourthat are directly related to the identified educational purpose of the company to fulfill its mission: inventing for life.Medical Forum. By attending one of our Merck Medical Forums, healthcare professionals participate in medical education on therapeutic and There is increased pressure for companies to adopt the EU Generalhealth care industry topics. The goal of this education is to provide Data Protection Regulation (GDPR) as the basis for their own privacymedical education to targeted HCPs. policies and programs. Our company is well positioned in that wehave based our global program on the GDPR. In addition, our PrivacyWith our strict standards for conducting Merck Medical Forums, program is flexible and adaptable to be compliant to new laws andwe comply with the PhRMA Code on Interactions with Health Care regulations that take effect in the jurisdictions where we conductProfessionals as well as with U.S. Food and Drug Administration (FDA) business. Examples include the California Consumer Privacy Actregulations, which ensures that product information is appropriately (CCPA) and California Privacy Rights Act (CPRA) in California, thebalanced to include the product's potential benefits and risks, and is Consumer Data Protection Act (CDPA) in Virginia and major revisionsconsistent with approved product labeling. to the Data Protection Acts in Singapore, Brazil and Switzerland.We believe that our marketing, sales and advertising activities In addition, there is increased regulatory scrutiny and interest inmake an important contribution to medicine by informing our customers companies that seek to collect and monetize personal informationof treatment options based on the most recent scientific information and without full transparency and permission from data subjects.findings from rigorous clinical studies. Our sales and marketing practices Regulators will continue to increase requirements in these areas andare governed by external laws and regulations and industry codes of levy fines. Again, we believe that we are well positioned for theseconduct, and by our own global Code of Conduct, our corporate policies changes due to the deployment of a comprehensive closed-loopand procedures and our ethics and compliance program. privacy program and our active engagement with regulators aroundthe world.For more information, please see our answers to GRI 417-1 and GRI417-2 on page 167. The Global Privacy Office reports into our chief ethics & complianceofficer who reports directly to our CEO. Oversight of the privacyprogram is conducted within the Privacy and Data Protection Board(PDPB). This is a cross functional board that connects to the CorporateCompliance Committee. The PDPB meets quarterly.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 168"
  },
  {
    "page": 169,
    "source": "text",
    "content": "We are increasingly reliant on third party partners and service both compulsory and voluntary learning opportunities designed toproviders to assist us in our global operations. Just as we need to pay encourage employees to make security-aware decisions regardingclose attention to privacy and data protection, so do the third parties our company's information security risks. Topics include, but arethat comprise our supply chain. Our company employs a robust third- not limited to, information protection, identity, email, browsing andparty due diligence process to ensure that we only do business with mobile security. Employees are also expected to maintain an up toreputable third parties who share our values and standards. date record of their qualifications that detail relevant cybersecuritywork experience, skills, certifications and internal, industry orOur approach is one of accountability and transparency. The heart of vendor-provided training they receive.this program is a leveraged, world class Global Privacy Program thatmanifests itself throughout the world as a network of over 200 PrivacyGlobal privacy programStewards deployed around the globe. Program maturity is measuredthrough a combination of annual privacy self-assessments at the entityOver the past 20 years, we have developed and continuallyand organization level and by comprehensive privacy audits conductedimproved a comprehensive global privacy program that promotesby internal audit.organizational accountability for privacy, data governance and dataOur company also provides annual mandatory cybersecurity training protection across our business and with our collaborative partnersto communicate and reinforce the guidelines in the Information and suppliers.Security Standards Handbook and our commitment to a strongWe were the first company in the world to obtain regulatory approvalcybersecurity culture. We have established a systematic approachin the EU for Binding Corporate Rules (BCRs) based in part on ourfor ensuring employees can understand and comply with companyexisting Asia Pacific Economic Cooperation (APEC) Cross-Borderpolicies. Our company developed a robust cybersecurity trainingPrivacy Rules (CBPRs) certified program.and awareness program that frequently and consistently deliversOur global privacy values Respect TrustWe have established a set of privacy values to guide all We recognize that privacy concerns often relate to theWe know that trust is vital to our success, so we strive to buildof our privacy, data stewardship and data protection essence of who we are, how we view the world and how weand preserve the trust of our customers, employees, patientsdecisions. These core tenets serve as the foundational define ourselves, so we strive to respect the perspectives and and other stakeholders in how we respect privacy and protectinterests of individuals and communities and to be fair andethical framework for our comprehensive global privacy information about people.transparent in how we use and share information about them.program and our compliance with the continuallyevolving legal and regulatory standards for privacy andPrevent harm Complydata protection.We understand that misuse of information about people can We have learned that laws and regulations cannot always keepcreate both tangible and intangible harm for individuals, so pace with the rapid change in technologies, data flows andwe seek to prevent physical, financial, reputational and other associated shifts in privacy risks and expectations, so we strivetypes of privacy harm to individuals. to comply with both the spirit and the letter of privacy anddata protection laws and regulations in a manner that respectsindividuals, instills trust and drives consistency and operatingefficiency for our global business operations.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 169"
  },
  {
    "page": 170,
    "source": "text",
    "content": "This achievement demonstrates that organizations can rely oncommon internal standards and processes to govern international dataSubstantiated complaints regarding breaches oftransfers across both the EU and APEC regions to simplify their ability GRI 418-1customer privacy and losses of customer datato address the growing regulatory challenges in this area.Our holistic approach to privacy has its origins in biomedical researchWe have a well-established process by which privacy incidents can beethics and the protection of participants in the research studiesreported to the Global Privacy Office and be investigated. The firstthat we sponsor and conduct. We have adapted human subjectstep of this process is to verify the facts reported and to substantiateresearch ethics standards for risk-benefit analysis, transparency,the concern. In 2020, we received 250 substantiated concerns. Thisanonymization, coding and prior review to other activities andmarked a substantial increase over the number seen the previous year.processes involving data about people.This increase can be attributed to the deployment by the companyof more sensitive network monitors. In 2020, none of the reportedPrivacy Incidents rose to the level requiring notification.Global privacy program 2016 2017 2018 2019 2020Number of concerns regarding privacy practices, breaches of 227 123 315 292 2503privacy and losses of personal data that were substantiated1Number of privacy breaches requiring notification by 1 0 2 2 0Merck & Co., Inc., Kenilworth, N.J., U.S.A., to individualsor government authorities1 P rivacy concerns reported here include all concerns about our privacy practices reported to our company's Privacy Office and substantiated or verified.Verified concerns are investigated as part of the company's Incident Management Process which includes a determination of whether regulatory or data subject notification is required.2 Change in reporting criteria to exclude non-privacy, quality related issues from the data.3 Increased sensitivity of network traffic monitors.Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 170"
  },
  {
    "page": 171,
    "source": "text",
    "content": "Global ReportingThe GRI Standards represent global best practices for reporting publicly on a range of economic,Initiative (GRI) environmental and social impacts. The table below summarizes where responses to the GRIdisclosures can be found throughout this report.General DisclosuresGRI 102 Organizational Profile102-1 Organization name (Core) Pages 26-27102-2 Primary brands, products, and services (Core) Pages 26-27102-3 Headquarters location (Core) Pages 26-27102-4 Location of operations (Core) Pages 26-27102-5 Ownership and legal form (Core) Pages 26-27102-6 Markets served (Core) Pages 26-27102-7 Scale of the organization (Core) Page 28102-8 Information on employees and other workers (Core) Page 28102-9 Supply chain (Core) Pages 29-33102-10 Organizational changes during the reporting period (Core) Page 33102-11 Precautionary principle (Core) Page 34102-12 External initiatives (Core) Pages 34-35102-13 Membership associations (Core) Pages 35-37GRI 102 Strategy102-14 CEO Letter (Core) Page 38102-15 Key impacts, risks, and opportunities Not reportedMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 171"
  },
  {
    "page": 172,
    "source": "text",
    "content": "GRI 102 Ethics & Integrity102-16 Values, principles, standards, and norms of behavior (Core) Pages 38-39102-17 Mechanisms for advice and concerns about ethics Pages 38-39GRI 102 Governance102-18 Governance structure of the organization (Core) Pages 40-42102-19 Delegation of responsibility Pages 40-42102-20 High-level accountability for sustainability topics Pages 40-42102-21 Access to the board Pages 40-42102-22 Composition of the board and its committees Pages 40-42102-23 Chair of the highest governance body Pages 40-42102-24 Board nomination and selection processes Page 42102-25 Board conflicts of interest Page 42102-26 Board and executive roles Page 42102-27 Board ESG knowledge Pages 42-43102-28 Board performance Pages 42-43102-29 Board identification of ESG impacts, risks and opportunities Pages 42-43102-30 Board ESG review of risk management processes Pages 42-43102-31 Frequency of board review Pages 42-43102-32 Report review Pages 42-43102-33 Board communication Page 43102-34 Concerns communicated to the board Not reported102-35 Remuneration policies for the board and senior executives Page 43102-36 Process for determining remuneration Page 43102-37 Remuneration shareholder resolutions Page 43Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 172"
  },
  {
    "page": 173,
    "source": "text",
    "content": "102-38 CEO/employee pay ratio Page 44102-39 CEO/employee pay increase ratio Not reportedGRI 102 Stakeholder Engagement102-40 Stakeholder engagement (Core) Pages 44-45102-41 Union representation (Core) Pages 44-45102-42 Stakeholder identification (Core) Pages 44-45102-43 Approach to stakeholder engagement (Core) Pages 44-45102-44 Key topics and concerns raised (Core) Not reportedGRI 102 Reporting Practice102-45 Entities included in financial statements (Core) Page 46102-46 Defining report content and topic boundaries (Core) Pages 47-49102-47 Material Aspects included (Core) Pages 47-49102-48 Restatements (Core) Page 49102-49 Reporting changes (Core) Page 49102-50 Reporting period (Core) Page 49102-51 Date of most recent report (Core) Page 49102-52 Reporting cycle (Core) Page 49102-53 Report contact (Core) Page 49102-54 Claims of reporting in accordance with the GRI Standards (Core) Page 49102-55 GRI content index (Core) Page 49102-56 External assurance (Core) Page 49Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 173"
  },
  {
    "page": 174,
    "source": "text",
    "content": "EconomicGRI 201 Economic Performance (2016)201-1 Direct economic value generated and distributed Pages 50-51201-2 Financial implications and other risks and opportunities due to climate change Page 52201-3 Benefit plan coverage Page 53GRI 203 Indirect Economic Impacts (2016)Management Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms for Pages 53-63evaluating the effectiveness of the company's strategy.203-1 Infrastructure investments and services supported Pages 64-72203-2 Indirect economic impacts Pages 64-72GRI 204 Procurement Practices (2016)Management Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms for Pages 73-75evaluating the effectiveness of the company's strategy.GRI 205 Anti-corruption (2016)Management Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms for Page 76evaluating the effectiveness of the company's strategy.205-2 Communications and training on anti-corruption Page 77GRI 206 Anti-Competitive Behavior (2016)Management Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms for Pages 78-79evaluating the effectiveness of the company's strategy.206-1 Anti-competitive behavior Pages 79-81GRI 207 Tax (2019)Management Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms for Pages 81-82evaluating the effectiveness of the company's strategy.207-1 Approach to tax Pages 81-82Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 174"
  },
  {
    "page": 175,
    "source": "text",
    "content": "EnvironmentalGRI 301 Materials (2016)Management Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms for Pages 83-87evaluating the effectiveness of the company's strategy.GRI 302 EnergyManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms for Pages 88-90evaluating the effectiveness of the company's strategy.302-1 Energy consumption within the organization (Scopes 1 + 2) Pages 91-92302-4 Energy reductions Pages 91-92GRI 303 Water (2018)Management Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms for Pages 93-94evaluating the effectiveness of the company's strategy.303-1 Water as a shared resource Page 95303-2 Water discharge-related impacts Pages 95-96303-3 Water withdrawal Pages 96-98303-4 Water discharge Pages 99-100GRI 305 Emissions (2016)Management Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms for Pages 100-101evaluating the effectiveness of the company's strategy.305-1 Direct GHG emissions (Scope 1) Pages 102-104305-2 Indirect GHG emissions (Scope 2) Pages 102-104305-3 Other indirect GHG emissions (Scope 3) Pages 102-104305-4 GHG emissions intensity Pages 102-104305-5 Reduction of GHG emissions Pages 102-104305-6 Ozone-depleting substances (ODS) Pages 104-106305-7 NOx, SOx and other emissions Pages 104-106Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 175"
  },
  {
    "page": 176,
    "source": "text",
    "content": "GRI 306 Waste (2020)Management Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms for Pages 106-107evaluating the effectiveness of the company's strategy.306-3 Waste generated Page 107306-4 Waste diverted from disposal Pages 108-110306-5 Waste directed to disposal Pages 108-110GRI 307 Environmental Compliance (2016)Management Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms for Pages 110-114evaluating the effectiveness of the company's strategy.307-1 Non-compliance with environmental laws and regulations Page 115GRI 308 Supplier Environmental Assessment (2016)Management Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms for Pages 116-117evaluating the effectiveness of the company's strategy.SocialGRI 401 Employment (2016)Management Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms for Pages 118-120evaluating the effectiveness of the company's strategy.401-1 New employee hires and turnover Pages 121-123401-2 Benefits provided to full-time employees Pages 123-127401-3 Parental leave Page 128GRI 403 Occupational Health & Safety (2018)Management Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms for Page 128evaluating the effectiveness of the company's strategy.403-1 Occupational health and safety management system Page 129Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 176"
  },
  {
    "page": 177,
    "source": "text",
    "content": "403-2 Hazard identification, risk assessment, and incident investigation Pages 129-132403-3 Occupational health services Pages 132-135403-5 Worker training on occupational health and safety Page 136403-6 Promotion of worker health Page 136403-9 Work-related injuries Pages 137-139403-10 Work-related ill health Pages 137-139GRI 404 Training & Education (2016)Management Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms for Page 140evaluating the effectiveness of the company's strategy.404-1 Average hours of employee training Pages 140-144404-2 Programs for upgrading employee skills and transition assistance programs Pages 140-144404-3 Percentage of employees receiving regular performance reviews Pages 144-145GRI 405 Diversity & Equal Opportunity (2016)Management Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms for Pages 145-152evaluating the effectiveness of the company's strategy.405-1 Diversity of governance bodies and employees Pages 153-154GRI 412 Human Rights Assessment (2016)Management Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms for Pages 154-156evaluating the effectiveness of the company's strategy.412-1 Operations that have been subject to human rights reviews Page 156412-2 Employee training on human rights policies and procedures Page 156412-3 Investment agreements and contracts that include human rights clauses or underwent screening Page 156GRI 414 Supplier Social Assessment (2016)Management Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms for Page 157-159evaluating the effectiveness of the company's strategy.414-1 New suppliers screened using social criteria Page 159Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 177"
  },
  {
    "page": 178,
    "source": "text",
    "content": "GRI 415 Public Policy (2016)Management Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms for Page 159evaluating the effectiveness of the company's strategy.415-1 Political contributions Page 160GRI 416 Customer Health & Safety (2016)Management Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms for Page 161evaluating the effectiveness of the company's strategy.416-2 Incidents of non-compliance concerning the health and safety impacts of products and services Pages 162-167GRI 417 Marketing & Labeling (2016)Management Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms for Page 167evaluating the effectiveness of the company's strategy.417-1 Requirements for product and service information and labeling Pages 167-168417-2 Incidents of non-compliance concerning product and service information and labeling Pages 167-168417-3 Incidents of non-compliance concerning marketing communications Pages 167-168GRI 418 Customer Privacy (2016)Management Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms for Pages 168-170evaluating the effectiveness of the company's strategy.418-1 Substantiated complaints regarding breaches of customer privacy and losses of customer data Page 170Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 178"
  },
  {
    "page": 179,
    "source": "text",
    "content": "Sustainability AccountingSASB is an independent standards-setting organization dedicated to improving theeffectiveness and comparability of corporate disclosure on ESG factors. The tableStandards Board (SASB) below summarizes how our existing reporting aligns with the recommended metricsfor the Biotechnology & Pharmaceuticals Standard within the Health Care sector,and where this information can be found in this report.Safety of clinical trial participants210a.1 Discussion, by world region, of management process for ensuring quality and patient safety during Pages 53-72clinical trials Clinical trials210a.2 Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that Pages 162-167resulted in: Voluntary Action Indicated (VAI) and Official Action Indicated (OAI)210a.3 Total amount of monetary losses as a result of legal proceedings associated with clinical trials in Not reporteddeveloping countriesAccess to medicines240a.1 Description of actions and initiatives to promote access to health care products for priority diseases Pages 53-72and in priority countries as defined by the Access to Medicine Index240a.2 List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Pages 53-72Medicines Programme (PQP)Affordability and pricing240b.1 Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved Not reportedpayments and/or provisions to delay bringing an authorized generic product to market for adefined time period240b.2 Percentage change in: average list price and average net price across U.S. product portfolio Pages 53-72compared to previous year240b.3 Percentage change in: list price and net price of product with largest increase compared to Pages 53-72previous yearDrug safety250a.1 List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for FAERS MedWatchHuman Medical Products databaseMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 179"
  },
  {
    "page": 180,
    "source": "text",
    "content": "250a.2 Number of fatalities associated with products as reported in the FDA Adverse Event FAERS MedWatchReporting System250a.3 Number of recalls issued, and total units recalled Pages 53-72FAERS MedWatch250a.4 Total amount of product accepted for takeback, reuse, or disposal Not reported250a.5 Number of FDA enforcement actions taken in response to violations of current Not reportedGood Manufacturing Practices (cGMP), by typeCounterfeit drugs260a.1 Description of methods and technologies used to maintain traceability of products throughout the Pages 53-72, 76-77supply chain and prevent counterfeiting260a.2 Discussion of process for alerting customers and business partners of potential or known risks Pages 161-167associated with counterfeit products260a.3 Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to Not reportedcounterfeit productsEthical marketing270a.1 Total amount of monetary losses as a result of legal proceedings associated with false Pages 79-81marketing claims270a.2 Description of code of ethics governing promotion of off-label use of products Pages 167-168Employee recruitment, development and retention330a.1 Discussion of talent recruitment and retention efforts for scientists and research and Pages 121-123development personnel330a.2 Voluntary and involuntary turnover rate for: executives/senior managers, mid-level managers, Pages 121-123professionals, and all othersSupply chain management430a.1 Percentage of entity's facilities and Tier I suppliers' facilities participating in the Rx-360 International Not reportedPharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs forintegrity of supply chain and ingredientsMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 180"
  },
  {
    "page": 181,
    "source": "text",
    "content": "Business ethics510a.1 Total amount of monetary losses as a result of legal proceedings associated with corruption Not reportedand bribery510a.2 Description of code of ethics governing interactions with health care professionals Pages 38-39Code of Conduct& ComplianceActivity metrics000.A Number of patients treated Not reported000.B Number of drugs in portfolio, and in research and development (Phases 1-3) PipelineMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 181"
  },
  {
    "page": 182,
    "source": "text",
    "content": "UN GlobalThe UNGC is a strategic initiative that helps companies align their business activities and strategieswith ten universally recognized principles in the areas of human rights, labor standards, environmentalCompact (UNGC) protection and the fight against corruption. The table below summarizes how our existing reportingaligns with these disclosures, and where the information can be found in this report, which serves asour Communication on Progress to UNGC.Human rights1 Businesses should support and respect the protection of internationally proclaimed human rights Pages 154-1562 Businesses should make sure that they are not complicit in human rights abuses Pages 116-117, 154-159Labor3 Businesses should uphold the freedom of association and the effective recognition of the rights to Pages 154-156collective bargaining4 Businesses should support the elimination of all forms of forced and compulsory labor Pages 154-1565 Businesses should support the effective abolition of child labor Pages 154-1566 Businesses should support the elimination of discrimination in respect of employment and occupation Pages 145-156Environment7 Businesses should support a precautionary approach to environmental challenges Pages 83-87, 93-100, 106-1108 Businesses should undertake initiatives to promote greater environmental responsibility Pages 83-1179 Businesses should encourage the development and diffusion of environmentally friendly technologies Pages 83-87, 93-100Anti-corruption10 Businesses should work against corruption in all its forms, including extortion and bribery Pages 38-39, 76-81, 157-159Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 182"
  },
  {
    "page": 183,
    "source": "text",
    "content": "UN SustainableThe SDGs are a set of 17 global goals whose aim is to end poverty, fightinequality and injustice, and tackle climate change by 2030. The tableDevelopment Goals (SDGs) below summarizes how our reporting aligns with the SDGs, and wherethis information can be found in this report. More information on ourpriorities can also be found on page 8.Goal Description ResponseSDG 1: No Poverty End poverty in all its forms everywhere Pages 53-72, 81-82SDG 2: Zero Hunger End hunger, achieve food security and improved nutrition and promote sustainable agriculture Merck Animal HealthSDG 3: Good Health & Ensure healthy lives and promote well-being for all at all ages Pages 53-72, 128-139Well-beingSDG 4: Quality Education Ensure inclusive and equitable quality education and promote lifelong learning opportunities for all Pages 140-145SDG 5: Gender Equality Achieve gender equality and empower all women and girls Pages 118-128, 140-154,157-159SDG 6: Clean Water Ensure availability and sustainable management of water and sanitation for all Pages 93-100, 107& SanitationSDG 7: Affordable & Ensure access to affordable, reliable, sustainable and modern energy for all Pages 88-92Clean EnergySDG 8: Decent Work & Promote sustained, inclusive and sustainable economic growth, full and productive employment and Pages 28, 44-45, 50-53,Economic Growth decent work for all 88-92, 118-139, 140-154,157-159SDG 9: Industry, Innovation Build resilient infrastructure, promote inclusive and sustainable industrialization and foster innovation Pages 50-72& InfrastructureSDG 10: Reduced Inequalities Reduce inequality within and among countries Pages 28, 118-128, 140-154SDG 11: Cities & Communities Make cities and human settlements inclusive, safe, resilient and sustainable Not applicableSDG 12: Responsible Ensure sustainable consumption and production patterns Pages 83-110, 167-168Consumption & ProductionSDG 13: Climate Action Take urgent action to combat climate change and its impacts Pages 52, 88-92, 100-106Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 183"
  },
  {
    "page": 184,
    "source": "text",
    "content": "SDG 14: Life Below Water Conserve and sustainably use the oceans, seas and marine resources for sustainable development Pages 34, 93-100SDG 15: Life on Land Protect, restore and promote sustainable use of terrestrial ecosystems, sustainably manage forests, Pages 93-110combat desertification, and halt and reverse land degradation and halt biodiversity lossSDG 16: Peace, Justice & Promote peaceful and inclusive societies for sustainable development, provide access to Pages 38-39, 40-43, 78-81,Strong Institutions justice for all and build effective, accountable and inclusive institutions at all levels 110-115, 128-139, 157-159,161-170SDG 17: Partnerships Strengthen the means of implementation and revitalize the global partnership for Pages 34-35, 44-45, 81-82for the Goals sustainable developmentMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 184"
  },
  {
    "page": 185,
    "source": "text",
    "content": "Culture of Health for The Culture of Health for Business (COH4B) is a framework for companies to disclosetheir impact on health of employees, families and communities, as well as brand andfinancial performance, that lead to both positive and negative business outcomes.Business (COH4B) The table below summarizes how our reporting aligns with the recommended metricsfor the Biotechnology & Pharmaceuticals Standard within the Health Care sector, andwhere this information can be found in this report.StrategicHealth culture Promoting an organizational culture of health Pages 123-127, 128-139,COVID-19Responsible corporate Activity that shapes public policy or public opinion Pages 159-160,Transparencypolitical activity DisclosuresResponsible marketing Commitments to responsible marketing Pages 167-168practicesPolicies & BenefitsHealth promotion and wellness Providing health promotion and wellness programs Pages 118-139Paid family and medical leave Allowing employees to earn pay while away attending to illness, a family member or newborn Pages 118-128Health insurance Providing employer-based health insurance Pages 118-128Equality, diversity Managing inequality, discrimination and diversity, including disability Pages 118-128, 145-156and impartialityFinancial literacy Providing financial literacy resources Pages 118-128Workforce & OperationsWork time Managing working hours, schedules and schedule control Pages 118-128Job security Managing job insecurity Pages 118-128Pay practices Managing wage policies, minimum wages, wage satisfaction Pages 118-128,Compensationand benefitsOccupational health and safety Mandatory and voluntary occupational health and safety Pages 128-139Physical environment Managing air quality, lighting, green buildings, health promotion attempts through the Pages 83-117built environmentMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 185"
  },
  {
    "page": 186,
    "source": "text",
    "content": "CommunityCommunity environmental Managing the environmental impacts of company operations on communities Pages 83-117,CDP Waterimpacts SecurityandCDP ClimateChangeSocial capital and cohesion Encouraging links, shared values and understanding Pages 16-18, 118-128Community involvement Investments in programs to benefit communities, including disaster response and recovery Pages 53-72, 118-128,Philanthropy, ImpactInvesting, MedicalOutreach ProgramMerck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 186"
  },
  {
    "page": 187,
    "source": "text",
    "content": "StakeholderAt the 2020 Annual Meeting in Davos, 120 of the world's largest companies supported efforts todevelope a core set of common metrics and disclosures for their investors and other stakeholders.Capitalism MetricsBelow is our alignment against the Core metrics from this framework developed by the WorldEconomic Forum, as well as select disclosures from the Explanded metrics.Principles of GovernanceGoverning PurposeSetting purpose (Core) Not reportedPurpose-led management (Expanded) Overview section (Pages 7, 9)Quality of Governing BodyGovernance body composition (Core) Pages 40-42Progress against strategic milestones (Expanded) Access to medicine (Pages 53-72)Product quality and safety (Pages 161-167)Public health risks (Pages 3, 53-72)Ethics in R&D (Pages 53-72)Employee health and safety (Pages 128-139)Employee engagement and diversity (Pages 145-154)Climate change (Pages 52, 88-92, 100-106)Business ethics (Pages 38-39)Data privacy and security (Pages 168-170)Governance structures and mechanisms (Pages 40-44)Remuneration (Expanded) Page 43Stakeholder EngagementMaterial issues impacting stakeholders (Core) Pages 44-45, 47-49Ethical BehaviorAnti-corruption (Core) Pages 76-77, 140-145Protected ethics advice and reporting mechanisms (Core) Pages 38-39Alignment of strategy and policies to lobbying (Expanded) Pages 159-160Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 187"
  },
  {
    "page": 188,
    "source": "text",
    "content": "Risk and Opportunity OversightIntegrating risk and opportunity into business process (Core) Pages 40-42, 47-49PlanetClimate ChangeGreenhouse gas (GHG) emissions (Core) Pages 102-104Paris-aligned GHG emissions targets (Expanded) Pages 100-106TCFD implementation (Core) We intend to perform a gap analysis on TCFD reportingfor our company in late 2021, and will provide moreinformation on our progress in our 2021/2022 ESG report.Nature LossLand use and ecological sensitivity (Core) Not reportedFreshwater AvailabilityWater consumption and withdrawal in water-stressed areas (Core) Pages 93-100Impact of freshwater consumption and withdrawal (Expanded) CDP Water SecurityAir PollutionAir pollution (Expanded) Pages 104-106PeopleDignity and EqualityDiversity and inclusion (Core) Pages 153-154Pay equality (Core) Pages 146-148Wage level (Core) Not reportedRisk for incidents of child, forced or compulsory labor (Core) Pages 154-156Human rights review, grievance impact and modern slavery (Expanded) Pages 154-156Freedom of association and collective bargaining at risk (Expanded) Pages 44-45, 157-159Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 188"
  },
  {
    "page": 189,
    "source": "text",
    "content": "Health and WellbeingHealth and safety (Core) Pages 137-139Employee well-being (Expanded) Pages 128-139Skills for the FutureTraining provided (Core) Pages 140-145ProsperityEmployment and Wealth GenerationAbsolute number and rate of employment (Core) Pages 118-128Infrastructure investments and services supported (Expanded) Pages 53-72Economic contribution (Core) Pages 50-532020 Form 10-KFinancial investment contribution (Core) 2020 Form 10-KSignificant indirect economic impacts (Expanded) Pages 53-72Innovation for Better Products and ServicesTotal R&D expenses (Core) 2020 Form 10-K (pages 59-60)Community and Social VitalityTotal tax paid (Core) Pages 81-82Additional tax remitted (Expanded) Pages 81-82Merck ESG Progress Report 2020/2021 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 189"
  },
  {
    "page": 190,
    "source": "text",
    "content": "Copyright © 2021 Merck & Co., Inc., Kenilworth, NJ USA, and its affiliates. All rights reserved.Forward-looking statementThis publication of Merck & Co., Inc., Kenilworth, N.J., USA (the \"company\") includes \"forward-lookingstatements\" within the meaning of the safe harbor provisions of the U.S. Private Securities LitigationReform Act of 1995. These statements are based upon the current beliefs and expectations of the company'smanagement and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurateor risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.Risks and uncertainties include but are not limited to, general industry conditions and competition; generaleconomic factors, including interest rate and currency exchange rate fluctuations; the impact of the globaloutbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation andhealth care legislation in the United States and internationally; global trends toward health care costcontainment; technological advances, new products and patents attained by competitors; challengesinherent in new product development, including obtaining regulatory approval; the company's ability toaccurately predict future market conditions; manufacturing difficulties or delays; financial instability ofinternational economies and sovereign risk; dependence on the effectiveness of the company's patents andother protections for innovative products; and the exposure to litigation, including patent litigation, and/orregulatory actions.The company undertakes no obligation to publicly update any forward-looking statement, whether as a resultof new information, future events or otherwise. Additional factors that could cause results to differ materiallyfrom those described in the forward-looking statements can be found in the company's 2020 Annual Reporton Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available atthe SEC's Internet site (www.sec.gov).No duty to updateThe information contained in this publication was current as of the date presented. The company assumesno duty to update the information to reflect subsequent developments. Consequently, the company will notupdate the information contained in this publication and investors should not rely upon the information ascurrent or accurate after the presentation date.Merck & Co., Inc.c/o ESG Strategy & Engagement2000 Galloping Hill Road (K1-3181)Kenilworth, N.J., U.S.A.Merck.comMerck & Co., Inc., Kenilworth, N.J., U.S.A., is knownas MSD outside the United States and Canada."
  }
]